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Abstract 
The bronchiectatic lung is a diseased state in which the airways are chronically 
damaged and dilated. This state is found in the clinical entities of cystic fibrosis 
and non-cystic fibrosis bronchiectasis. These are two highly relevant chronic 
suppurative lung diseases in which an understanding of the microbiology of these 
patients is considered key to appropriate management. This has traditionally 
been via the use of traditional culture techniques. However, with the development 
of molecular methodologies, the previously perceived wisdom is being 
challenged.  
In both cystic fibrosis and non-cystic fibrosis bronchiectasis, Pseudomonas 
aeruginosa is considered the most significant pathogen. In CF there has been 
considerable concern surrounding the risk of transmission of Pseudomonas 
aeruginosa between patients on the basis of a significant quantity of research into 
this matter. In contrast, there has been very little research performed into the 
equivalent risk in non-cystic fibrosis bronchiectasis. In this thesis we describe an 
extensive single-centre epidemiological review of Pseudomonas aeruginosa 
spanning both these diseases. Via this we have shown evidence of cross-
infection within a non-cystic fibrosis bronchiectasis cohort. This epidemiological 
review has included multiple genotyping methods including multilocus sequence 
typing and whole genome sequencing, As an extension of the epidemiological 
review, we have performed an in silico prediction of hypermutator status from the 
whole genome sequencing data to provide greater understanding of the likelihood 
of cross-infection, and have also demonstrated a culture-independent adaption 
of multilocus sequence typing for potential screening for cross-infection. 
In addition to Pseudomonas aeruginosa, we have also looked at the wider 
bacterial community in the lungs of patients with these two conditions via culture-
independent techniques. We have shown that whilst Pseudomonas aeruginosa 
is often an important component, these are clearly complex communities. We 
have primarily investigated the cohort with non-cystic fibrosis bronchiectasis, but 
we have demonstrated associations between clinically-relevant markers and 
complexity of the bacterial communities within the lungs of both these cohorts of 
patients. Whilst we have used the gold-standard technique of 16S rRNA 
sequencing, we have also shown the validity of a simple and potentially more 
feasible profiling technique for standard clinical care.  
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In summary, through the application of culture-dependent and independent 
molecular techniques, this research has shed light on the epidemiology of 
Pseudomonas aeruginosa within our respiratory cohorts, and the complexity and 
clinical relevance of the wider microbial communities within these patients. Such 
studies are essential if we are to advance our understanding of the bronchiectatic 
lung and optimise strategies for patient management. 
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“The rather impressive status of P. aeruginosa as a 'harbinger of death' for CF 
patients has been greatly reduced by medical and scientific advances, and there 
is every reason to be optimistic that further research will show a way for it to be 
relegated to a lower and more manageable league of microorganisms in CF.”[1] 
T. Pitt, 1986 
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Preface 
This thesis has been written for submission to the University of Exeter Medical 
School for the degree of Doctor of Philosophy in Medical Studies. This is the 
product of a three year period working in the Department of Biosciences at the 
University of Exeter and the Department of Respiratory Medicine at the Royal 
Devon and Exeter NHS Foundation Trust. Additional support has been provided 
by the Department of Microbiology at the Trust, and the University of Exeter 
Medical School.  
The main focus of this work is the bacteria Pseudomonas aeruginosa in the 
setting of the bronchiectatic lung. The majority of the patients studied have the 
diagnoses of non-cystic fibrosis bronchiectasis, but the work extends to those 
with cystic fibrosis as well. I have initially investigated the epidemiology of 
Pseudomonas aeruginosa in our patients, before looking at its place within the 
wider microbial community by culture-independent methods. This work has been 
performed through both the use of gold-standard molecular techniques, and also 
alternative options with their utility assessed.  
This thesis is divided into three main sections. Part A begins with an introductory 
chapter reviewing our relevant knowledge of the bronchiectatic lung, 
Pseudomonas aeruginosa and the wider bacterial community in this setting. The 
techniques used to address these issues are also discussed, as are the aims of 
this body of work. This section is completed by a “Methods and Materials” 
chapter. Part B contains the investigative work where the research performed is 
presented in the style of extended journal papers. Part C presents the 
conclusions of this work and additional material. 
It is hoped that the following text will both interest the reader, and provoke further 
thought around the subjects covered. 
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Chapter 1- Introduction 
1.1 The Bronchiectatic Lung 
The human lung is a highly complex organ which facilitates the transfer of oxygen 
into the body, and the expulsion of carbon dioxide from it. This is achieved 
through the ongoing ventilation of approximately 10,000 litres of air per day along 
the respiratory tract.[2] The respiratory tract is divided into upper and lower 
components, with the lungs contained in the lower component. The path of 
inhaled air through the lower respiratory tract starts within the main trachea before 
separating into the main bronchi, subsequently dividing into other bronchi and 
bronchioles, and then finally reaching the alveoli where gas exchange occurs 
(see Figure 1.1). Gases pass in the opposite direction in the expiratory phase of 
respiration. This ventilatory process helps the human body to maintain 
physiological homeostasis. However, the transfer of gases is not the only 
movement along these airways which is crucial to the maintenance of lung health. 
Along the respiratory tract there is also the potential travel of particles, including 
microbes. Immigration of these microbes can occur via simple inhalation, micro-
aspiration and dispersion along the respiratory tract.[3] For the maintenance of 
health the lung also has various mechanisms of elimination, which help prevent 
acute infection and chronic colonisation with pathogens. These include coughing, 
mucociliary clearance and the host immune system. In situations where the 
balance between immigration and elimination is lost, lung health may not be 
maintained. An example of this is the bronchiectatic lung. 
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Figure 1.1 Anatomy of the lower respiratory tract. Image taken from NIH- 
National Cancer Institute 
Rene Laënnec is generally credited with first describing bronchiectasis in the 19th 
Century.[4, 5] Bronchiectasis is a description of a pathological state where there 
is irreversible dilatation of part of the bronchi. In the 21st Century this is now 
defined by radiological assessment via high-resolution computerised tomography 
(HRCT) of the thorax.[6] Dilatation is defined by the internal diameter of a 
bronchus being larger than the accompanying vessel.[7] An alternative way of 
expressing this is an airway-to-vessel ratio of greater than one. Despite this 
apparently straight-forward criteria and the sophistication of HRCT, this remains 
a flawed process. Assessment of the images produced can be affected through 
the optical illusion of comparing hollow circles (as bronchi appear) and solid 
circles (as vessels appear), with the consequence being the over-diagnosis of 
bronchiectasis in some cases.[8] More worryingly for the integrity of the diagnosis 
is that the airway-to-vessel ratio may change with age. Potentially over 40% of 
25 
 
healthy subjects over the age of 65 meet the radiological criteria for 
bronchiectasis.[9] A further concern for the robustness of the radiological 
diagnosis is illustrated by work suggesting that an abnormal airway-to-vessel 
ratio can be driven by small vessels rather than enlarged airways.[10]  
Rather than relying entirely on radiological findings, it is clearly important for a 
patient to have a relevant clinical presentation for a useful and relevant diagnosis 
to be made. The presentation of those considered to have clinical bronchiectasis 
is characterised by features such as a chronic cough, increased sputum 
production, haemoptysis, dyspnoea, fatigue, chest pain, and recurrent 
exacerbations of respiratory symptoms which are often suspected to be driven by 
infection. Clinicians will identify patients with these features who do not meet the 
radiological criteria for bronchiectasis.[11] This group of patients consequently do 
not have a diagnosis of bronchiectasis. They may as a result be poorly-served 
and miss out on specific trials and therapies. Young patients are at particular risk 
of this due to the radiological reasons described above. However, despite the 
issues raised above, there is clearly a significant group of patients who have the 
characteristic clinical syndrome alongside the radiological findings. This is the 
group of patients studied in this thesis. 
When a patient is suspected and subsequently confirmed to have bronchiectasis, 
a key step in the management of the patient is the screening of potential 
aetiologies.[12] One cause which may be screened for is the life-limiting genetic 
condition of cystic fibrosis. This brings about the main split in the diagnostic 
labelling of patients with bronchiectasis: those described as having cystic fibrosis 
(which will be referred to as CF for the remainder of this thesis); and those with 
non-cystic fibrosis bronchiectasis (which will be referred to as NCFB hereafter). 
This distinction is a very important one to make, particularly for those with CF 
where the care and support structures are better established. Historically CF has 
received more research attention and as a result there have been many examples 
of treatments being used in NCFB on the basis of success in CF. Notably 
however, this has not always been successful, and indeed has on occasion 
resulted in harm.[13] CF research and drug development is now reaching the 
point where genomic-based therapeutics may transform the health-potential of 
many patients.[14] This may lead to further divergence in the management of the 
two categories of patients with bronchiectasis. 
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1.1.1 Non-Cystic Fibrosis Bronchiectasis 
The majority of the work in this theses has involved patients with NCFB. Having 
previously been seen as an orphan disease of decreasing relevance, NCFB is 
now receiving significantly more attention.[15] I shall now describe this disease 
in more detail including its importance, its impact on patients, and the 
microbiological issues associated with it.  
Epidemiology 
The epidemiology of NCFB is surprisingly difficult to express clearly. This is for 
multiple reasons. There have been a variety of quoted rates of NCFB around the 
world. A frequently quoted prevalence had been 52/100,000 based on data from 
the United States of America (USA).[16] This dataset suggested prevalence 
ranging from 4.2/100,000 in 18-34 year olds to 272/100,000 in those over 75. It 
has subsequently been suggested that these figures are underestimates.[17] 
Australasian paediatric data revealed a prevalence rate of 1,470/100,000 in a 
Central Australian Indigenous population.[18] This was described as 
unacceptably common in this cohort. German data published as recently as 2015 
reported a prevalence rate of 67/100,000 overall, and 228/100,000 when 
investigating men aged 75-84 years old.[19] A very large dataset from the United 
Kingdom (UK) was published in 2016 by Quint et al and reported a point 
prevalence of 566/100,000 in adult women and 486/100,000 in adult men.[20] In 
those over 80 years old, the prevalence rates for the population were 
1,206/100,000. These UK figures are truly striking and significantly change our 
impression of how common NCFB is. Also of note from this report is the 
increasing prevalence rates between 2004 and 2013. What is clear from these 
various cohorts is that NCFB is a disease that is more prevalent in women, the 
middle-aged and the elderly.[21, 22] Other details are more subtle and require 
more explanation.  
Studies where low rates had been described, may have been underestimates 
due in part to under-recognition of the condition. One study has suggested a 
striking 17 year delay in diagnosis in a cohort.[23] Due to the symptoms of NCFB 
being non-specific and shared by other respiratory diseases, if radiological 
investigations by HRCT is not performed, another diagnostic label may be 
applied. An example would be chronic obstructive pulmonary disease (COPD). A 
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patient presenting with chronic cough, recurrent exacerbations of respiratory 
symptoms, and abnormal lung function tests could easily be diagnosed with 
COPD, particularly if they had a history of smoking. If however, an HRCT was 
performed, the diagnosis may change to NCFB. A study which illustrates this was 
a prospective review of patients who had been seen by in primary care and 
treated in the community for an exacerbation of COPD.[24] The patients 
subsequently underwent an HRCT when they were stable, and almost a third 
showed evidence of bronchiectasis. A secondary care study found 69% of 
patients admitted for their first exacerbation of COPD had NCFB.[25] It is 
becoming clear that these diagnoses are not mutually exclusive and interest is 
developing in the concept of a COPD-NCFB overlap syndrome.[26, 27] As well 
as COPD, asthma may be another respiratory disease which may distract 
clinicians from a diagnosis of NCFB, particularly with the non-allergic/neutrophilic 
phenotype.[28] Another possible reason for lower reported rates may be intricate 
politico-economic reasons. It has been verbally suggested in international forums 
that the rates in Germany may have been falsely low due to differences in 
financial charges for patients when the diagnosis is COPD rather than NCFB. 
Of the studies with the higher rates of NCFB the most striking is in the Australian 
indigenous population, particularly when it is taken into account that this is a 
paediatric cohort. This is used as an example of how poor access to healthcare 
and high rates of childhood infection increases the risk of developing NCFB. Of 
note, data from neighbouring New Zealand showed that the socioeconomically 
disadvantaged Maori and Pacific population had the highest rates of hospital 
admissions with NCFB.[29] That there is such a burden in high-income countries, 
suggests that there could be even greater problem in less developed nations. The 
other study with particularly high rates is the UK based study by Quint et al, and 
this is the most relevant in relation to this piece of work.[20] The diagnosis of 
NCFB was based on it being entered on a primary care system. As NCFB is a 
diagnosis confirmed in secondary care in the UK, even this study could still be an 
under-estimation. 
On the face of it, the Quint study and others suggest that the prevalence of NCFB 
is rising.[20, 21] This is not necessarily true. Trying to interpret the changing 
prevalence of NCFB is complicated by the increasing use of HRCTs 
demonstrating less severe NCFB, and also revealing NCFB when a different 
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diagnosis was suspected.[30] The increase in imaging was illustrated by an 
estimation that the numbers of computerised tomography (CT) scans in 2014 in 
the USA was approximately 27 times greater than in 1980.[15] The increasing 
awareness of NCFB alongside the increasing use of imaging modalities may be 
increasing the diagnosis of NCFB, rather than the true prevalence rising. 
However, it would seem likely that even if we do not have a true rise in prevalence 
yet, that it is likely in the future. It would be expected that an ageing population 
would have a higher incidence of NCFB. In addition increasing antibiotic 
resistance, and the threat of multi-drug resistant pathogens such as 
Mycobacterium tuberculosis (TB) may lead to an increase in NCFB following 
significant infection.[31, 32] Consequently, NCFB is likely to remain an important 
and relevant condition to understand in the future. 
Aetiology 
Bronchiectasis is a pathological state which is reached in NCFB as a result of 
wide-ranging aetiologies. In the UK the national guidelines set out 
recommendations for investigations to be performed to establish the aetiology of 
bronchiectasis.[6] This is important because there are certain aetiologies where 
identification can influence treatment and prognosis (such as immune 
deficiencies, allergic bronchopulmonary aspergillosis (ABPA), nontuberculous 
mycobacterial pulmonary disease (NTM-PD) and CF). There have been several 
studies over the last two decades describing aetiology.[12, 20, 23, 33-35] When 
assessing these data, there are a couple of points to make. First of all, despite 
being conducted by researchers with a specialist interest, there are a large 
number of patients with a diagnosis of “idiopathic” or the vague “post-infective” 
label. Secondly, there is almost certainly issues with consistency between studies 
with regards to what are considered causative factors, and what are just 
associations.[15] When looking at specific studies, the high representation of 
COPD and Asthma in the study by Quint et al is likely to be due partly to the 
recording of disease in primary care, and is in part a reflection of association 
rather than aetiology.[20] The study by Lonni et al spans seven European 
centres, has large numbers and had aetiology assessed in a rigorous way.[33] 
Consequently, it is probably the most relevant study of aetiology. Despite the 
focused approach, “idiopathic” was the leading aetiology in this study. 
Interestingly COPD was associated with more severe disease. Idiopathic disease 
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was associated with lower severity as was “inflammatory-bowel disease” and 
“aspiration/oesophageal reflux”. 
Like all idiopathic diagnoses in medicine, there is almost certainly a cause which 
has not yet been revealed. It is possible that some of the cases are due to genetic 
predispositions.[36] An interesting outlier with regards to aetiology is the paper 
by McShane et al.[34] In this single centre study in the USA, an aetiological cause 
was identified in over 93% of patients. “Immune dysregulation” was the 
predominant cause with a rate of 63%. This umbrella term included ABPA, 
autoimmune diseases, haematological malignancy, and immune deficiency. It 
may be that better understanding of genetics and immunology will lead to future 
reductions in the numbers labelled with the idiopathic aetiology. 
Disease Burden 
The impact of NCFB on patient health is variable. Work has looked into what 
patients find difficult with regards to their disease. The six issues which were 
found difficult by over 60% of patients were “Sputum”, “Exacerbations”, 
“Tiredness”, “Not feeling fit for daily activity”, “Shortness of breath”, and 
“Cough”.[37] Many patients will experience a baseline level of symptomatology 
punctured by episodes which are referred to as “exacerbations”. Exacerbations 
will be discussed at various points through this thesis so it is worth briefly 
introducing the concept now. Historically there has been no universal definition 
of what an exacerbation is, and indeed some studies include multiple criteria.[38] 
Essentially what is meant by the term is an acute worsening of respiratory 
symptoms relating to their chronic condition. Very recently a consensus 
statement has been published on what an exacerbation is, but it will take a long 
time before a significant amount of clinical research has used this.[39] The 
aetiology of these events is often unknown, though a bacterial driver is often 
blamed, and patients often receive antibiotics for the management of their 
exacerbations. Exacerbations can crudely be described as severe if hospital 
admission and/or intra-venous (IV) antibiotics are administered. However, 
sometimes symptoms may not be severe but a lack of oral options mean IV 
therapy is required. Despite its flaws, the concerns of exacerbations are of great 
importance to both patients and experts.[37] This is exemplified by data showing 
that a rate of more than three exacerbations per year is significantly associated 
with mortality.[40] 
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Some appreciation of exacerbation rates can be gleaned from recent European 
multi-centre data. In a cohort of 1,310 patients, an exacerbation frequency of 1.8-
3 per year and a hospital admission rate over a two year period of 26.6-31.4% 
was described.[40] It should be noted that exclusion criteria for this dataset 
included patients on long-term antibiotic therapy, and patients with active 
malignancy, NTM-PD or Human Immunodeficiency Virus (HIV). It would be 
expected that these patients would have a higher exacerbation rate, and 
consequently the “real-world” exacerbation rates are likely to be higher.  
As well as a symptom burden, there is also a significant finance burden to NCFB. 
Recent estimates of the mean healthcare costs per year in Spain were over 
4,500Euros per patient per year.[41] Australian data suggested a higher 
healthcare burden for individual NCFB patients than those with heart failure or 
diabetes.[42]  
In addition to significant morbidity, NCFB has also been associated with a 
reduced life-expectancy compared to the general population. A UK study 
following a cohort for 13 years reported a mortality rate of almost 30%.[43] In this 
study the survival rate at 4 years was 91% which approximately fits with findings 
from Belgium where survival rates were 89.4% over 41 months.[44] Despite this 
group of patients tending to be elderly with other co-morbidities, respiratory failure 
tends to be a prominent cause of death. Various cohorts have suggested that 
between 50-70% of deaths of patients with NCFB are due to respiratory 
complications.[43, 45, 46] NCFB has a clear burden on patient’s health and 
requires proper directed therapies and research. 
Management 
The principles of management of NCFB are relatively straightforward and Peter 
Cole’s “Vicious Cycle” hypothesis is a good starting point (see Figure 1.2).[47] 
Strategies and treatments should be put in place to break the cycle. By achieving 
this, patients should have a reduction in symptoms and exacerbations, reduction 
in sputum volume and purulence, and improvement in quality of life. An example 
of the consequences of breaking this cycle is that the reduction in exacerbations 
is likely to have an impact on the rate of decline of lung function, and reduced 
lung function is associated with an increased risk of exacerbation.[40, 48] 
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Figure 1.2 Cole’s vicious cycle hypothesis Image taken from Chalmers et al. 
[49] Current therapies are listed alongside each component of the “cycle”. 
 
As would be expected of a chronic suppurative lung disease, the use of antibiotics 
are key to the management of NCFB. Their usage tends to fall into four main 
categories, namely acute oral courses, acute IV courses, prophylactic oral 
antibiotics, and prophylactic nebulised antibiotics. The results of previous 
microbiological investigation will commonly impact the choice of antimicrobial 
agent used. Acute courses for the treatment of exacerbations are often given over 
a longer period than in other lung conditions. The evidence for when to use IV 
antibiotics is limited.[50] The British Thoracic Society (BTS) guidelines suggest 
considering IV usage if a patient is unwell and requires hospital admission, or if 
resistant organisms are not responsive to oral therapies, or if the patient has not 
responded to oral therapy.[6] 
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Prophylactic antibiotics have been an area of increasing interest and research. 
The aim of this therapy is to reduce exacerbation rates and consequently reduce 
further damage to the lung’s structure and function. With regards to oral 
therapies, the macrolides have been prominent with three randomised controlled 
trials (RCTs) in recent years.[38, 51, 52] All three RCTs demonstrated a reduction 
in exacerbation rates, though questions remain about long-term consequences 
and side effects as none of these studies lasted beyond a year. These therapies 
are thought to have anti-inflammatory and immunomodulatory effects in addition 
to antibacterial properties. Promotion of gastric emptying may also have an 
impact if reflux is indeed clinically significant to the lung pathology. However, of 
particular interest and concern, there appears to be an increasing potential for 
antibiotic resistance.[53]  
Several antibiotics have been used in inhaled form such as gentamicin, 
tobramycin, ceftazidime and colistin. Whilst the concept of inhaled antibiotics is 
very appealing, tolerability has often been an issue.[17] Of late, ciprofloxacin has 
been trialled in the inhaled form and hopes remain with regards to its 
potential.[54, 55] 
All patients should be engaged in the practice of chest physiotherapy.[6, 42] The 
aim is to compensate for impaired mucociliary clearance and consequently 
reduce the retention of respiratory secretions and enable the elimination from the 
lung of particles for the maintenance of health. Mechanical devices can be 
included to help the process.[56] A Cochrane review only contained 51 patients 
but did suggest that airway clearance techniques improved expectoration, 
reduced hyperinflation, and improved quality of life scores.[57] A recent small 
RCT has been published since and suggests benefits with regards to 
exacerbations and quality of life measures.[58] Whilst the evidence-base for 
these techniques is weak, they continue to be considered an important part of 
management. Additional therapies have been trialled as adjuncts such as 
mucoactive agents and inhaled saline solutions.[59-62] One highly significant 
study of a mucoactive agent trialled DNase.[13] Despite being an effective 
therapy in CF, a RCT suggested it may be harmful in NCFB. Another aspect of 
care linked to physiotherapy is the undertaking of a pulmonary rehabilitation 
course. This should be offered to patients who have breathlessness affecting their 
daily lives.[6]  
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Others therapies that are used in NCFB are bronchodilators, inhaled 
corticosteroids and anti-inflammatory agents.[63-70] The evidence for these 
therapies is variable and taken from small studies. Surgical interventions, such 
as lung resection in localised disease, are occasionally considered though they 
are not without their risks.[71, 72] Additional basic standards of care include 
pneumococcal and influenza vaccinations, and smoking cessation services being 
offered. Finally, with a significant proportion of NCFB cohorts being elderly, co-
morbidities are to be expected and therefore should be sought and assessed.[73] 
There is clearly scope for improving the armoury available to the managing 
physician. Unsurprisingly, antimicrobial therapies will continue to be at the 
forefront of interest. This will include attempts to utilise old therapies in a more 
effective way (such as inhaled ciprofloxacin), but also the investigation of novel 
agents.[74, 75] Another potential target could be the inflammatory process 
leading to the destructive changes found in NCFB. A single-centre study has 
looked at the use of statins in NCFB with the hope of utilising the anti-
inflammatory effects of this class of drug.[70] Some improvements were noted 
and further studies are awaited. With neutrophilic inflammation so prominent in 
NCFB, this is also viewed as a potential therapeutic target. CXCR2 is a neutrophil 
trafficking receptor and it is hoped that antagonism of this may reduce, but not 
prevent, neutrophil recruitment.[76] The danger of immune system manipulation 
is uncontrolled infection, and consequently achieving the right balance will be 
crucial. 
1.1.2 Cystic Fibrosis 
The other group of patients studied in this work are those with CF. Historically 
this has been a far more studied disease. In our local hospital, they are a smaller 
cohort than those with NCFB and in this piece of work they are also in the 
minority. I shall now describe the condition in order to illustrate its differences 
from NCFB.  
Epidemiology 
Whilst the epidemiology of NCFB is muddled for the host of reasons discussed 
previously, it is a clearer picture in CF, particularly in settings with well-maintained 
registries.[77, 78] As would be expected with a genetic disease, different 
populations can have very different rates. The continents with the highest 
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prevalence are North America, Europe and Australasia, with the occurrence 
seeming to be in those of European descent. Within Europe, there are higher 
rates in the UK and Ireland than in Eastern European and Baltic nations.[79]  
It is commonly quoted that approximately 1 in 25 Caucasians carry a disease 
causing mutation and that 1 in 2,500 live births have CF. Data for the Cystic 
Fibrosis Trust in the UK from 2014 reported 10,583 patients and in the USA 
approximately 28,000 have the condition.[80, 81] My work has taken place in 
Devon, a county in the South-West of England. Approximately 2.3% of the UK 
CF population are living in Devon, and the prevalence in the county is 
approximately 21 per 100,000. Despite having greater public awareness, CF is a 
far rarer disease than NCFB in the UK. Another noticeable difference is the lack 
of female predominance seen in NCFB. 
As would be expected of a life-limiting genetic disease, the age profile of CF 
patients is very different to those with NCFB. New-born screening is now 
common-practice in the UK, and the median age of diagnosis of paediatric 
patients was 26 days in 2015.[82] When the UK population is looked at as a 
whole, the current median age of a CF patient is 19 years of age. 
Aetiology 
Unlike NCFB, the aetiology of CF is relatively well understood. CF is an 
autosomal recessive condition. The disease was 1st named “Cystic Fibrosis” in 
the 1930s by the American pathologist Dorothy Andersen who went on to note its 
autosomal recessive nature in the 1940s.[83, 84] However, it took until the 1980s 
for advances in genomics to identify the relevant gene on the long arm of 
chromosome 7.[85] This is now known as the Cystic Fibrosis Transmembrane 
Conductance Regulator (CFTR) gene. The gene codes for a protein called CFTR 
which enables the transport of chloride ions across the cell membrane, as well 
as other regulatory roles including sodium transport.[86] The dysfunction of CFTR 
may have numerous consequences which contribute to a pathological state 
including hydration status, mucociliary clearance, increased inflammation and 
impaired immunity.[87] CFTR is expressed in many organs including the lungs, 
the liver, the pancreas and the gastro-intestinal tract.  
Since the discovery of the CFTR gene, approximately 2,000 mutations have been 
identified, however only a small minority are confidently considered to be disease-
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causing.[88] CFTR mutations are grouped into 6 classes based on the resulting 
mechanistic abnormality. Classes I, II and III are associated with a more severe 
phenotype and no CFTR function. By far the most commonly identified 
abnormality is the class 2 mutation known as F508del. In the UK 90% have this 
mutation at least once, and 50% are homozygous for it.[82] The next most 
common mutation in the UK is known as G551D and is a Class III, or “gating” 
mutation. As will be explained later on, this genetic information is becoming 
increasingly important in the management of CF.  
Disease Burden 
The clinical impact of CF is variable but often devastating and the disease is 
considered the most severe autosomal recessive disease in Caucasians. Whilst 
it is a multi-organ disease the respiratory system endures the greatest burden in 
patients. Patients will tend to suffer from progressively declining lung function, 
with persistent symptoms of cough, sputum production, shortness of breath and 
chest pain. Periods of relative stability will be interrupted by episodic 
exacerbations.[86] Exacerbations are associated with worse quality of life, 
worsening of lung function, and mortality.[89-91] This may lead to multiple 
courses of oral and IV antibiotics for patients. Registry data suggest that the 
median number days of IV antibiotic usage in the UK for all CF patients is 28 
days.[82] As well as the burden of symptoms and intermittent requirements for 
acute antibiotic courses, patients will often have a long and complex list of time-
consuming daily therapies. 
The UK registry data also gives a clear picture of the non-respiratory based 
morbidities in CF patients. In those over the age of 16 approximately a third have 
CF-related diabetes. Liver disease and gastro-oesophageal reflux are present in 
approximately a fifth of patients. Other notable complications include intestinal 
obstruction, osteopenia/osteoporosis, renal dysfunction, infertility and 
depression.  
The natural disease process leads to a premature death either with or without 
organ transplantation. In the UK the current median predicted survival is 47 
years.[82] Whilst this appears a shockingly young age, it is a remarkable 
improvement on where life expectancy used to be (see Figure 1.3). CF used to 
essentially be a paediatric disease, however in developed areas we are now 
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seeing more adults with the condition than children.[81, 92] The reasons for this 
improvement are multi-factorial but include pancreatic enzyme replacement, 
nutritional input, mucoactive therapies and a better understanding of treatment of 
infection.[92-94] The expectation should be for this trend to continue though there 
is still a long way to go for the life-expectancy to be comparable to those with 
NCFB.  
 
 
Figure 1.3 Life expectancy in cystic fibrosis Image taken from CF Trust 
Website. Relevant advances in management are included in the graph of 
improving life expectancy, as are potential therapies of the future. 
 
Management 
There is clearly some cross-over in the management of NCFB and CF, 
particularly with regards to the management of the pulmonary system. In both 
conditions there is an aim to preserve lung function through physiotherapy based 
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airway clearance techniques, and the management of acute exacerbations and 
chronic airway infection. 
As in NCFB, even though there is a paucity of high-quality evidence, 
physiotherapy techniques to facilitate airway clearance are considered of great 
importance in prominent guidelines.[95] Unlike NCFB, there is good evidence for 
the effectiveness and safety of DNase as an adjunct therapy.[96] Further adjuncts 
with better evidence in CF are hypertonic saline and Mannitol.[97, 98] In the UK 
currently, over half of patients use DNase, approximately a quarter use 
Hypertonic Saline and less than 5% use Mannitol.[82] 
Antimicrobial usage (both antibiotics and antifungals) is the cornerstone of CF 
management. Like NCFB, oral, IV and inhaled antibiotics are used in a variety of 
regimes for the management of exacerbations, chronic prophylaxis and 
attempted eradication of pathogens. Antibiotic administration is highly dependent 
on the pathogens isolated by microbiological techniques. The microbiology of 
these conditions will be discussed in more detail shortly.  
The non-respiratory management of CF is dependent on the disease-related 
complications experienced by the patient. This may include insulin for CF-related 
diabetes, supplemental pancreatic enzymes and lipid soluble vitamins, fertility 
techniques and psychological support.  
Perhaps the most exciting development has been the interest in therapies which 
actual address the CFTR defect. There has long been interest in the actual 
delivery of a cloned CFTR gene to the lung via nebulisation. Whilst hugely 
appealing, optimum delivery and efficacy are yet to be achieved.[99] The most 
striking example so far of addressing the CFTR defect is Ivacaftor, an orally 
administered small molecular therapy. Pre-clinical studies demonstrated that 
Ivacaftor corrected Chloride transport in most class III mutations.[100, 101] 
Subsequent clinical trials have shown impressive effects, particularly in patients 
with the G551D mutation.[102-104]. For the greatest impact on the CF community 
as a whole, therapy which improves CFTR function in those with F508del would 
be the most desirable. Ivacaftor has been used in this group in combination with 
another small molecule therapy (lumacaftor), and whilst benefit has been shown, 
it has not been as impressive.[105, 106] The future of this line of therapy is very 
exciting and has come about through deep understanding of the underlying 
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pathology in CF. Unsurprisingly, in NCFB where there is far greater heterogeneity 
of pathogenesis, there are no equivalents to this route of therapy. 
1.1.3 The Microbiology of the Bronchiectatic Lung 
In the diseases where bronchiectasis is present, and patients suffer recurrent 
symptoms which are believed to be driven by pathogens, an understanding of the 
microbiology would seem to be essential. Consequently sampling of respiratory 
secretions has become common practice in the management of both NCFB and 
CF, and the results of these investigations often dictate subsequent antimicrobial 
management. 
Culture-based techniques have been used since the 1880s to investigate the 
presence of potential pathogens. In these techniques, samples are inoculated 
onto selective media to enable the growth and subsequent identification of 
bacteria and fungi. In the last few years culture-independent techniques have 
been employed in research facilities to investigate the microbiology of the 
bronchiectatic lung, but this has not crossed over to standard clinical practice yet. 
I shall now describe the current knowledge of bacterial pathogens in these 
conditions as revealed in the everyday practice of culture. Insight gleaned from 
culture-independent techniques will be addressed later. 
Non-Cystic Fibrosis Bronchiectasis 
There are now many cohorts whose microbiological status has been described 
from a variety of different settings and countries (see Table 1.1). Some of this 
data comes from cohorts enrolled for drug trials, others from severity score 
derivation studies, and some from unselected observational cohorts.[38, 40, 107]. 
Despite the potential inherent biases to some of these studies, when looking at 
the question of prevalence, it is undeniably clear that Pseudomonas aeruginosa 
(PA) and Haemophilus influenzae (HI) are the predominant pathogens. Many 
other pathogens are cultivated from sampling of NCFB patients and include 
Moraxella catarrhalis (MC), Streptococcus pneumoniae (SPn), Staphylococcus 
aureus (SA), Aspergillus species and Non-tuberculous mycobacteria (NTM). 
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Reference Year Origin N PA HI SA SP MC Myco NP 
[40]a 2014 UK 608 12 29 8 6 10 ND 28 
[44]a 2012 BEL 479 30 31 23 20 15 NR NR 
[107]b 2014 UK 155 49 57 23 33 25 3 6 
[38]c 2012 NZ 141 12 28 3 3 4 NR NR 
[108]d 1995 USA 123 31 30 7 11 2 23 23 
[109]e 2002 THA 50 20 14 NR 6 4 6 36 
 
Table 1.1 Pathogens of non-cystic fibrosis bronchiectasis 
The identification rates of each pathogen are expressed as a percentage. The 
abbreviations for the pathogens are as follows: PA- Pseudomonas aeruginosa, 
HI- Haemophilus influenzae, SA- Staphylococcus aureus, SP- Streptococcus 
pneumoniae, MC- Moraxella catarrhalis, Myco- Mycobacterium. NP- no 
pathogen. ND- not done and NR- Not reported. The studies are from a variety of 
countries. UK- United Kingdom, BEL- Belgium, NZ- New Zealand, USA- United 
States of America and THA-Thailand. The data has been recorded in different 
ways. aColonisation status. bPathogen isolated during median follow-up of 46 
months. cClinical trial cohort. Cross-sectional baseline data. dPathogens 
isolated during retrospective review. eCross-sectional first visit data 
 
Even though HI is frequently reported as the more prevalent pathogen in NCFB, 
PA has received more attention. As shown in Table 1.1, the rates of pathogen 
prevalence vary, and in part depend on whether they are referring to isolation in 
a cross-sectional study, or colonisation. As an aside, the definition of colonisation 
is not consistent, as demonstrated by a meta-analysis identifying 8 different 
definitions between 21 studies.[110] A recent study in the North-East of England 
reported that approximately half of their patients had at least one sample positive 
for PA in a cohort who had a median follow-up of 46 months.[107] However of 
these, only 62% met the defined criteria for colonisation. Whilst it has long been 
acknowledged that there is an association between PA isolation and extensive 
disease in NCFB, it has been debated whether the isolation of PA is a marker or 
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a cause of disease severity. Some studies have suggested it is either not clear, 
or that PA is a marker of disease severity.[111, 112] The cohort from the North-
East of England did show isolation of PA from patients with minimal airflow 
obstruction, though at a much lower rate than in those with more severe 
limitation.[107] Various studies have shown PA’s association with morbidity. 
These have included worse quality of life, worse radiological appearance, worse 
lung function, increased inflammation in the airways, more frequent 
exacerbations and a greater rate of decline in lung function.[44, 48, 111, 113-
115]. A mortality review of a historical cohort suggested that PA had an 
independent effect on mortality and was therefore likely to not just be a marker of 
disease severity.[43] A recent meta-analysis showed a very strong association 
between PA colonisation and mortality with an odds ratio of almost 3.[110] There 
are no studies showing such worrying trends with HI. There is however a 
suggestion that colonisation with recognised pathogens other than PA, is 
associated with increased disease severity.[40] 
It is this author’s belief that PA colonisation is a marker of disease severity, but 
also a contributor to it. Its contribution to disease severity scores clearly illustrate 
it status as a marker of disease. PA has been extensively studied in the in vitro 
setting with many virulence factors, toxin production pathways and mechanisms 
for pathogenicity discovered.[116-119] We also see clinical responses in patients 
who reliably use antipseudomonal therapies.[120] In light of these findings, it 
seems very unlikely that PA is just a marker of disease severity, and not also an 
active aggressor against the lung.  
Cystic Fibrosis 
A good insight into the microbiology of CF can be derived from registry data.[81, 
82] In CF the prevalence of various pathogens varies with age. In the initial years 
HI and SA tend to be the prominent pathogens (see Figure 1.4). In the UK the 
rates of SA are possibly lower than other countries such as the USA (see Figure 
1.5). This difference may well be due to the aggressive anti-staphylococcal 
regimes used in UK paediatric patients.[95] What is consistent across the UK and 
USA data is the rising prevalence of PA with age. In adulthood, PA becomes the 
most prevalent pathogen as assessed by culture techniques.  
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Figure 1.4 CF pathogens in the USA by age. Image taken from the CF 
Foundation Patient Registry Annual Data Report 2015. B. cepacia complex- 
Burkholderia cepacia complex, S. aureus- Staphylococcus aureus, MRSA- 
Methecillin-Resistant Staphylococcus aureus, S. maltophilia- Stenotrophomonas 
maltophilia, MDR-PA- Multi drug resistant Pseudomonas aeruginosa 
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Figure 1.5 CF pathogens in the UK by age. Image taken from the CF Trust’s 
UK CF Registry 2015 Annual Report.  
As in NCFB, PA is not just prevalent but also of high clinical importance. Various 
studies have illustrated its impact on lung function, morbidity and survival.[121-
128]. Whilst its prevalence changes with age, its impact affects all ages. Registry 
data showed that the presence of PA was the greatest predictor of mortality in 
those aged 1-5 years old.[125] Other data showed that the majority of those under 
the age of 7 who were chronically infected had a marked reduction in lung 
function.[122] Another study showed 72.5% of patients had isolated PA within 
their first 3 years of life.[129] A commonly quoted figure for prevalence of PA in 
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adult CF patients is 80%.[130, 131] In the UK this figure is not currently accurate. 
The latest annual report by the CF Trust suggested that just under half of all 
patients over the age of 16 are chronically colonised, whilst a further 15% 
intermittently isolate PA.[82]  
Of possible encouragement, the rates of chronic infection with PA in the UK 
appear to be falling.[82] There are however plenty of other pathogens for the CF 
community to be aware of. There are lower rates in the UK than the USA of the 
NTMs and Methicillin-Resistant Staphylococcus aureus (MRSA), but they still 
provide a degree of disease burden. The Burkholderia cepacia complex (BCC) is 
rarely of clinical significance outside the CF community and is not common within 
it. When present however, it can be associated with poor outcomes, particularly 
in the case of the so called Cepacia syndrome, when a rapidly progressing 
pneumonitis is accompanied by bacteraemia. Other pathogens which are 
receiving increasing interest are the “emerging” non-fermenting gram-negative 
bacilli, which include Stenotrophomonas maltophilia, Achromobacter 
xylosoxidans, Pandorea species and Ralstonia species.[132, 133] 
Potential pathogens in CF are not limited to just bacteria. Viruses are noted as a 
driver of some exacerbations.[134] An example of a potential mechanisms is 
rhinovirus disrupting PA biofilms resulting in freed motile bacteria.[135] Fungi 
such as Aspergillus species have a clear association with a variety of clinical 
syndromes.[136-138] For others such as Exophiala, the significance is less 
clear.[139]  
The prevalence of pathogens will likely evolve as life expectancy changes and 
new therapies develop. Our description and understanding will advance through 
culture-independent sequencing techniques. 
1.2 Pseudomonas aeruginosa 
As has been illustrated above, PA is both highly prominent and clinically 
significant in the bronchiectatic lung, and clearly warrants research attention. PA 
is classified in the Proteobacteria phylum alongside other significant human 
pathogens such as Escherichia coli and Salmonella.[140]. It is a gram-negative 
rod and is part of the Pseudomonadaceae family. It has an adaptable genome of 
5.2-7.1 Mega Base Pairs (Mbps) and is made up of a core genome of 
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approximately 4,000 genes and an accessory genome of approximately 10,000 
genes.[141, 142].  
1.2.1 Niches 
With its high level of adaptability and complexity, PA is present in a large number 
of settings. I shall briefly describe its presence in the environment and the human 
lung. Whilst it is associated with pathology in other parts of the human body, such 
as the urinary tract and the soft tissues of burns victims, this will not be focused 
on here.  
PA in the Environment 
PA is often described as ubiquitous. It is commonly found in soil and water, and 
on the surfaces of hosts ranging from worms to mammals.[143] Further striking 
examples of its adaptability including its survival in fluids ranging from distilled 
water through to jet fuel.[1]  
PA has many characteristics which facilitate its resilience to a wide-variety of 
environments. Whilst its metabolism is respiratory, it can grow in the absence of 
oxygen. It can be found in biofilms on surfaces or as a unicellular organism. In its 
unicellular state it is seen as a vigorous swimmer propelled by a polar flagellum. 
It can survive with minimum nutrition as demonstrated by its presence in distilled 
water. However, it can also use more than 75 organic compounds for 
growth.[144] Whilst it will ideally grow at a normo-thermic human temperature, it 
can grow at temperatures as high as 42°C.[144] As well a temperature tolerance, 
PA can also deal with high concentrations of salts, dyes and antibiotics. 
PA’s resistance to antibiotics is due to a variety of reasons. The permeability 
barrier of it gram-negative outer membrane causes natural resistance to some 
antibiotics. In addition, its resistance has evolved due to its natural environment 
in soil being host to bacilli, Actinomycetes and moulds and their naturally 
occurring antibiotics.[144] 
Through these characterises and others, PA has become a highly successful 
environmental bacteria.[145] 
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Adaptation to the human lung 
The most important PA niche within the limits of this work is the human lung. 
Whilst PA can be present in many lung conditions, it is at its most significant in 
CF and NCFB. 
The human lung inhales a very large quantity of air each day, estimated to be  of 
the magnitude of 10,000 litres per person.[2] This results in frequent and 
repetitive inhalation of micro-organisms including ubiquitous bacteria such as PA. 
Mechanisms are however in place to prevent acute infection and chronic 
colonisation of the lung in health. These include effective mucociliary clearance, 
as well as epithelial cells producing antimicrobial peptides, and macrophages in 
the airways.[146] However these mechanisms can fail if there are structural, 
functional or immunological deficits. This can therefore allow inhaled pathogens 
to persist and multiply, with the outcome of lung damage and chronic infection.  
Experimental models have suggested that depressed mucociliary clearance is 
associated with PA infection.[147] Mucociliary clearance is impaired in CF and 
NCFB. With clearance reduced, PA is likely to initiate a foothold in the lung 
through adhesins such as pili and flagellae. In vitro work suggests that PA 
preferentially adheres to mucus and damaged epithelium, as well as creating 
more local damage.[148-150] PA may then inhibit mucociliary clearance further 
through pyocyanin production.[151] Once PA is established in the lung, multiple 
adaptations are employed to aid long-term colonisation. 
A particularly well-documented adaptation is the formation of a biofilm. This 
protects the bacteria from attack from phagocytes, humoral responses, and 
antibiotics. Despite being under this parapet, PA can still drive significant antigen-
antibody responses that lead to neutrophil recruitment. It may even be the case 
that isolates which do not produce biofilms in vitro can be incorporated in the 
biofilms of those who do produce.[152]  
Interestingly, PA does not seem to maintain colonisation through increased 
virulence, but in fact the opposite.[153, 154] This includes a switch to a non-
flagellated, non-motile phenotype and downregulation of quorum sensing (an 
inter-organism signalling system).[155-157] This tactic may be of benefit due to 
a reduced energy cost and reduced detection by the host. 
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Another important adaptation to highlight is a change to a hypermutable 
state.[158] Hypermutators occur when there is a defect in DNA repair leading to 
increased mutation, of which some may have a benefit to the bacteria. There are 
suggestions that the chronic state of a condition like CF drives hypermutation 
more than an acute environment.[159, 160] Hypermutators are considered an 
important factor in antimicrobial resistance and are common in CF with possible 
rates of approximately 40%.[159, 161]  
When considering adaptation to the human lung, it should be remembered that 
more research has been done in CF patients than NCFB patients. It is possible 
that there are specific factors in the CF airway which enhance PA colonisation. 
This could include dehydration of the airway surface and possible receptors of 
PA on the membranes of epithelial cells.[162, 163]. Others factors may be less 
unique to CF and include hypoxic niches in mucus plaques.[164] 
The complex process of adaptation is highly successful in those with NCFB and 
CF as demonstrated by high prevalence rates in these conditions. This is despite 
CF and NCFB guidelines advocating aggressive attempts at eradication of early 
PA.[6, 95] Regimes vary but can include prolonged usage of a combination of 
oral, IV and inhaled antibiotics.[165-167] If this fails, patients will often be put onto 
long-term anti-pseudomonal therapy. This is with the aspiration of managing 
chronic infection, and no longer of eradicating it. This approach will often involve 
inhaled antibiotics such as tobramycin or colistin.[120, 168-170]  
1.2.2 Acquisition 
With these disease processes being so impacted by PA, it is logical for there to 
be a desire to understand how it is acquired. With its status as a ubiquitous 
pathogen it was long assumed that the environment was where patients acquired 
their strain from. As investigation into this has advanced, it has been suggested 
that patient-to-patient transmission is also a possible route. 
I will now discuss these two sources of acquisition. 
Environmental 
PA’s ubiquity clearly make the environment a highly plausible source of 
acquisition. This is further backed up by data which suggest that the local 
environment influences acquisition. The majority of the relevant research has 
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been into the CF population. Interestingly it has seemed rare for patients to 
initially acquire PA from their own home.[171] However, it is very likely that a 
patient can colonise the home environment including everyday high-use objects 
such as a toothbrush.[172] This type of on-going reservoir is then a potential 
threat to successful eradication. The environment outside the home seems to be 
significant to acquisition risk, and the presence of water is a regular theme. An 
Australian study suggested an increased risk of first PA acquisition in non-city 
dwellers, with sprinkler use seemingly being associated with acquisition.[173] In 
a Belgium study, the proximity that a patient lived to a large body of water was 
associated with PA infection in a case-control study.[174] Water’s capacity for 
containing a huge collection of strains has been illustrated by the presence of 
almost the entire global diversity of PA in a Belgium river.[175] Other associations 
which have been made with PA acquisition and the environment include warmer 
ambient temperature, dew point, longitude, latitude and elevation.[176, 177] 
Patient-to-Patient Transmission 
Whilst it is would seem difficult to prevent acquisition from the environment, it may 
be an expectation for cross-infection between patients not to be a significant 
issue. It has however become clear that cross-infection occurs and can be of 
great clinical significance.  
In general it is felt that human-to-human transfer of respiratory pathogens takes 
place by contact transmission (direct and indirect), droplet transmission and 
airborne transmission.[178, 179] A pertinent point of note with regards to contact 
transmission is that PA can survive in dried sputum for at least a week.[180] An 
unusual example of indirect contact which was recently described was via aroma-
therapy oils used by different patients on an Intensive Care Unit.[181] Droplet 
transmission generally refers to particles greater than 5 µm in size which do not 
remain airborne, while droplet nuclei are smaller than 5 µm and can be 
inhaled.[182]  
Cross-infection via the airborne route with droplet nuclei is of particular concern. 
Knibbs et al demonstrated that cough aerosols containing viable PA could travel 
at least 4 metres and be detected at a 45 minute time period.[178] This 45 minute 
time period was consistent with a previous aerobiological model of viable 
PA.[183] An older study found evidence of a transmissible strain via air sampling 
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1-3 hours after patients left their ward room. This study also found the same strain 
when sampling ward corridors, as well as spirometry tubing and chairs after use 
by colonised patients.[184] It is possible that survival in aerosols may be 
enhanced in strains expressing a mucoid phenotype- a common finding in chronic 
CF strains.[183] 
It used to be common practice for patients to mix at CF holiday camps. Whilst not 
a universal finding, several studies suggested that the sharing of pathogens, 
including PA, was occurring at these camps.[185-188] There were studies 
advocating the continuation of holiday camps as they felt the benefits outweighed 
the risks, however the overall body of work led to the cessation of these 
camps.[189] Person-to-person transmission was also suspected between 
siblings and also the participants of CF fundraising events.[185, 190, 191]  
It had been hoped that cross-infection was limited to settings of particularly high 
personal contact, and that the hospital setting would not be of concern. 
Unfortunately, CF units were also appearing to be a site of transmission.[192, 
193] Not only were patients seemingly acquiring the pathogen from other 
patients, but it appeared in many cases to be associated with clinically significant 
deterioration, increased resistance and virulence, and increased use of health-
care resources.[194-199] However, it should also be noted that not all 
transmissible strains have clinically significant impacts.[200] A further 
counterpoint to note is that the risk of cross-infection can be low, particularly in 
small centres.[201-203] 
The above findings have contributed to the varied practice of segregation in CF 
cohorts.[95, 179] These policies may include complete segregation or specific 
clinics for patients with specific strains or pathogens. Before these practices there 
was a strong argument that shared strains were merely a consequence of 
common source acquisition rather than cross-infection. However, changes in 
hospital policy with regards to hygiene and segregation have shown significant 
effects, and hence strengthened the case for cross-infection over common-
source acquisition. The demonstrated benefits of these policies have included 
delayed chronic infection with PA, stopping the spread of a common strain, and 
reduced prevalence of a transmissible strain.[200, 204-206]. It appears that just 
implementing measures against contact and droplet transmission does not halt 
the spread of transmissible strains without strict segregation.[207, 208] This adds 
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weight to the concerns of transmission with droplet nuclei being a major factor. 
Beyond PA, there is also evidence of epidemic strains of BCC, MRSA, 
Mycobacterium abscessus, Stenotrophomonas maltophilia, Achromobacter 
xylosoxidans, Ralstonia, Cupriavidus and Pandoraea.[179] 
There has been less research into NCFB patients, but they are not protected from 
transmissible strains. A case in Australia demonstrated the transmission of a 
multi-drug resistant strain of PA to a 14 year old after sharing facilities with CF 
patients over several in-patient admissions.[209] Work looking specifically at 
NCFB-to-NCFB transmission is very limited. Pujana et al looked at 16 patients 
and concluded that cross-infection or common-source acquisition did not appear 
to have occurred.[210] The largest piece of work looking at this took place in the 
North-East of England on a site where CF patients did not attend for health-care 
provision.[131] The study included 40 patients with NCFB, of whom 36 were seen 
in a specific bronchiectasis clinic. The authors felt that there was probably one 
case of cross-infection. They did question if they would have obtained the same 
results if they were on a site which also cared for CF patients. A recent whole 
genome sequencing (WGS) epidemiological study of PA in NCFB showed closely 
related isolates, which highlighted the possibility of cross-infection.[211] A 
publication by a large European Network listed the issue of cross-infection and 
segregation as a research priority in NCFB.[37] 
Cross-infection will continue to be a concern in these two lung diseases. Whilst 
CF patients look set to continue with segregation, there is at present no apparent 
appetite to segregate patients with NCFB. The evidence in this cohort is limited 
and needs re-visiting in settings where both cohort groups share site facilities. 
1.2.3 Epidemiology 
The development of various molecular techniques has allowed more in-depth 
analysis rather than simply identifying a bacteria’s species, or describing its 
phenotype and antibiogram. This has facilitated the identification of strains of PA. 
Techniques have suggested that on a global scale PA essentially has a non-
clonal population structure but with the presence of a few highly successful 
clones.[212-215] This has not been an entirely universal finding and others have 
suggested that PA has a clonal population.[216] When trying to understand the 
true population structure it is difficult to know if the actual population has been 
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accurately represented in sampling. Understandably the investigation of clinical 
samples is likely to be disproportionately high due to interest and accessibility, 
but diversity is probably different in different niches. For example, there may be 
more diversity in the general environment and less in CF, COPD and acute 
infection.[217] A reasonable expectation would be that different clones have 
different capacities to infect humans. 
The different strains of PA have become a major area of research interest. As 
discussed previously, this may be in relation to cross-infection but also with 
regards to virulence, pathogenesis, and resistance patterns. Whilst techniques 
such as Multilocus Sequencing Typing (MLST) have recorded over 2,000 strains, 
there is a narrow range of strains which have received the most attention.[213] I 
shall now review some of these. 
Common Strains 
As described above, there are some strains which appear to be more abundant 
than others. This is important when considering cross-infection. The mere 
presence of shared strains in a population may not mean that cross-infection has 
taken place, as a high prevalence of the strain in the local environment could 
suggest that independent acquisition has occurred. Two examples of common 
strains are Clone C and PA14, which are claimed to be the most common 
worldwide clones.[214, 217, 218] Clone C and PA14 have been described in a 
wide range of environments including salt and fresh water, domestic and wild 
animals, plants, and acute and chronic human infection.[145, 219, 220] 
With recombination believed to be common in PA, it may be expected that strains 
could be relatively transient. Clone C was described over 20 years ago in a 
German study however, and is still frequently found.[218] In this initial study, 
isolates were investigated from a variety of sources including CF patients, non-
CF clinical isolates, isolates from a CF clinic environment and from distant aquatic 
environments. Clone C was found across the various settings including 
approximately a quarter of a CF cohort, and a fifth of the local CF unit 
environment, and an unrelated aquatic environment 300-400KM away. The strain 
had also been reported in an ear infection in another German city. An 
interpretation of this study was that the high prevalence of this strain in clinical 
samples was due to its high background rate. The lead author of this initial work 
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published further epidemiological work, reporting Clone C in the UK from urine 
and peritoneal fluid.[221] It has also been reported in the literature from North 
America to Australasia.[145, 222]. In the UK estimates of its prevalence in the 
clinical setting are in the range of 2-6% based on CF, NCFB and all-source 
studies.[131, 223, 224]   
Transmissible Strains 
As discussed above, there are multiple studies suggesting cross-infection in CF 
populations. This has brought about the concept of the “transmissible strain”. The 
list of widely acknowledged transmissible strains is limited. This may be in part 
due to a genuinely low number, but also difficulties in convincingly proving 
transmissibility. There will be a very large number of populations who have not 
undergone extensive epidemiological study, and even in those who have, the 
presence of shared strains may be due to common-source or independent 
acquisition of a highly-abundant background clone. 
An early suggestion of a transmissible strain originated in Denmark.[193] At this 
point in time the techniques for strain identification were weak and the Danish 
study was based on antibiograms. They implemented an isolation policy, which 
was claimed to stop the epidemic strain. Subsequently the availability of 
molecular techniques allowed the more convincing reporting of other putative 
transmissible strains including the Liverpool Epidemic Strain (LES). In a single 
paediatric CF unit in Liverpool, 55 patients were shown to have the same strain 
as defined by Pulse Field Gel Electrophoresis (PFGE) and flagellin 
phenotyping.[192] Subsequent review of the adult unit revealed the presence of 
the strain in almost 80% of patients who were positive for PA.[225] Whilst there 
is no clear evidence of the presence or absence of LES in the environment, the 
significant rates in these populations and the lack of evidence for an alternative 
source, strongly supported LES as a truly transmissible strain. This was further 
supported by segregation policies having a marked effect on the prevalence of 
LES.[205] Whilst clearly present in Liverpool, LES has also been found in multiple 
other CF centres, both in the UK and internationally. A UK survey of CF isolates 
in 2004 found LES in almost half the centres involved in England and Wales and 
an estimated overall prevalence of 11%.[224] Canada is another country with a 
notable presence.[194]  
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Whilst the principle to avoid chronic colonisation of PA is a firmly held one, the 
importance of transmissible strains are in part dependent on their clinical 
significance and pathogenicity. LES’s significance has been clearly 
demonstrated. LES has been shown to cause superinfection in those already 
colonised by other strains, to be associated with increased morbidity, to have a 
significant impact on 3 year survival; and to be associated with renal failure and 
empyema.[194, 196, 226-228] It also appears to have enhanced airborne 
survival.[184]  
There has been evidence for other transmissible strains in the UK. In the 
previously mentioned 2004 survey, after LES, the second most common 
genotype was referred to as Midlands1. This was present in 10% of patients and 
29% of centres. When considering its high rate it should be noted that the 
Midlands as a region was a very large contributor to this survey. One centre found 
rates of 30%, though despite its marked prevalence, it has not been as heavily 
researched or shown to be as pathologically significant as LES. Whilst likely to 
be a transmissible strain, the evidence is not nearly as convincing as for LES. 
The other UK transmissible strain of note is the Manchester Epidemic Strain 
(MES). This was first reported in 2001 when 14% of patients were found to share 
a novel strain by PFGE.[229] The evidence for this being a transmissible strain is 
very convincing. The cohort who were studied contained three different patient 
groups who did not come into contact with each other: namely a group of patients 
with CF and PA, a group with CF and BCC and PA, and a group with PA but not 
CF. MES was not present in either of the last two groups. In addition to this, its 
spread was controlled by a strict segregation policy.[207] With regards to clinical 
impact, MES has been shown to be highly-resistant to anti-pseudomonal 
therapies and has been associated with a greater use of healthcare resources 
and antibiotics.[198, 229] 
Outside of the UK other strains have been claimed to be transmissible including 
AES-1, AES-2 and AES-3 from Australia.[222] Of significance AES-1 has been 
associated with greater treatment requirements than unique strains; AES-1 and 
AES-2 with IV antibiotic usage; and AES-3 with exacerbations requiring 
hospitalisation.[222, 230, 231] In Europe claims have been made with regards to 
transmissible strains in Holland, Denmark and Norway.[232] North American 
work had shown LES to be present in Canada and also another potential 
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transmissible strain, termed Strain B.[194] A further putative transmissible strain 
described in Canada is the Prairie Epidemic Strain (PES).[233] Its association 
with increased morbidity and mortality has recently been shown.[234] Another 
suggested transmissible strain in North America was Houston-1.[235] This strain 
was associated with recent hospitalisation, and transmission was halted following 
adoption of infection control guidelines.  
At this point in time, there has not been a clear explanation of what makes some 
strains transmissible and others not. It may be that there are many currently 
unidentified transmissible strains. There may be some which have been 
described as transmissible, but may not be as transmissible as others. 
Conceivably all strains could be transmissible some of the time with specific 
exposures and conditions, but that some are more transmissible than others. 
Either way, in some circumstances patient-to-patient transmission is clearly a risk 
to patient’s long-term health and prognosis. Consequently, avoidance is highly 
desirable. 
High Risk Clones 
The concept of high risk clones has been promoted in recent years.[236-238] 
These are commonly referred to in the context of significant antibiotic resistance. 
Examples of these include clones producing metallo-beta-lactamases. High risk 
clones have been reported globally and include the MLST described Sequence 
Types (STs) 111, 175, 233, 235, 277, 357, 654, and 773.[239-242]  
Epidemiology in the South West of England 
The work described in the investigative chapters of this thesis was performed on 
isolates obtained from the Royal Devon & Exeter Hospital (RD&E) in Exeter. 
Exeter is the smaller of the two cities in the county of Devon and is situated in 
South West of England. Historical data of which strains are prominent in the local 
area is limited. The 2004 survey of PA in CF did however give a breakdown of 
the prevalence of LES, MES, Clone C and Midlands1 by hospital.[224] The 
hospitals were not described by name in the publication, but three centres in the 
South West were listed as contributing 57 isolates. The rates for LES were 18%, 
and 2% for Clone C. Midlands1 and MES were not found.   
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1.2.4 Genotyping Techniques 
Techniques exist which define different examples of the same species. These 
various techniques are of great importance for the understanding of bacteria, their 
function, their impact and their epidemiology. In settings where cross-infection or 
the source of infection is deemed of interest and importance, these techniques 
are crucial.  
A concept often described when considering these issues is that of a “strain”. 
Whilst it is a commonly used word, it is actually a little ambiguous. A strain can 
be defined as a different genetic variant of a species. Due to this, it suggests that 
knowledge and assessment of the genome is required to differentiate strains. 
However, early descriptions were based heavily on phenotypic traits.[180] As 
molecular microbiology has advanced, the sophistication of techniques to 
differentiate between different examples of the same species has markedly 
changed. It could be said the technique of WGS is the ultimate strain typing 
technique due to it unparalleled resolution, however differentiating strains on the 
basis of a small and potentially irrelevant part of the genome is of little practical 
use. It may be best to refer to the techniques as “typing techniques” or 
“genotyping” rather than “strain typing”. Another concept or description used is 
that of lineage, or clonal complexes. This is when a collection of isolates can be 
clustered together due to their alikeness with the inference of a recent common 
ancestor. The concept of “strains” in relation to real-world application is perhaps 
best summarised as those with a similar genetic core who behave, or are able to 
behave, in a predictable way to various environments and pressures.    
There have been many techniques used to differentiate genotypes. Since the 
utilisation of extracted Deoxyribonucleic acid (DNA) for these purposes, these 
techniques can largely be divided into Molecular Fingerprinting and Sequencing 
techniques. In these techniques, DNA tends to be extracted following cultivation 
of the bacteria in the laboratory, and subsequent picking of a colony. One 
potential issue with this is that the results of a single colony may not be 
representative of the sample overall, and may lead to the under-reporting of 
important strains. 
In this thesis three techniques have been used and they will now be focused on 
within their categories. 
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Molecular Fingerprinting 
Molecular fingerprinting techniques involve the utilisation of template DNA to 
produce a visual pattern where different examples of a species can be 
differentiated. Examples of these techniques include PFGE, Random Amplified 
Polymorphic DNA (RAPD), and Polymerase Chain Reaction (PCR) based Open 
Read Frame Typing.[243-245] They often involved a PCR step followed by 
separation of products via gel electrophoresis. The resulting pattern can then be 
interpreted either by eye or with assistance of computer software. The 
fingerprinting technique used in this work has been RAPD. 
Random Amplified Polymorphic DNA (RAPD) 
RAPD has been used to genotype a variety of bacteria including PA for over 20 
years.[246-248] It works by using short arbitrarily chosen primers for PCR with 
the aim of producing a “strain” specific pattern. Isolates with similar patterns are 
considered highly likely to be the same strain. RAPD has been a prominent 
method in PA genotyping studies and it has been a key technique in the study of 
CF cohorts, burns units, and comparisons between water supplies and patient 
genotypes.[189, 195, 203, 249, 250] It is appealing due to being able to cheaply 
and quickly discriminate between isolates. 
As with any technique, initial comparisons with established techniques are 
required, and subsequently again with novel ones. Early on, RAPD illustrated it 
usefulness by showing greater discriminatory potential than traditional serotyping 
schemes.[251] PFGE has been considered a gold-standard of genotyping, and 
some early work suggested that RAPD could be as discriminatory.[244, 247] 
These were however in small and selected cohorts. The most recent useful study 
comparing molecular techniques which included RAPD was published by Waters 
et al in 2012.[252] The study was blinded and multi-centred. RAPD, MLST and 
PFGE were compared. A potentially significant design factor in the outcome of 
this study was that an isolate was described as clonal if there was agreement 
between at least two methods. As the study showed a greater congruence 
between PFGE and MLST (though overall this was relatively poor), there was a 
bias against RAPD. Even considering this bias, RAPD did appear to be inferior in 
all of the tested criteria in comparison to MLST and PFGE.  
Additional limitations of RAPD should be highlighted. A major weakness of the 
technique is its lack of portability. Output between laboratories cannot reliably be 
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compared as very subtle differences can change the results. This includes which 
batch of enzymes are used and the source of the primers; and heat-transfer 
issues such as the thickness of the PCR tube, and the make and age of the 
thermocycler.[253] Even within the same laboratory there may be a lack of 
reproducibility by factors such as the ambient temperature that day. A further 
potential source of difference may be the hand that the pipette is in. It has been 
demonstrated that the duration the pipette tip is immersed can impact 
reproducibility due to errors when very small quantities are being used. 
Consequently an experienced technician may get a different output to a 
ponderous novice despite all other conditions being equal.[253]  
Once RAPD has been performed there is still potential for differences in 
interpretation. With human visualisation there will clearly be a degree of variability 
in interpretation. As the number of isolates increases, so does the distance over 
which comparisons are made, and consequently the accuracy may wane. Other 
discrepancies occur when considering what a sufficiently different pattern is. In 
some cases the total number of bands will be taken into consideration when 
assessing “unique” patterns, or alternatively the presence or absence of a certain 
number of bands. This may vary depending on the question asked.  For example, 
if you were looking to screen isolates to take forward for a confirmatory second 
technique, you may choose a different cut-off to if it is your only technique. 
Despite these limitations, and the development of more sophisticated techniques, 
RAPD continues to have value in the correct setting and it is recognised by the 
CF Foundation as an appropriate genotyping method in CF cohorts.[179] We 
believe it has value as a cheap first-line screening technique when examining a 
large number of samples. This can then allow more targeted use of more 
sophisticated techniques. To minimise its limitations it ideally should be 
performed in a single run with the same vials of reagents and the same scientist. 
When the number of samples analysed creates such a distance between 
products on a gel that uncertainty occurs, computer analysis should be 
incorporated.  
Sequencing 
The use of sequencing technology to determine genetic differences within a 
species is a logical step in genotyping particularly as its cost decreases, and 
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quality and availability increase. There are a variety of ways that sequencing is 
used, and this ranges from the sequencing of specific regions or genes, through 
to sequencing the entire genome. In this thesis the two examples we have used 
are MLST and WGS, which I shall now describe. 
Mulitlocus Sequence Typing (MLST) 
MLST was first described for Neisseria at the end of the 20th Century and was an 
advancement on the concepts of Multilocus Enzyme Electrophoresis.[254] The 
scheme was subsequently adapted for PA and the most commonly used version 
was published in 2004.[213] 
MLST contains two main steps: the amplification of housekeeper genes by PCR 
and subsequently the sequencing of the products. In the scheme for PA, seven 
loci were selected. The selection of these seven were based on biological role, 
size, location, suitability of primer design, and sequence diversity.[213] The 
sequencing data is used to assign novel alleles within each locus an arbitrary and 
unique number. The combination of the allocated numbers is then used to create 
an ST. For examples the allele combination of 1,1,1,1,1,1,1 is defined as ST-1. 
With this output a database has been created where scientists can submit and 
compare their “Sequence Types” (STs) with a global population. An alternative 
way to analyse MLST data is by a nucleotide based interpretation of 
concatenated data. Whilst this may be more accurate, it is less accessible and 
more complex to perform and report.  
With other typing techniques preceding MLST, work was obviously required to 
compare this to established techniques. At the point of the introduction of MLST, 
PFGE was considered the gold-standard technique. Various studies have shown 
a variety of outcomes on this matter. There is some evidence that PFGE may be 
more discriminatory for detecting genetic differences, whilst MLST is better at 
detecting genetic relatedness.[252, 255, 256] It is worth noting that MLST 
exclusively interrogates well-preserved genes which is not the case in PFGE 
where a genome-wide interrogation takes place. With PFGE a single mutation 
can cause significant profile changes.[257] Therefore in strains with significant 
instability of the accessory genome, the discriminatory power of PFGE can fail to 
identify isolates with a common core genome. There have been occasional 
descriptions of a change in MLST type despite a consistent PFGE profile, though 
this is rare.[258, 259] It could be argued that PFGE is more suited to situations 
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where there is no time for mutations to influence output, such as a real-time 
outbreak, whilst MLST is more suited to a longer study duration. Issues with 
previous typing techniques including PFGE, revolved around the reproducibility 
between laboratories and the comparison of outputs globally. The unambiguous 
MLST scheme and an easy to negotiate database has helped to address this. 
However, it is worth remembering that the genome of PA is in the range of 5.2-
7.1 Mbp, and the MLST scheme for PA only interrogates regions totalling 2882 
base pairs (bp)[260]. Consequently there may be a gene of particular interest to 
an investigator, such as those responsible for specific virulence factors, which is 
not examined.  
For MLST to be a strong longitudinal technique, the so-called housekeeper genes 
(acsA, aroE, guaA, mutL, nuoD, ppsA and trpE) need to be stable. Molecular 
clock speed calculations have suggested that this is the case, though there have 
been concerns in other studies about the stability of the mutL allele.[258, 261]. 
Other limitations of the scheme include its cost in certain environments. Others 
have suggested the time consuming nature of the technique to be a drawback, 
and alternatives and variations have been tried to combat this.[262-264] 
Despite some of the weaknesses described above, the portability and lack of 
ambiguity of this technique has been valuable. 
Whole Genome Sequencing (WGS) 
Whilst techniques such as MLST have their undoubtable use, there can be 
circumstances requiring greater resolution. This may be when considering 
transmission pathways or interrogating the bacteria for genes associated with 
virulence or resistance. WGS provides this greater resolution by sequencing the 
entire genome. Whilst it is a relatively new tool with regards to cross-infection, it 
has already shown its real-world ability to enhance the understanding of 
outbreaks and the evolution of strains.[265-267]. It is a realistic expectation that 
WGS will be a very useful tool for both transmission studies and antibiotic 
susceptibility testing, with Mycobacterium tuberculosis a potential exemplar 
pathogen.[268] 
Despite the obvious appeal of WGS, there are downsides which must be 
considered. The cost of WGS is continuing to decrease but is clearly more 
expensive than the preceding techniques. The output is vast and a large amount 
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of the information gleaned may be of no interest or even if it is, may well not be 
fully understood. When considering episodes of cross-infection, the technique 
can give ambiguity. In cases where there is essentially no difference between 
isolates, or a very large difference, then the chances of cross-infection can 
become much easier to assess. In-between these scenarios, it is less clear. 
Single Nucleotide Polymorphisms (SNPs) are often used as a value to compare 
samples. Approximations of mutation rates may allow interpretation of whether a 
difference of SNPs is likely to be significant over a period of time.[266, 267]. 
However, we know that clinical isolates of PA can acquire a hypermutator status 
and this can have a dramatic impact on mutation rates.[269] Consequently 
interpretation in the presence of hypermutators is far from straightforward, and 
has not been adequately addressed in cross-infection studies so far. 
1.3 Pseudomonas aeruginosa and the Wider Bacterial Community 
A large amount of the research into PA has been conducted in the in vitro 
environment. It is also often done with PA being the sole focus. Whilst there is a 
logic to this, we live in a polymicrobial world where bacteria are constantly coming 
into contact with each other. It would therefore seem sensible that when 
considering real-world scenarios, PA is not looked at merely in isolation, but in 
the context of the other bacteria which may be present in the lung. Examples of 
why this may be important include the seemingly antagonistic relationship 
between PA and HI; the potential of PA to thrive off Streptococcus anginosus; 
and the possible synergy between PA and Stenotrophomonas maltophilia.[270-
273] Consequently, this thesis will contain work into the wider bacterial 
community in the lung, including PA’s place within it. 
1.3.1 Culture-independent Techniques 
The microbiological assessments which has been described so far in this thesis 
have been based on culture-based techniques. Culture-based techniques have 
been used for over a century and remain the process used in everyday clinical 
care. These techniques have been refined and adapted to provide information on 
a specific clinical question: is there evidence of a pathogen which is a potential 
cause of the patient’s current illness? Consequently, in different clinical 
scenarios, different protocols will be used to increase the chances of finding a 
pathogen which is believed to be clinically-relevant. Extended and adapted 
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culture protocols which can yield obligate anaerobes are not routinely performed, 
but are possible and an excellent example of how protocol can influence 
outcome.[274, 275] An inherent bias of this is that our knowledge of putative 
pathogens is based on what has previously been cultured and therefore bacteria 
which are difficult to cultivate in a laboratory are likely to be less well understood 
in a disease process. Despite this limitation, traditional culture has remained 
useful. What it has not been optimised for, and unsurprisingly is not very useful 
for, is describing a bacterial community. For understanding of this specific area, 
culture-independent techniques are required.  
Culture-independent techniques typically use extracted DNA as a template to 
reveal community diversity and, potentially, composition. They are theoretically 
providing unbiased insight into what is actually there, rather than what grows in a 
biased artificial laboratory environment. However, culture-independent 
techniques do have some caveats, and these can be before the technique even 
begins.  
In respiratory medicine, the samples which are used for microbiological 
investigation are predominantly sputum samples or samples obtained via 
bronchoscopy. In both these scenarios, between the sample originating in the 
lungs and it’s containment in a sample pot, it must pass through the upper 
respiratory tract, either directly or via a bronchoscope. It is consequently 
susceptible to contamination by the upper respiratory tract. Despite this risk, 
various studies have suggested that this does not seem to impact results 
significantly.[276, 277] This may in part be due to aspiration from the oropharynx 
being a significant contributor to the bacterial community in the lung. A further 
issue with the sample itself is that it may only be representative of a small area 
of the lung, and a sample from a different region may give a different result.[278] 
These caveats are also factors when interpreting data from culture results.  
Once the sample has been adequately stored, the next key step is the extraction 
of DNA. This stage can also impact the output of these techniques. Bacteria differ 
with the ease with which DNA can be extracted and different approaches may 
influence the success of DNA extraction. Examples of this include gram-positive 
bacteria such as SA, from which DNA may be difficult to extract.[279, 280] Steps 
such as mechanical disruption of the cell wall are included in some but not all 
protocols to try and mitigate for this.[281] A further concern, particularly with low 
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biomass samples, is that DNA extraction kits can be an unpredictable source of 
contamination.[282] A “sterile” kit will not contain viable bacteria but may have 
the presence of dead bacteria from which DNA can be extracted. This is a 
reminder of a further limitation: culture-independent techniques may not be 
reflecting which bacteria are actually living in the lung, but what has been there. 
This may still give a useful signal clinically. For example, the presence of a large 
amount of PA may reflect a moderate amount of viable PA and impaired airway 
clearance resulting in the retention of non-viable cells. Methods have been 
employed to differentiate DNA from viable and non-viable sources, however 
these are not routinely incorporated in clinical studies.[283] 
At present culture-independent techniques are not used in everyday healthcare 
systems like the National Health Service (NHS). Whilst there are technical and 
financial reasons for this at the moment, there is also a deficit in understanding 
how to utilise these techniques and what their outputs actually mean for patient- 
care. When considering these techniques, like the previously described 
genotyping techniques, they can be divided into community fingerprinting and 
sequencing techniques. I shall now describe these in more detail with specific 
attention to the one example of each that I have used. 
Community Fingerprinting 
These are the original techniques which provided some insight into bacterial 
communities. They tend to involve a PCR step which amplifies a discriminatory 
genomic region, and then visualising the products via electrophoresis. Examples 
of community fingerprinting techniques include Denaturing Gradient Gel 
Electrophoresis (DGGE), Terminal Restriction Fragment Length Polymorphism 
(T-RFLP) and Ribosomal Intergenic Spacer analysis (RISA).[133, 284, 285] 
These techniques have the universal appeal of being relative quick, cheap and 
simple in comparison to sequencing techniques. These advantages predictably 
come with limitations. The techniques give a visual overview of the community 
structure but do not provide actual taxonomic identification. Taxonomy can be 
speculated based on the output, which could direct subsequent 
investigation.[133] They also have reduced sensitivity to low abundance 
species.[285, 286] Ecological communities can however be dominated by 
relatively few bacteria, and hence despite this underestimation of richness, these 
techniques can still differentiate communities.[287] 
62 
 
In this body of work, one community fingerprinting technique has been used- 
RISA. I shall now describe this in more detail. 
Ribosomal Intergenic Spacer Analysis (RISA) 
The RISA technique involves the interrogation of a specific region between two 
genes: the 16S rRNA gene and the 23S rRNA gene. The principle of the 
technique is that this intergenic region is variable in length between different 
species. Following a PCR step to amplify this region, the PCR products from 
different bacteria are separated on an electrophoresis gel providing a complex 
band pattern for visualisation. As with the RAPD technique previously described, 
computer software can be used to analyse the PCR products more accurately 
and consistently.[133] 
Its background has historically been in complex environmental samples and 
some evidence suggests the technique has greater accuracy than T-RFLP.[288-
291] It has also been used in mammalian work with the suggestion of reasonable 
concordance with more sophisticated sequencing data.[292] RISA has not been 
used much in Respiratory research and when it has been, it has exclusively been 
in CF cohorts.[133, 270, 293, 294] All of these studies have suggested potential 
usefulness in clinical practice.  
Like other fingerprinting techniques, there appears to be a reduced sensitivity to 
all species. A further potential issue is that the bands of different species may be 
close together and inaccuracies in observing the output may impact the 
observations. At present there have been no investigations into the utility of RISA 
in NCFB. 
Sequencing 
As described already, sequencing techniques are potentially very powerful tools. 
As well as being of use when investigating a single species, they can also be 
applied to complex microbial communities. A metagenomic approach can be 
taken with shotgun sequencing where all the genes are sequenced to give an 
appreciation of the capability of a community. An alternative, and currently a more 
frequent approach, is the cataloguing of species present by 16S rRNA 
sequencing. This is the approach used in this body of work and will be described 
in more detail below.  
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These techniques have the same problems as the fingerprinting techniques with 
regards to the template obtained to work with. They are also subject to 
sequencing errors and considerably more cost that the fingerprinting techniques 
despite recent reductions.[270] Following the sequencing, considerable 
bioinformatic input is then required. 
16S rRNA Sequencing 
16S ribosomal RNA is a part of the 30S subunit. The gene which codes for it, the 
16S rRNA gene, has been interrogated since the late 1970s for the purposes of 
identification.[295, 296] Initially it was met with significant scepticism, but is now 
widely used and accepted.[297] The reason that this technique works is that the 
16S rRNA gene is conserved across bacterial species; is not present in non-
bacterial species; and has nine hypervariable regions. Consequently it allows 
both the detection of bacteria and phylogenetic identity. It has an impressive 
ability to detect very low levels of abundance. For example it may pick up 
abundance levels of 0.01%, whilst in contrast fingerprinting techniques may just 
pick up 1%.[286]  
However, the technique is not perfect. The usual grouping of bacteria is based 
on a certain level of sequence identity (normally greater than 97%). The 
groupings are referred to as Operational Taxonomic Units (OTUs). OTUs have 
variable resolution to species or genus level, and consequently can group non-
pathogenic and pathogenic species in the same group. Different variable regions 
have been sequenced for the purposes of identification, and sequencing different 
regions may give you a different result.[298] Also, using a different sequencing 
platform may also change your result.[299]  
Despite these limitations, this technique has taken our understanding of bacterial 
communities in the lung to a new level. 
1.3.2 Bacterial Communities in the Lung 
Interest in the interaction between bacteria and health has been on the rise in the 
last decade, and has been typified by the Human Microbiome Project.[300] The 
long-held dogma had been that the lung was essentially a sterile site in health, 
and it was not included in this initial project. Subsequently it has been shown that 
this dogma is incorrect.[301]  
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In retrospect it does not seem a surprising finding that the lungs are not sterile. It 
has long been acknowledged that we breathe in a huge number of organisms 
and that micro-aspiration occurs from the bacteria laden upper airways.[302]  
Once it has been acknowledged that the lung is not sterile, it is worth considering 
how the community in the lung is formed and develops. The ecological modelling 
description as presented by Dickson et al is a clear way of conceptualising 
this.[303] Like any population, a community is reflective of the effects of 
immigration, emigration and intra-site reproduction. Immigration is essentially via 
inhalation, micro-aspiration and direct mucosal dispersion. Elimination in the 
healthy state will be by cough, mucociliary clearance and the host immune 
system. In a steady state you would expect a balance between immigration and 
elimination, and subsequently very little intra-site residence and reproduction. 
With this in mind, it becomes conceptually easy to see how dysbiosis could occur 
through changes in immigration and/or elimination (see Table 1.2). In an 
environment where a steady state is not maintained, long-term residents will exist 
in this situation, and local factors will bias some community members over others. 
These factors could include pH, oxygen tension, nutrient availability, local 
microbial competition and local inflammatory response. 
 
Factor affecting Immigration Factors affecting Elimination 
Oro-pharyngeal microbial burden Mucociliary clearance 
Minute ventilation Cough 
Gastro-oesophageal reflux Microbial growth conditions 
Medications Innate Immune Response 
Gross aspiration Adaptive Immune Response 
Laryngeal Dysfunction Medications 
 
Table 1.2 Factors influencing immigration and elimination of bacteria into 
and out from the lung 
These concepts would point to certain disease states having specific community 
profiles. This has been investigated in both health and disease over the last few 
years and it has indeed been the case that different diseases appear to have 
different profiles. Whilst this has been of great interest, there remain key 
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questions and issues. These include: how much of a pathogenic entity is the 
microbiome or is it more a consequence of the process; can knowledge of the 
microbiome positively influence therapy; and if so how can this information be 
delivered in the real-world in a prompt and affordable manner? The microbiome 
may influence the inflammatory process on epithelial surfaces, and the potential 
of microbiome manipulation is intriguing.[304] It is likely that important 
components are the fungal and viral communities in the lung (the “Mycobiome” 
and “Virome”), but that is beyond the scope of this work which will focus on 
bacteria.[305] 
I shall now describe the main findings with regards to bacterial communities in 
the healthy lung and in CF and NCFB.  
The Healthy Lung 
The first main piece of work which included healthy controls was a study looking 
at Asthma and COPD patients.[301] The key finding from this work was that the 
healthy lung appeared to have a bacterial community similar to the upper airway 
and that those with chronic respiratory disease had distinctly different 
communities. There has been subsequent work which has created an 
appreciation of the composition of a “normal” microbiome.[302] It appears that 
the prominent phyla are Bacteroidetes and Firmicutes, whilst Prevotella, 
Veillonella and Streptococcus are the common genera. The healthy lung has also 
been shown to contain Staphylococcus, Pseudomonas, Fusobacteria, 
Acinetobacter and others.[306, 307] There are varying degrees of similarity 
between the mouth and the lung, and this may be a reflection on factors such as 
oral hygiene and difference in reflux and aspiration. Aspiration is common during 
deep sleep in healthy subjects and there is data to suggest that the GI tract may 
have a significant impact on the lung microbiome.[308-310] The undamaged 
airways of the healthy lung will have less regional variation in growth conditions, 
resulting in the communities being relatively uniform throughout the lung.[311] 
The CF Lung 
The CF lung was unsurprisingly an early target for culture-independent 
investigation and, via fingerprinting techniques, this gave the first hints of the 
wealth of detail not revealed by culture.[284] As more 16S rRNA sequencing has 
been performed, more specific observations have been made. There appears to 
66 
 
be a reduction in community diversity with increasing age and disease 
severity.[286, 312-314] In end-stage disease, there can be evidence of just a 
single pathogen which has complete domination of the site. The loss of diversity 
appears most tightly correlated with cumulative antibiotic usage.[314, 315] The 
true driver of reduced diversity is however very difficult to identify as cumulative 
antibiotic usage will increase with both age and disease severity. However, there 
does seem to be an association with greater rate of decline of lung function in 
less complex communities, which may suggest a pathogenic aspect to certain 
bacterial communities.[316] The intriguing link between the microbiota in the gut 
and the lung has shown reduced gut diversity in those with severe lung 
disease.[317] Again the impact of cumulative antibiotics may be a significant 
contributor to this observation. 
Whilst traditional culture results effectively give a binary outcome for a specific 
pathogen (i.e. either cultivated or not), 16S rRNA sequencing reports both the 
presence and the abundance of a pathogen. As previously described, PA and SA 
are recognised as the predominant pathogens by culture. When considering 
mere presence or absence though, Streptococcus and Prevotella may be more 
common. Pseudomonas may be the next most common OTU, with Veillonella, 
Rothia, Granulicatella, Gemella and Fusobacterium, all more frequently present 
than Staphylococcus.[318] However, there may be an anomaly with 
Staphylococcus as it appears to be more frequently revealed by culture than 
culture-independent techniques. It is unclear if this is due to difficulty extracting 
the DNA from SA, or poor amplification of the 16S gene in a mixed sample.[319] 
When abundance rather than mere presence is looked at, there are notable 
pathogens which when present appear to be in high abundance and dominate 
the community. These include the OTUs of Pseudomonas, Staphylococcus, 
Stenotrophomonas, Burkholderia and Achromobacter.[318] With the exception of 
SA, all the main pathogens in CF are potentially under-reported by culture. 
Consequently, important clinical information may be being missed. 
The NCFB lung 
As in CF, significant weight is placed on culture-dependant results when clinical 
decisions are being made. Often to the frustration of the treating physician, 
microbiological investigation of sputum can fail to give useful guidance. One study 
suggested that 40% of purulent samples did not isolate a recognised 
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pathogen.[320] Culture-independent investigation is therefore clearly of interest 
in this disease cohort as well. 
So far there has been a small collection of interesting studies into NCFB and the 
associations between microbiomes and severity. A study by Rogers et al looked 
at samples from 41 patients and concluded that bacterial diversity positively 
correlated to the forced expiratory volume in one second (FEV1).[321] This study 
identified “core” bacteria in NCFB and unsurprisingly included Pseudomonas and 
Haemophilus, as well as others including Streptococcus, Veillonella and 
Prevotella. Further work by Rogers also suggested that richness was negatively 
correlated with sputum weight, age and inflammatory markers; that communities 
dominated by Pseudomonas or Haemophilus had reduced richness; and that 
those dominated by Pseudomonas were most likely to suffer an exacerbation 
followed by those dominated by Veillonella.[322, 323] Of possible note, they did 
not find an association between diversity and antibiotic use. 
Not all work in NCFB has found associations between the bacterial community 
and disease severity.[271, 319, 324] There are a few possible explanations for 
these conflicts. It is possible that in fact there is not a strong association between 
community profiles and disease severity, and that in some cohorts an association 
will not be revealed. This may particularly be the case in studies with limited 
numbers. It could be that geographical location makes an impact. The work of 
Rogers et al is often Australian-based whereas most of the other main papers are 
UK based. There are some interesting points to make from the UK papers which 
may give some hints about the relationships of the bacterial communities and 
NCFB patients. In the NCFB cohort from the North-East of England, there was 
greater richness in those who were “culture-negative” and less in those who 
cultured PA.[271] The study based in London found reduced diversity in those on 
long-term antibiotics, those with a positive culture result, and if mucoid PA was 
isolated.[319] The studies from London and Belfast showed impressive 
longitudinal stability of profiles even in the face of exacerbations and 
antibiotics.[319, 324] These studies and others are a reminder of our lack of 
understanding of exacerbations in the bronchiectatic lung and what antibiotic 
therapy actually does. 
A further reason why we are not entirely clear on the association between disease 
severity and community profile may in part be due to the markers of severity 
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studied. For example, FEV1 certainly has limitations as a disease marker.[283] 
There are now two severity indexes for NCFB.[40, 325] While they both contain 
FEV1, additional factors include age, BMI, culture results and radiological 
changes, and they predict morbidity and mortality. These severity scores may be 
a useful tool when comparing bacterial communities to severity. 
1.4 Key Points of Chapter 1 
In the above sections key points have been raised which are of particular note 
when considering the investigative work that has been performed for this thesis. 
They can be summarised in the following main points which can be divided 
between clinical and scientific issues. 
1.4.1 Key Points- Clinical 
- The bronchiectatic lung is a pathological state found in patients with NCFB 
and CF. 
- NCFB and CF are important diseases associated with significant morbidity 
and mortality rates. 
- PA is a highly prominent and clinically-important pathogen in both these 
diseases. 
- PA has been shown to be transmissible between patients in CF, leading 
to changes in practice. The equivalent risk is unknown in NCFB and 
patients are potentially in danger of significant cross-infection. 
- The lungs are a polymicrobial communities. The relationship between PA, 
the wider microbial community, and disease severity is unclear in NCFB. 
1.4.2 Key Points- Scientific 
- Multiple genotyping techniques are available with different advantages 
and disadvantages.  
- Whilst WGS may be the future of these techniques, resources may limit its 
use in some settings. Also, determining cross-infection with WGS is not 
clear-cut, particularly in circumstances where hypermutator strains are 
involved.  
- Most genotyping technique involve the cultivation of a pathogen in the first 
instance. This is time-consuming, not always possible, and may lead to 
the typing of an unrepresentative colony. 
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- Culture-independent techniques such as 16S rRNA sequencing have 
revealed polymicrobial communities in the lung, but issues with 
complexity, time and cost may limit clinical utility. 
 
1.5 Aims of the Thesis 
With these key points in mind, this thesis had set aims which have been 
addressed and described in Part B. This has been achieved with the methods 
and materials which are described in Chapter 2. The aims were as follows 
1) To perform an epidemiological review of PA in NCFB utilising a variety of 
genotyping techniques to investigate the likelihood of cross-infection with 
PA. 
2) To gain insight into the prevalence of hypermutable PA in NCFB and its 
impact on WGS-based studies addressing cross-infection. 
3) To test the utility of a novel culture-independent genotyping technique for 
PA. 
4) To investigate the relationship between disease severity and the bacterial 
community composition in NCFB. 
5) To test the clinical utility of RISA as a cheaper and quicker alternative to 
16S rRNA sequencing.  
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Chapter 2- Methods and Materials 
In this chapter this I will describe the main methods and materials used through 
this body of work.  
2.1  Sample Acquisition 
All the samples used in this work have come through clinical practice at the RD&E 
hospital. All respiratory samples were expectorated sputum rather than via 
bronchoscopy and were all collected for microbiological investigation as part of 
the patients routine care. All respiratory patients were recruited prospectively and 
consented either as agreed with the local ethics committee, or for the donation of 
the sputum sample to the local National Institute of Health Research (NIHR) 
tissue bank. The recruitment process included the collection of clinically-relevant 
information. The only other clinical samples obtained and studied were isolates 
of PA from non-respiratory origins. For these samples no patient details were 
known beyond type of sample (e.g. urine) and health-care setting of origin (e.g. 
hospital ward). Consequently, no consent was obtained from any non-respiratory 
patients.  
The sputum samples all initially went to the Exeter Clinical Laboratory which 
contains the accredited microbiology services used by the RD&E. Following 
receipt of a sputum sample, an equal volume of Mucolyse (dithiothreitol) was 
added before vigorous shaking for 10 seconds and being left at ambient 
temperature for 15 minutes. After a further 10 seconds of shaking, up to 4mls was 
aliquoted into 2 ml vials for the samples identified for culture-independent 
investigation (see Chapters 5, 6 and 7). The samples in these vials were 
subsequently heat-treated for de-activation for safe transfer. The heat-treatment 
was performed at 95°C for 20 minutes. This protocol was chosen on the basis of 
advice from a National Mycobacteria laboratory, as the principle reason for heat-
treatment was the potential of samples to harbour Mycobacterium tuberculosis. 
Before commencing our studies, DNA extraction had been performed on samples 
in the Exeter Clinical Laboratory both before and after heat-treatment to look for 
possible impact on downstream uses of the DNA. Heat-treatment was found to 
have no significant impact on DNA yield or PCR success. 
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The aliquoted sputum samples were transferred on dry-ice to a University of 
Exeter laboratory for storage at -80°C. From the sample remaining in the Exeter 
Clinical Laboratory, a 10 µl loop of digested sputum was added to 5ml of 
Maximum Recover Diluent (MRD). Plates were then inoculated immediately after 
dilution. The plates used were based on the clinical diagnosis. For NCFB patients, 
Blood and Chocolate Agar plates were incubated in Carbon Dioxide; and Cystine 
Lactose Electrolyte Deficient (CLED), Mannitol and Sabouraud Agar plates were 
incubated in air. For samples from CF patients, Burkholderia cepacia agar was 
also used.  
For the isolates from which the epidemiological review of PA was done (see 
Chapter 3), 10 representative colonies were picked and subsequently stored on 
MicrobankTM microbial storage beads (Pro-Lab Diagnostics). These were 
transferred on dry-ice to a University of Exeter laboratory for storage at -80°C. 
PA was identified by technician observation, an oxidase test and confirmation 
with the VITEK®MS MS Matrix-assisted Laser Desorption/Ionisation- Time Of 
Flight Mass Spectrometry (MALDI-TOF MS) (Biomerieux).  
2.2  DNA Extraction 
DNA extraction has been a key step in much of the investigative work described 
in this thesis. There are many different techniques and commercial kits available. 
For different stages of this work, three different approaches were required. These 
were for the extraction of DNA from PA colonies; the extraction of DNA from 
whole sputum to investigate PA; and the extraction of DNA from whole sputum to 
investigate the wider bacterial community. The reason for two different protocols 
when working with sputum is that some gram-positive bacteria are harder to 
extract DNA from. An example of this is the difficulty of extracting the important 
respiratory pathogen SA.[280] To improve extraction of DNA from SA, a 
mechanical disruption step is required, however this is not required for the gram-
negative bacteria PA.  
I shall now describe the different methods used. 
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2.2.1 DNA Extraction of PA 
This process was performed for the extraction of PA from stored isolates obtained 
from sputum from NCFB and CF patients, and from stored isolates from non-
respiratory samples.  
PA was re-grown from microbial storage beads on plates of LB agar and 
incubated at 37°C. Re-plating and ongoing incubation took place if required to 
allow single colony picking.  
Single colonies were inoculated into 5mls of LB broth for overnight incubation 
(37°C, 200RPM). 2mls from the overnight culture was then used for the DNA 
extraction protocol. The process was performed with the GeneJET Genomic DNA 
Purification Kit (ThermoFisher Scientific). A modified version of the Gram-
Negative Bacteria Genomic DNA Purification Protocol was performed. The only 
adaption was a reduced eluting volume (100 µl) in order to obtain an adequate 
concentration for downstream applications.   
The DNA was checked for quantity and quality by a NanoDropTM 1000 
Spectrophotometer (ThermoFisher Scientific).  
2.2.2 DNA Extraction From Whole Sputum for PA MLST 
In order to perform DNA extraction to apply the MLST scheme on whole sputum 
a different kit was used, namely the QIAamp DNA mini kit (Qiagen). The “DNA 
purification from Blood or Body Fluids (Spin Protocol)” was followed using 400µl 
of sputum and modifications as described previously.[326]  
2.2.3 DNA Extraction From Whole Sputum for the Assessment of the 
Bacterial Community   
A different approach to DNA extraction was performed for the purposes of 
assessing the bacterial community of the lung. This is due to the need to extract 
DNA from both gram-positive and gram-negative bacteria. Concerns persist 
about gram-positive bacteria being under-represented in microbial community 
profiling studies due to a tougher cell wall and the need for mechanical disruption 
to overcome this.[280, 281] Several kits and protocols were trialled including: the 
protocol used in 2.2.2 with and without bead-beating, the UltraClean Microbial 
DNA Isolation Kit (Mo Bio), and the FastDNATM Spin Kit for Soil (MP Biomedicals). 
As RISA was the principle downstream application, several samples were tested 
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via these different kits and visualised by gel electrophoresis. There was no 
discernible difference between the samples based on RISA output. Due to no 
evidence of inferiority or failure to produce DNA which could be amplified, it was 
decided that a protocol that included mechanical disruption should be used to 
avoid the concerns in the literature surrounding extraction from gram-positive 
bacteria. Due to personal recommendations and prominent use in the literature, 
the FastDNATM Spin Kit for Soil was used.[319, 327-330] 
DNA extraction was performed as described in the manufacturer instructions with 
minor adaptations. An updated protocol was released by the company after the 
first few samples were processed, and these were consequently re-done so that 
all underwent the same protocol. The manufacturer’s protocol used 500mg of soil 
as the starting product and we used 500µl of sputum. In addition, instead of the 
FastPrep Instrument, the Precellys 24 (Bertin Instruments) was used for 
homogenisation. This was performed three times at 6,440 RPM for 30 seconds 
with cooling on ice in-between cycles. The other adaptation was that the SpinTM 
Filter underwent its 5 minutes of air drying at 60°C in order to aid removal of 
residual ethanol. This step was adapted following personal correspondence with 
the company. 
2.3  Random Amplified Polymorphic DNA (RAPD) 
In this work, RAPD was used as an initial screening method so that we could 
work with a large number of isolates in the first instance, before narrowing down 
to a lower number to enable targeted higher-resolution investigation. The process 
involved an initial PCR reaction on template DNA with negative controls to ensure 
an absence of contamination. The subsequent PCR products were then analysed 
either by human visualisation or via microfluidic amplicon separation analysis. 
PCR products were only compared if they were part of the same experiment- i.e. 
with the same batch of reagents and were amplified in the same run.  
For assessment by human visualisation, the RAPD products were separated by 
electrophoresis using 1.5% TAE-agarose gel supplemented with Midori Green 
Advanced DNA stain (5µl/100mls). 10μl of PCR product was mixed with 2μl of 6X 
DNA loading dye (ThermoFisher Scientific) before placement into the wells. The 
gel was run with a GeneRuler 1KB DNA ladder (ThermoFisher Scientific). The 
gel was then visualised under ultra-violet light. Bands were considered either 
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“major” or “minor” on the basis of visual interpretation of band intensity within 
each sample. Samples with a difference of one major band or two minor bands 
were considered different. All visual assessment were conducted by Philip 
Mitchelmore (PM).  
For assessment via microfluidic amplicon separation analysis, 1µl of each PCR 
product was run on an Agilent 2100 Bioanalyser using a DNA 7500 chip (Agilent). 
The resultant fingerprints were subsequently clustered using GelCompar II 
software (Applied Maths). Pearson’s method was chosen with 2% optimisation. 
In order to gain optimal performance, significant experimental modifications were 
trialled to previously described protocols before the isolates were formally 
tested.[244, 331] The initial PCR was performed in a 25µl reaction volume 
containing 1x reaction buffer, 40 pmol of primer,  0.25mM of dNTP, 1 unit of Taq 
DNA polymerase (New England Biolabs) and 40-80 ng genomic DNA. Primer 272 
(AGCGGGCCAA) (Eurofins Scientific) was primarily used, with 208 
(ACGGCCGACC) (Eurofins Scientific) also used to confirm appropriate output. 
PCR was performed on a TProfessionalTRIO Thermocycler (Biometra).  The 
mixture was cycled 4 times through 94°C for 5 minutes; 36°C for 5 minutes and 
68°C for 5 minutes then 30 cycles at 94°C for 1 minute; 36°C for 1 minute and 
68°C for 2 minutes. A final extension of 68°C for 10 minutes completed the 
process. This initial process did not lead to any visible bands on electrophoresis. 
A variety of concentrations of Magnesium Chloride (MgCl2) were trialled with the 
first evidence of visible bands on electrophoresis from reactions containing 
1.5mM MgCl2, in the 208 Primer group. Subsequently the protocol of Hafiane et 
al was trialled which included the use of Invitrogen reagents instead of New 
England Biolab.[331] This led to faint bands so a modified cycle programme was 
set up consisting of 94°C for 2 minutes followed by 5 cycles of 94°C for 1 min; 
35°C for 1 min and 72°C for 5 min before 40 cycles of 94°C for 1 min; 35°C for 1 
min and 72°C for 2 minutes before a further extension at 72°C for 10 minutes.  
The modifications included an extended DNA chain extension phase in the first 5 
cycles, followed by an additional 5 cycles ontop of what was used in the original 
protocol. This lead to inconsistently visible bands when using both primers. 
After discussions with a collaborator (Prof E. Mahenthiralingam, Cardiff 
University), a different manufacturers products were used (Qiagen), and an 
extended cycle. This included the addition of Q Solution, which was part of the 
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manufacturer’s reagent package. The PCR mixture was performed in 25µl 
containing 1x reaction Buffer, 40 pmol of primer, 0.25 mM of dTNPs, 1.5mM of 
MgCl2, 1x Q Solution, 1 unit of Taq DNA Polymerase, and 40ng of genomic DNA. 
The reaction took place under the following cycling conditions: 3 minutes at 94°C; 
35 cycles of 94°C for 1 minute, 36°C for 1 minute, and 72°C for 2 minutes; before 
a final 10 minutes at 72°C. This produced visible bands on electrophoresis for 
both primers with no evidence of contamination in the negative control lane. 
Consequently, this protocol was adopted for all further studies. 
2.4  Multilocus Sequence Typing (MLST) 
The protocol was performed according to the Pseudomonas aeruginosa MLST 
website (http://pubmlst.org/paeruginosa/).[332] The initial phase was 
amplification of the seven housekeeper genes (see Table 2.1). The amplification 
mixture contained a total volume of 50μl. This was made up of 10-40ng of DNA; 
20 pmol of both forward and reverse primers; 1x PCR Buffer; dNTP solution 
(10mM each); and 1.25 units of Taq DNA Polymerase (Qiagen). The reaction 
conditions were as follows: initial denaturation at 96°C for 1 min, followed by 30 
cycles of denaturation at 96°C for 1 minute, primer annealing at 55°C for 1 min 
and extension at 72°C for 1 min. A final extension period of 10 minutes at 72°C 
then completed the process. To look for evidence of successful amplification, 
10µl of the products were then put through gel electrophoresis. 
When MLST was performed on DNA extracted directly from sputum there was 
only intermittent success with the standard protocol for the nuoD locus. This 
persisted even with increasing the number of cycles during PCR and titrating the 
primer annealing temperature. Consistent PCR product was achieved after using 
some of the modifications suggested by Van Mansfeld et al, including the addition 
of Q buffer (Qiagen) to the PCR mixture and using the primers described in their 
work for nuoD (forward primer: GGGACATGTACGGCATCACCT and reverse 
primer: GCGCAGGATGCTGTTCTTCA).[333]    
Subsequent sequencing of the products was performed commercially by Eurofins 
Scientific with the sequencing primers listed in Table 2.1. This was initially 
performed on PCR products purified by Eurofins Scientific as part of the 
commercial service. However, due to a disappointing return of data, we 
subsequently conducted purification of PCR products ourselves before sending 
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those purified PCR products for sequencing. This was performed with the 
GeneJET Gel Extraction kit (ThermoFisher Scientific), using the manufacturer’s 
protocol for simple PCR clean-up. The DNA was checked for quantity and quality 
by a NanoDropTM 1000 Spectrophotometer (ThermoFisher Scientific).  
Following the return of sequencing data, the forward and reverse reads were 
aligned using Vector NTI software (ThermoFisher Scientific). The consensus 
sequence was then interrogated via the MLST database website and the allele 
number recorded. This was repeated for all 7 loci and our sequences were used 
to search the database to identify corresponding loci and ST numbers. 
 
 
77 
 
Table 2.1 Primers used for the MLST scheme 
.  
Locus  Gene Product Amplification Primers Sequencing Primers 
acsA Acetyl coenzyme A synthetase Forward   ACCTGGTGTACGCCTCGCTGAC 
Reverse   GACATAGATGCCCTGCCCCTTGAT 
Forward   GCCACACCTACATCGTCTAT 
Reverse   AGGTTGCCGAGGTTGTCCAC 
aroE Shikimate dehydrogenase Forward   TGGGGCTATGACTGGAAACC 
Reverse   TAACCCGGTTTTGTGATTCCTACA 
Forward   ATGTCACCGTGCCGTTCAAG 
Reverse   TGAAGGCAGTCGGTTCCTTG 
guaA GMP synthase Forward   CGGCCTCGACGTGTGGATGA 
Reverse   GAACGCCTGGCTGGTCTTGTGGTA 
Forward   AGGTCGGTTCCTCCAAGGTC 
Reverse   GACGTTGTGGTGCGACTTGA 
mutL DNA mismatch repair protein Forward   CCAGATCGCCGCCGGTGAGGTG 
Reverse   CAGGGTGCCATAGAGGAAGTC 
Forward   AGAAGACCGAGTTCGACCAT 
Reverse   GGTGCCATAGAGGAAGTCAT 
nuoD NADH dehydrogenase I chain 
C, D 
Forward   ACCGCCACCCGTACTG 
Reverse   TCTCGCCCATCTTGACCA 
Forward   ACGGCGAGAACGAGGACTAC 
Reverse   TGGCGGTCGGTGAAGGTGAA 
ppsA Phosphoenolpyruvate synthase Forward   GGTCGCTCGGTCAAGGTAGTGG 
Reverse   GGGTTCTCTTCTTCCGGCTCGTAG 
Forward   GGTGACGACGGCAAGCTGTA 
Reverse   GTATCGCCTTCGGCACAGGA 
trpE Anthralite synthetase 
component I 
Forward   GCGGCCCAGGGTCGTGAG 
Reverse   CCCGGCGCTTGTTGATGGTT 
Forward   TTCAACTTCGGCGACTTCCA 
Reverse   GGTGTCCATGTTGCCGTTCC 
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2.5  Whole Genome Sequencing (WGS) 
The WGS included in this thesis was performed by the Exeter Sequencing 
Service (ESS) (including all the bioinformatics analysis) with DNA extracted by 
PM. For this, the data was generated from the Illumina MiSeq system using 2 x 
300bp read lengths. The subsequent analysis was carried out using the MRC 
CLIMB infrastructure with a Virtual Machine pre-installed with the Nullarbor 
package (https://github.com/tseemann/nullarbor).[334] This package then 
generated core genome variants, and determined MLST profiles, resistomes, 
SNP distance matrices and a pan-genome report. It also trimmed low quality and 
adaptors present in reads using Trimmomatic, used Kraken to assign reads to 
taxonomic groups and SPAdes to assemble genomes (using the --accurate 
option).[335-337] Annotation was then performed using Prokka and variants 
called with Snippy (https://github.com/tseemann/snippy).[338] 
Publicly-available genomes were also included in analysis by the Nullarbor 
package. Many of these were not created via Illumina sequencing and in order 
for these to be incorporated into the Nullarbor package, the genomes were 
processed using the wgsim package (v 0.3.2) to generate simulated short paired-
end reads for re-assembly. The following parameters were used to generate 
2x300bp reads with zero changes with respect to the reference genome: -e 
0.000000 -d 600 -1 300 -2 300 -r 0.000000 –R 0.0000 -X 0.0000 -h -s 0 -N 
1100000 -A 0.000. 
Additional assessment of WGS data was performed for in silico prediction of 
hypermutators. Reads were quality and adapter trimmed using fastq-mcf using 
parameters -q 20 with skew settings switched off. Reads were aligned using bwa 
mem to the reference genome (Pseudomonas aeruginosa PAO1; NC_002516) 
and sorted and converted to BAM using samtools. The mpileup component of 
samtools was used to call variants and perform local re-alignment of sequences. 
The BCF formatted files were converted to VCF format using bcftools and filtered 
to exclude sites with coverage < 10 or variant quality < 60. Data was analysed 
using the Zeus computational infrastructure at the University of Exeter. From the 
list of SNPs and Indels generated by this method, we identified those occurring 
within seven genes known to be implicated in proofreading and/or DNA repair, 
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namely mutS (PA3620), mutL (PA4946), mutY (PA0357), mutM (PA5147), dnaQ 
(PA1816), mutT (PA4400) and uvrD (PA5443). SNAP2 and PROVEAN were then 
used to predict whether the observed SNPs and Indels would be neutral or 
deleterious with regards to protein function.[339, 340] If the prediction was for a 
deleterious effect in one of these genes, then the isolate was predicted to be a 
hypermutator. 
2.6  Hypermutator Assay for Pseudomonas aeruginosa 
Hypermutator assays were performed on PA isolates as previously described by 
assessing spontaneous resistance to rifampicin.[158] Stored isolates of PA were 
re-cultured on Mueller-Hinton agar (MHA) plates at 37°C. Overnight cultures were 
then set up in triplicates, each inoculated with 3-5 colonies in 20mls of Mueller-
Hinton broth (MHB) (37°C, 200 RPM). The cells from these overnight cultures 
were then pelleted by centrifugation at 3,000 RPM for 5 minutes and re-
suspended in 1ml of MHB. Serial dilutions with Phosphate Buffered Saline were 
made from this neat stock ranging from 10-1 to 10-8. Pre-prepared plates of MHA, 
and MHA with 300 µg rifampicin per ml (MHA/Rif), were subsequently inoculated. 
The neat, 10-1 and 10-2 solutions were plated onto the MHA/Rif plates, and the 
10-6, 10-7 and 10-8 solutions were plated onto MHA plates. The plates were 
incubated for 36 hours at 37°C and the colonies subsequently counted to obtain 
a mutant frequency. The counts were obtained from the most appropriate MHA 
and MHA/Rif plates as defined by the plate with the highest number of countable 
colonies. A mean was calculated from the triplicates for each sample. All batches 
included isolates from the same PAO1 stock for inter-batch comparison. 
Examples of mutators were streaked onto rifampicin plates in order to check 
stability of their resistance to rifampicin.     
2.7  Ribosomal Intergenic Spacer Analysis (RISA) 
RISA was performed as previously described.[133] The initial step involved a 
PCR step to amplify the intergenic spacer regions. The 25µl reaction mixture 
contained 1µl of template DNA (approximately 20 to 40 ng), 10pmol of each 
primer, 1x PCR buffer, 0.25mM of each dNTP, 1x Q solution, 1 unit of Taq DNA 
polymerase (Qiagen) and an additional 1.5mM of MgCl2.The primers were 1406F 
(TGYACACACCGCCCGT) and 23SR (GGGTTBCCCCATTCRG), both from 
Eurofins Scientific. The reaction conditions were as follows: 95oC for 5 min; 34 
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cycles of 95°C for 30 sec, 55°C for 30 sec and 72°C for 60 sec followed by 72°C 
for 5 min.  
Following the PCR reaction, products were visualised by gel electrophoresis in 
the same manner that RAPD PCR products had been (see Section 2.3). After 
confirmation of PCR product, further analysis was performed with micro-fluidic 
amplicon separation on the Agilent Bioanalyser as had previously been done for 
RAPD PCR products except with 2 µl of product rather than just 1 µl. Analysis of 
this data was again performed with the use of GelCompar II software (Applied 
Maths). The analysis included a dendrogram created by Pearson’s correlation co-
efficient, an estimate of richness based on counting bands, and estimations of 
Shannon’s diversity and evenness based on the band concentrations as a 
surrogate of abundance.  
 
2.8  16S rRNA Sequencing 
The 16S rRNA sequencing process was conducted by the ESS on DNA extracted 
by PM according to the protocol in section 2.2.3. Negative controls from each 
DNA extraction kit and DES used to pre-dilute samples were also submitted for 
sequencing in order to detect suspected contaminants. This was conducted as 
per the 16S rRNA gene amplification Illumina MiSeq protocol with primers used 
to amplify the V1-V2 region. Subsequent bioinformatics analysis was performed 
by the ESS via the Dada2 software package.[341] This is a specific software 
package for the modelling and correction of Illumina sequencing errors. It also 
gives higher resolution to the standard OTU output. Removal of chimeras occur 
after trimming and denoising of data. 
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Chapter 3- Genotyping of Pseudomonas 
aeruginosa in an unsegregated 
bronchiectasis cohort sharing hospital 
facilities with a cystic fibrosis cohort 
3.1 Abstract 
Introduction: Whilst PA cross-infection is well-documented amongst CF patients, 
the equivalent risk amongst NCFB patients is unclear. There is some evidence of 
rare cross-infection with PA in a NCFB cohort managed in a centre without CF 
services. There is no evidence with regards to the risk of cross-infection in a 
centre where both NCFB and CF patients are managed  
 
Methods: We performed an epidemiological analysis of PA within a single centre 
that manages an unsegregated NCFB cohort alongside a segregated CF cohort. 
This was performed through the prospective collection of sputum samples from 
patients who had previously isolated PA. Ten isolates were analysed per patient 
by RAPD and unique profiles were further analysed by MLST. Shared strains as 
defined by MLST underwent WGS with comparison to publicly-available 
unconnected genomes of the same strain. Further comparison with non-
respiratory clinical isolates of PA was performed by MLST. 
 
Results: Positive isolates of PA were obtained from 46 NCFB patients and 22 CF 
patients. A further 76 isolates were obtained from non-respiratory clinical isolates. 
We found no evidence of cross-infection between the two cohorts or within the 
segregated CF cohort with the exception of a pair of siblings. However, within the 
unsegregated NCFB cohort, evidence of cross-infection was found between three 
patients. Multiple other shared strains were found, but these were believed to be 
due to environmental acquisition.    
 
Conclusion: This epidemiological review has shown evidence of uncommon 
cross-infection between NCFB patients. At present this level of evidence does 
not suggest that the implementation of segregation policies would be appropriate, 
though longitudinal surveillance should be performed. 
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3.2 Introduction 
PA is a highly significant pathogen in chronic suppurative lung diseases. Its 
significance in CF is extensively described, where it is the most frequently 
cultured pathogen in adults with CF, and is a predictor of mortality.[127, 342] It is 
less well studied in other suppurative states such as NCFB, but is again 
associated with significant morbidity and mortality.[43, 44] The Bronchiectasis 
Severity Index (BSI) illustrates its significance by giving the same score for 
colonisation with PA as an FEV1<30%, or a Medical Research Council (MRC) 
dyspnoea score of 5.[40]  
It is well established that PA cross-infection occurs between CF patients having 
been observed in a variety of settings including siblings, holiday camps and CF 
units.[187, 190, 192] Whilst not universal, some transmissible strains appear to 
have greater clinical impact than environmentally acquired strains.[196, 197] 
Studies highlighting cross-infection with pathogens such as PA have led to the 
practice of segregation of CF patients.[205] NCFB and other cohorts affected by 
PA tend not to be segregated. The need to review this has been highlighted as a 
research priority [37]. 
NCFB was considered an “orphan” disease and unsurprisingly there has been 
little research into cross-infection risk.[343] One UK study concluded that cross-
infection was rare.[131] However, in that study, the NCFB patients were managed 
in a different hospital to the local CF cohort. Similarly, a recent multi-centre study 
highlighted the potential for PA cross-infection through identifying closely related 
isolates by WGS in the same clinical centre.[211] This was again exclusively 
focused on NCFB cohorts. In many hospitals, including ours, CF and NCFB 
patients share the same facilities and healthcare professionals. Therefore, in the 
study described herein, we have conducted an epidemiological review of strains 
of PA in our unsegregated NCFB cohort and our segregated CF cohort to assess 
cross-infection within and between cohorts. In addition, parallel analysis of local 
non-respiratory PA isolates has allowed us to compare CF and NCFB PA isolates 
with those present in the wider hospital population. This work incorporates three 
different genotyping techniques (namely RAPD, MLST and WGS) and highlights 
the strengths and weaknesses of these in this setting. The true definition of a 
“strain” is debatable. For the purposes of this work, it refers to an ST-type as 
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described by the MLST scheme. The ST-type can be determined either by MLST 
or by WGS. 
3.3 Methods 
 
3.3.1 Study Population  
All patients were recruited at the Royal Devon & Exeter Hospital, a teaching 
hospital in the South-West of England with a catchment area of approximately 
400,000. Isolates of PA were obtained from three cohorts. The first cohort were 
patients with a documented diagnosis of NCFB (“NCFB Cohort”), followed by 
collections from patients with CF (“CF Cohort”), and from clinical samples not 
from a respiratory source (“Non-Resp Cohort”). 
3.3.2 NCFB Cohort and CF Cohort 
Patients in these cohorts were opportunistically recruited from adult services only. 
For inclusion, patients required the confirmed diagnosis of NCFB or CF, and to 
have previously grown PA.  Maintenance anti-pseudomonal therapy was not an 
exclusion for recruitment. Patient data was collected including details on previous 
hospital and departmental attendance. If PA was not identified from the sample, 
then a future sample could be included if the patient submitted a further sample 
for clinical assessment within the recruitment window. 
3.3.3 Sputum Processing 
After consent, spontaneous sputum samples were submitted to the hospital’s 
microbiology services and cultured in the usual manner (as described in Chapter 
2). When PA was identified, 10 representative colonies were picked per sputum 
sample (based on colony morphologies) and stored on MicrobankTM microbial 
storage beads (Pro-Lab Diagnostics) at -80°C. Initial identification of PA was 
based on colony morphology and a positive oxidase test, and was subsequently 
confirmed by VITEK MS MALDI-TOF MS (Biomerieux). 
3.3.4 Non-Resp Cohort 
Isolates of PA were obtained prospectively from both community and hospital 
samples from different patients. These were samples submitted to the local 
microbiology department as part of standard practice and confirmation of PA 
identity was performed as described above. The only detail obtained was the 
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origin of the sample (for example: urine sample from General Practice). One 
colony was picked per patient and stored on beads at -80°C. 
3.3.5 DNA Extraction 
Following re-growth of isolates on Luria broth (LB) agar, single colonies were 
inoculated into LB broth and incubated overnight at 37°C with shaking. 
Subsequently, DNA was extracted from bacterial cell pellets using the GeneJET 
Genomic DNA Purification kit (ThermoFisher Scientific) as per the relevant 
manufacturer’s instructions. The extracted DNA was checked for quantity and 
quality by the NanodropTM 1000 Spectrophotometer (ThermoFisher Scientific) 
and stored at -20°C.  
3.3.6 Random Amplified Polymorphic DNA (RAPD) 
RAPD was performed on each isolate from the NCFB Cohort and the CF cohort, 
using a modified version of the previously described protocol.[244] In brief, PCR 
was carried out in a 25µl volume containing 1x PCR Buffer, 1U Taq Polymerase 
(Qiagen), 0.25mM (each) deoxynucleoside triphosphate, 1x Q-Solution, 1.5 mM 
MgCl2, 40 pmol primer, and 40 ng of genomic DNA. Initially, RAPD was performed 
on all isolates using primer 272, and re-checked using primer 208. Reaction 
mixtures were run on a TProfessionalTRIO Thermocycler (Biometra) as follows: 
3 minutes at 94°C; 35 cycles of 94°C for 1 minute, 36°C for 1 minute and 72°C 
for 2 minutes; followed by 72°C for 10 minutes.  
In the first instance, RAPD products were subjected to conventional agarose gel 
electrophoresis (1.5% (w/v) agarose) and visualisation via a Gel Doc XR (Bio-
Rad) to enable identification of unique profiles. Batches were performed on one 
patient at a time to facilitate the visualisation of all unique RAPD profiles within 
the 10 isolates per patient. The criteria for visually defining a unique RAPD profile 
was (a) the presence/absence of a major band, (b) the presence/absence of two 
minor bands, or (c) a difference in one band being major/minor and the 
presence/absence of another band. From each NCFB patient, a representative 
of each unique profile (based on visual inspection of the two runs) was taken 
forward for repeat RAPD analysis within a single batch encompassing 
representatives from all patients. For the repeat RAPD analysis, RAPD profiles 
were analysed via microfluidic amplicon separation (Agilent 2100 Bioanalyser), 
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with cluster analysis subsequently performed using Gelcompar II software 
(Applied Maths), with Pearson’s Method and 2% optimisation.  
3.3.7 Multilocus Sequence Typing (MLST) 
MLST was performed on the same NCFB isolates that underwent repeat RAPD 
analysis via the Bioanalyser, and on unique profiles from the CF isolates as 
defined by visual inspection. This was to provide an epidemiological analysis 
using a distinct method and to compare our isolates to a global database. This 
was performed as previously described, with allele sequences being compared 
between patients to identify shared strains, and also to the MLST database 
(www.pubmlst.org/paeruginosa) to identify matches to previously documented 
strains.[213] A modified “cascade” version of MLST was then performed on 
isolates from the Non-Resp Cohort to look for the shared strains identified within 
the respiratory cohorts. Analysis of the MLST alleles was performed sequentially, 
starting with the most discriminatory alleles in the original description of the 
scheme.[213] The cascade process continued until either all seven alleles were 
analysed or until the isolate could not match at least six of the seven alleles of a 
shared strain from the respiratory cohorts.  
3.3.8 Whole Genome Sequencing (WGS) 
WGS was performed on the shared strains from the respiratory cohorts. One 
isolate was chosen per patient with the exception of the most abundant strain for 
which three were chosen per patient. DNA was quantified by Qubit (Thermo 
Fisher Scientific) before submission to the ESS who undertook the process which 
included the running of the Bioinformatic pipeline. WGS was performed on the 
Illumina MiSeq platform. Bioinformatic analysis was performed via the Nullarbor 
pipeline. Further details of this process are described in Chapter 2.   
In addition to our samples, relevant reference genomes obtained from the 
Pseudomonas Genome Database were included in our Nullarbor pipeline 
analysis to enable isolates to be compared to clonally-unconnected 
representatives of the same sequence type.[344] Three genomes were selected 
for each Sequence Type (ST) that had undergone WGS. This was not possible 
for ST564 for which no publicly-available genomes were available. Relevant 
genomes were selected on the basis of them being either complete or with a high 
Contig N50 (Table 3.1). 
87 
 
 
ST 
type 
Isolate 
identifier 
Accession 
Number 
Origin Country 
17 BL02 SAMN02360715 CLIN (Vitreous fluid) USA 
C20 SAMN02360744 ENV Unknown 
C23 SAMN02360745 ENV  Unknown 
27 AZPAE14980 SAMN03105677 CLIN (Intra-abdominal) USA 
BWHPSA011 SAMN02360683 CLIN (Tissue middle 
turbinate) 
USA 
BWHPSA022 SAMN02360694 CLIN (Sputum) USA 
146 
 
LES431 SAMN02641592 CLIN (Parent of CF patient) UK 
LESB58 SAMEA1705916 CLIN (CF isolate) UK 
AZPAE13757 SAMN03105416 CLIN (Respiratory Tract)  Canada 
235 
 
BTP032 SAMN03787333 CLIN  USA 
JJ692 SAMN02360667 CLIN (UTI)  USA 
NCGM2.S1 SAMD00061003 CLIN (UTI)  Japan 
252 
 
AZPAE12420 SAMN03105411 CLIN (CF isolate)  USA 
AZPAE15012 SAMN03105709 CLIN (Intra-abdominal)  Germany 
BWHPSA028 SAMN02360700 CLIN (Sputum)  USA 
253 
 
BL16 SAMN02360729 CLIN (Corneal scraping)  USA 
BWH058 SAMN02402442 CLIN Unknown 
UCBPP-PA14 SAMN02603591 CLIN (Burn wound) Unknown 
274 
 
AZPAE14926 SAMN03105624 CLIN (UTI)  Brazil 
AZPAE14981 SAMN03105678 CLIN (UTI)  France 
BWHPSA040 SAMN02360704 CLIN (Sputum) USA 
395 
 
3581 SAMN02584694 CLIN Unknown 
BWH059 SAMN02402443 CLIN Unknown 
BWHPSA045 SAMN02360709 CLIN (Sputum) USA 
Table 3.1 Publicly-available genomes used for comparison with shared 
strains from the NCFB and CF cohorts Where available, relevant information 
is provided on the origin of isolates. CLIN, Clinical; ENV, Environmental; UTI, 
Urinary Tract Infection. Based on the available information, there is no evidence 
that any of the isolates above are directly linked to our patient cohorts. 
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3.3.9 In silico Prediction of Hypermutators 
An in silico prediction model was performed on the WGS data as described in 
Chapter 2. SNPs and insertion-deletion events (Indels) within seven genes 
implicated in proofreading and/or DNA repair were identified. These were mutS 
(PA3620), mutL (PA4946), mutY (PA0357), mutM (PA5147), dnaQ (PA1816), 
mutT (PA4400) and uvrD (PA5443).[158, 345] Two software tools (SNAP2 and 
PROVEAN), were used to predict the impact of SNPs and Indels on protein 
function.[339, 340]  
3.4 Results 
3.4.1 Cohort Demographics 
In a twelve month recruitment window 63 NCFB patients were recruited of whom 
46 produced samples positive for PA. Of those with positive samples, 89% were 
under the care of the two Respiratory consultants who care for all the adult CF 
patients in the RD&E Hospital. In a five month recruitment period, 32 CF patients 
were recruited. The demographics of these patients are shown in Table 3.2 
  
 NCFB  CF  
Recruitment Period (Month/Year-Month/Year) 07/14-
06/15 
09/15-
01/16 
Subjects 46 22 
Median Age (in years) 69 27.5 
IQR for age 65.8-76 24.5-40.3 
Male 10 (21.7%) 10 (45.5%) 
Time since 1st PA isolate 
- Less than 1 year 
- 1-5 years 
- 5-9 years 
- More than 9 years 
 
12 (26.1%) 
11 (23.9%) 
11 (23.9%) 
12 (26.1%) 
 
0 
9 (40.9%) 
4 (18.2%) 
9 (40.9%) 
Co-pathogens 
- Staphylococcus aureus 
- Aspergillus fumigatus 
- Exophiala species 
- Other 
 
1 (2.2%) 
0 
0 
7 (15.2%) 
 
9 (40.9%) 
1 (4.5%) 
2 (9.1%) 
3 (13.6%) 
Antibiotic therapy 
- Current azithromycin use 
- Current inhaled anti-pseudomonal use 
- Neither azithromycin nor inhaled anti-
pseudomonal use 
 
18 (39.1%) 
16 (34.8%) 
17 (37%) 
 
12 (54.5%) 
18 (81.8%) 
1 (4.5%) 
Table 3.2. Patient demographics for PA-positive NCFB and CF cohorts 
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Between September and November 2015, 76 isolates of PA were collected for 
our Non-Resp Cohort. Their origins are displayed in Table 3.3 
 
Source Community Hospitala Total 
Genito/Urinary 25 16 41 
Wound Site/Skin 1 15 16 
ENT 1 8 9 
Faeces 4 5 9 
Unspecified Pus 0 1 1 
Total 31 45 76 
 
Table 3.3. Origin of samples for the non-respiratory cohort 
aSamples were considered as “Hospital” origin if they were collected from a 
patient attending out-patient services or during a ward admission. 
 
3.4.2 RAPD/MLST Genotyping Pipeline- NCFB 
From the 46 samples which grew PA, 10 representative colonies were stored for 
all but one sample, for which 9 were stored. This resulted in 459 isolates being 
available for interrogation. Following initial RAPD analysis by the visualisation of 
products by gel electrophoresis, 59 isolates were identified as representatives of 
unique RAPD profiles. These were taken forward for repeat RAPD analysis via 
microfluidic amplicon separation on a Bioanalyser. This panel of 59 isolates 
included a minimum of one isolate per patient, and multiple isolates from 8 
patients. 
The Bioanalyser analysis of the RAPD output revealed the presence of 7 clusters 
containing samples from more than one patient with a cut-off of 90% for clonality, 
suggesting that shared strains were present in the cohort (Figure 3.1). Of the 8 
patients who were identified as having multiple unique RAPD profiles by visual 
inspection, 5 (63%) did not appear to have multiple RAPD profiles as defined by 
a 90% cut-off.  
The panel of 59 isolates subsequently underwent MLST analysis. By this method, 
35 different concatenated sequences were identified with 5 of these being shared 
between patients, and 25 had exact matches on the MLST database. Two 
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patients displayed evidence of multiple strains. The most prevalent ST type was 
ST17 which predominated in the largest cluster on RAPD analysis. This is better 
known as Clone C. By MLST, this was found in 8/46 patients (17%). The other 
shared ST types were found in either two or three different patients (Table 3.4) 
 
Fig 3.1. Dendrogram of RAPD profiles of NCFB PA isolates, derived using 
microfluidic amplicon separation (Agilent 2100 Bioanalyser). The 
dendrogram was produced using Gelcompar II (Applied Maths) with Pearson’s 
method and 2% optimisation. A 90% cut-off (denoted by the vertical blue line) 
was used to identify clusters. 
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3.4.3 RAPD/MLST Genotyping Pipeline- CF 
From the 22 samples from which PA was grown, 10 representative colonies were 
stored for all but one sample, for which 9 were stored. This resulted in 221 isolates 
being available for interrogation. Following initial RAPD analysis by the 
visualisation of products by gel electrophoresis, 26 isolates were identified as 
unique profiles to be taken forward for further investigation by MLST. This panel 
of 26 isolates included a minimum of one isolate per patient, and multiple isolates 
from 3 patients. 
By MLST, 20 ST types were identified of which two were shared between multiple 
patients. ST146 (the Liverpool Epidemic Strain, (LES)) was shared between a 
pair of twins, and ST27 was shared by three patients. One patient had evidence 
of multiple strains. When reviewed alongside the NCFB data, five ST types were 
seen in both the NCFB and CF cohorts (ST27, ST235, ST274 and ST395).  
3.4.4 Cascade MLST for Non-resp Isolates 
The cascade method of MLST resulted in 28 of the 76 samples being completely 
assessed. Of the 9 shared strains evident within the NCFB and/or CF cohorts, 5 
were also found in the non-respiratory samples (Table 3.4). Of these, the most 
prominent in the non-respiratory samples were ST253 (better known as PA14) 
and ST17 (Clone C).  
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MLST type Alias NCFB  
(n=46) 
CF  
(n=22) 
Non-resp  
(n=76) 
Total 
(n=144) 
ST17 Clone C 8 (17%)  7 (9%) 15 (10%) 
ST27  1 (2%) 3 (14%) 5 (7%) 9 (6%) 
ST146 LES  2 (9%)  2 (1%) 
ST235  1 (2%) 1 (5%)  2 (1%) 
ST252  3 (7%) 1 (5%)  4 (3%) 
ST253 PA14 2 (4%)  10 (13%) 12 (8%) 
ST274  1 (2%) 1 (5%) 2 (3%) 4 (3%) 
ST395  3 (7%) 1 (5%) 3 (4%) 7 (5%) 
ST564  3 (7%)   3 (2%) 
 
Table 3.4 Shared strains of PA identified within the respiratory (CF and 
NCFB) and non-respiratory cohorts, as defined by MLST One NCFB patient 
was co-infected with ST17 and ST564. Isolates in the non-respiratory cohort 
originated from genitourinary, wound, ENT and faecal samples from community 
and hospital investigation.  
 
3.4.5 Whole Genome Sequencing of Shared Strains 
WGS was focused on the ST types which were shared among the NCFB and/or 
CF patients. WGS was performed on three isolates of ST17 from each of the 8 
patients who harboured it, and one isolate per patient of the other 8 shared 
strains. The primary measure was the pairwise comparison of SNP difference 
between isolates. This ranged from 4-3925. The analysis also included three 
publicly-available genomes per ST type, with the exception of ST564 for which 
there is not one.  This was performed to enable comparison to unconnected 
representatives of the same ST type. These additional pairwise comparisons are 
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illustrated in Figure 3.2 and demonstrate that the CF and NCFB isolates 
belonging to ST17, ST27, ST235, ST252, ST253, ST274 and ST395 are as 
divergent from each other (Figure 3.2; circles) as they are from unconnected 
representatives of the same sequence type (Figure 3.2; grey crosses). This was 
not the case with ST146 where the pairwise comparison between two of our 
isolates showed far less divergence from each other than the unconnected 
genomes. These two isolates came from siblings with CF who have long been 
colonised with PA and were previously known to harbour ST146 (more commonly 
known as LES). The analysis also showed that the ST17 isolates revealed 
significantly greater ST17 diversity between patients than within patients. This 
gives further confidence in the interpretation that this does not represent likely 
cross-infection with this strain. 
Apart from ST146, the significant outlier in this analysis is ST564. The isolates 
with this ST type were near-identical and differed by only 4-12 SNPs. ST564 was 
found in three bronchiectasis patients and not in either the CF cohort or among 
the non-respiratory isolates. Two of the three patients were co-infected with 
another ST type. Via a review of hospital attendance data, it was noted that two 
of the three patients shared a waiting area and lung function room approximately 
17 months prior to recruitment. This potential cross-infection event did not 
coincide with a clear change in PA culture status as one of the patients 
intermittently isolated PA before and after this event, while the other patient had 
evidence of multiple PA strains (and therefore superinfection may have 
occurred). We were unable to identify a potential cross-infection event involving 
the third patient, but a difference of only 4 SNPs strongly supports cross-infection. 
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Figure 3.2. Genetic diversity within PA isolates, as defined by whole 
genome sequencing. The number of single nucleotide polymorphisms (SNPs) 
was calculated across the core genome of all sequenced isolates. Each data 
point represents a pairwise comparison within each ST, with the bar representing 
the mean. Circles represent pairwise comparisons that are exclusively between 
PA isolates from our own respiratory cohort (CF or NCFB), with the open circles 
representing those comparisons in which at least one isolate is a predicted 
hypermutator. The grey crosses represent pairwise comparisons in which one 
isolate is from our respiratory cohort and the other is an unconnected 
representative of the same sequence type (using publicly-available genomes). 
For ST17, SNP numbers are shown that reflect the diversity observed between 
patients (ST17-inter) and within individual patients (ST17-intra; based on 
sequencing of three isolates per patient). 
3.4.6 Hypermutators by in silico Prediction 
The in silico prediction model identified nine patients in whom isolates had 
putative hypermutator status (see Table 3.5). No deleterious mutations were 
found in uvrD or mutT.  The pairwise comparisons which included at least one 
putative hypermutator are shown in Figure 3.2 by open circles, and these 
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comparison have a significantly greater difference than those which do not 
include at least one putative hypermutator (see Figure 3.3).  
 
  Gene and nature of mutation 
Isolatea STb mutS mutL mutY mutM dnaQ 
PIB16 ST17 L52P Q52X  L342P  
PIB26 ST17 Frameshift     
PIB45 ST27 V264E     
PIB01 ST235 ΔL541-
S544 
    
PIB23 ST252     R33H 
PIB58 ST252  H469R   R33H 
PIB67 ST252     R33H 
PIC30 ST252  Frameshift   R33H 
PIB63 ST253 Frameshift  H72R   
Table 3.5 Prediction of hypermutators based on the identification of 
deleterious mutations in genes conferring DNA proof-reading and 
mismatch repair functions All of the indicated amino acid substitutions are 
predicted to be deleterious by both SNAP2 and PROVEAN, whilst the frameshift 
mutations each cause premature truncation of the gene product. a PIB isolates 
are from NCFB patients, whilst PIC isolates are from CF patients. b Sequence 
Type, as defined by Multilocus Sequence Typing (MLST). 
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Figure 3.3 SNPs distances in pairwise comparison with and without 
predicted hypermutators Predicted hypermutable PA isolates exhibited 
significantly elevated levels of genetic divergence (SNP distance) relative to 
predicted non-hypermutable PA. 
3.5 Discussion 
This study shows that while cross-infection with PA is highly likely to have 
occurred in our NCFB cohorts, it does not appear to be common. The possibility 
of cross-infection was raised by the findings of shared strains by three molecular 
techniques. The declaration of a transmissible strain however requires more than 
just the confirmation of shared strains and deserves particular consideration and 
judgement.  
Current technology does not allow certainty with regards to cross-infection. In 
addition, the assessment of sputum may not be representative of all regions of 
the lungs. Consequently, a transmissible strain may be missed. Despite these 
issues, investigators can accumulate evidence to comment on the likelihood of 
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cross-infection. This may include: the proportion of shared strains in a cohort; 
how genetically related isolates are; the plausibility of transmission episodes 
occurring; and a knowledge of abundant strains and interventions affecting new 
acquisition.  
Cross-infection is plausible in NCFB. Growing cohorts of patients with NCFB, the 
establishment of specialist clinics for NCFB, and appropriate referral to 
pulmonary rehabilitation courses enhance this risk.[6, 42] The LES, a known 
transmissible strain in CF cohorts, has been identified in the air where patients 
have been present several hours before, and other work has shown the potential 
for viable PA to remain airborne for at least 45 minutes.[178, 184] Consequently, 
aerosolisation is a plausible route and therefore patients may not even have had 
contemporaneous presence for transmission to occur. Whilst basic infection 
control measures should ideally prevent the risk of direct and indirect contact 
transmission being an issue, it would be naïve to assume these are always 
followed. In addition, hospitals contain non-clinical areas such as shops and 
canteens where infection control guidelines cannot be enforced.   
Previously we have had significant evidence for cross-infection in CF but not in 
NCFB, and the reasons why need to be considered. It should be noted that there 
have been multiple studies where cross-infection has not appeared to be a 
significant issue in CF cohorts and some evidence for cross-infection has come 
from episodes of high exposure including holiday camps and between 
siblings.[187, 202, 203, 346] CF cohorts are also more likely to be seen at more 
frequent intervals in disease-specific clinics, and the duration of appointments 
may be longer due to multidisciplinary reviews. Consequently the period of time 
that patients may be at risk is likely to be greater. In addition, the burden of the 
pathogen is likely to be higher in CF cohorts in whom a considerably higher 
proportion are chronically colonised with PA.[107, 130, 347] NCFB patients have 
therefore traditionally not been exposed to as much of a bacterial burden. It may 
also be that the relative lack of investigation of NCFB cohorts for shared strains 
has not revealed significant cross-infection. However, there have been two recent 
publications suggesting the possibility of the occurrence of cross-infection.[131, 
211] 
The strong evidence of cross-infection in this study comes from isolates from 
three patients which were identified as ST564 by both WGS and MLST, and 
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clustered together by RAPD. Between the isolates from these three patients there 
was considerably less SNPs difference by pairwise comparison than observed 
among isolates from other patients. This strain was also absent from the other 
cohorts. ST564 only has 3 entries on the global database but these submissions 
are from three separate countries and two continents. It is not a well-described 
strain in the literature. There was an identifiable occasion when two of these 
patients (B9 and B26) attended the same clinic and would have used the same 
waiting and lung function rooms. This potential cross-infection event did not 
coincide with a clear change in PA culture status as one of the patients 
intermittently isolated PA before and after this event whilst the other patient had 
evidence of multiple PA strains (and therefore super-infection may have 
occurred). Whilst we were unable to identify potential cross-infection event(s) 
involving the third ST564-infected patient (who also carried multiple strains), a 
difference of only 4 SNPs strongly supports cross-infection. Interactions may 
have occurred in or outside the hospital that are not apparent via the review of 
clinical notes. Furthermore, we believe ST564 acquisition from a common 
environmental source is highly unlikely due to its absence from other cohorts, and 
it being so sparsely described previously.   
Whilst the lack of SNPs difference creates a strong argument, interpretation of 
other ST types is not clear cut. There has been some longitudinal work showing 
mutation rates of 1-5.5 SNPs/year which may help to interpret cross-infection 
risk.[154, 348-350] Our example of two patients sharing facilities and within 18 
months having isolates only 10 SNPs different, does therefore seem plausible. 
When considering the other strains in this study, it must be noted that other work 
has demonstrated that hypermutators may generate rates of change in the region 
of 100 SNPs/year.[351] We have provided evidence that hypermutator status is 
a real issue in interpretation of this kind of data, by showing significantly greater 
genetic diversity by pairwise comparison of isolates when predicted 
hypermutators are involved. Also of note, paired samples from the same patient 
may have significant differences in SNPs.[352] Consequently, large numbers of 
SNPs difference cannot provide absolute certainty that cross-infection has not 
occurred and a strict cut-off value cannot be used to confirm cross-infection. 
Therefore, there may have been episodes when cross-infection has occurred but 
WGS analysis does not make it as apparent. In order to gain greater insight into 
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the expected level of diversity of unconnected isolates of the same strain, we 
incorporated publicly-available genomes of the relevant ST types. With these 
points in mind, it is important to consider the other shared strains in detail. 
The most abundant strain in the NCFB cohort was Clone C (ST17). This is a well-
described abundant strain which has high rates in clinical and environmental 
settings.[218] Multiple studies in both CF and mixed cohorts have consistently 
demonstrated its presence.[221, 223, 224] Strikingly, we did not identify Clone C 
within our CF cohort. Among the NCFB patients who have this strain, there were 
time points when cross-infection could have occurred. The WGS data however 
suggested greater between-patient diversity than within-patient diversity and 
large SNP differences. In those in whom hypermutator status was predicted, the 
pairwise comparisons showed particularly marked genetic diversity (see Figure 
3.2).  Importantly, the comparison with the unconnected genomes which were 
incorporated showed similar diversity. Also of note, Clone C was shown to be 
present in non-respiratory samples from both the hospital and community setting. 
With this accumulation of evidence, we believe that Clone C is likely to be a 
prominent strain in the local environment and that cross-infection with this strain 
has probably not taken place. The only other strain which was shared among 
NCFB patients but not CF patients was ST253, which is also known as PA14. 
This was shared between two patients and had a large number of SNPs 
difference (741). Whilst hypermutator status was predicted in one of the two, the 
lack of an identifiable cross-infection event, the isolates having greater diversity 
between them than some of the unconnected genomes, the common-occurrence 
of this strain in our non-respiratory cohorts, and ST253 being recognised as a 
major globally abundant strain, suggest that this is not a case of transmission 
between patients.  
There were 2 shared strains in our CF cohort including one strain (LES/ST146) 
shared between a pair of twins. The twins had been infected with PA for many 
years, and before their care began in our unit. Their high levels of personal 
contact and relatively few SNP differences, point strongly to cross-infection. 
These two isolates were noticeably closer to each other genetically than they 
were to the unconnected genomes which were incorporated in our analysis. The 
WGS analysis of the other shared strain in our CF cohort (ST27) does not support 
cross-infection. ST27 is a common environmental strain and our isolates had 
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similar diversity when compared to unconnected genomes. Owing to our strict 
segregation policies for our CF cohort, these patients should not have come into 
contact with each other. In the out-patient clinics, patients go directly to their own 
consultation room, avoiding a communal waiting area. No other patient in the 
study uses that room during the clinic. During in-patient admissions, patients are 
managed in a single room and do not use shared facilities. The exceptions to 
these procedures are siblings. Consequently we do not have evidence of our 
segregation policy failing in its purpose. 
In addition to the strains shared exclusively within the respiratory cohorts, there 
were 5 strains which were shared across the cohorts including the previously 
described high risk clones ST175 and ST235.[238] Importantly these isolates 
have shown as high levels of diversity when compared to the unconnected 
genomes as they did to each other, as illustrated in Figure 3.2. When looking at 
this Figure, it should be noted that with ST252 a pairwise comparison between 
two clinical samples was clearly less than the others in our cohorts. Whilst similar 
to some unconnected genomes, its predicted hypermutator status may raise 
concerns of this being an example of cross-infection which is not immediately 
apparent by simple SNP comparison. ST252 was a strain found in 3 NCFB 
patients, 1 CF patient, and has been found in distant locations such as Australia 
and Brazil on the MLST database.[332] The pairwise comparison in question had 
a difference of 156 SNPs and was between two NCFB patients. Review of clinical 
attendance could not identify a potential cross-infection events. In light of this, the 
degree of genetic difference and the demonstration of some unconnected strains 
having similar diversity, it is felt that this is unlikely to have been an example of 
cross-infection. The large genetic difference between the CF isolate of this strain 
and the others (greater than 3600 SNPs), does not suggest cross-infection 
between the CF cohort and the NCFB even when taking into account the 
hypermutator status of all the ST252 isolates. None of the other shared strains 
raised concerns of further cross-infection events either within or across cohorts. 
ST395 showed a lower level of diversity than the other strains which were shared 
across cohorts, however none of the isolates were predicted to be hypermutators 
and the pairwise comparisons showed very similar diversity amongst themselves 
as to when they were compared to the unconnected genomes.  
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This study has multiple strengths. It gives a comprehensive epidemiological 
review of PA in an unsegregated NCFB cohort who share both healthcare 
professionals and facilities with a CF cohort. The collection took place over a 
relatively short period of time and hence provides a “snap-shot view”. Examining 
multiple isolates reduces concerns that strains were being missed through 
investigating just single colonies. The use of three molecular techniques adds to 
the robustness of this study but their limitations must be noted, and warrant 
highlighting.  
RAPD is an effective discriminator of strains, but its output is not reliably 
interpretable between cycles and gel electrophoresis of RAPD products 
introduces unacceptable variability.[244] Our study design circumvented these 
issues by ensuring that all isolates with unique RAPD profiles were re-analysed 
within a single batch, and employing Bioanalyser analysis to enable a robust and 
reproducible comparison of RAPD profiles. It could be argued that a large number 
of isolates did not undergo full analysis due to their exclusion following the initial 
visual inspection stage, and that this is a limitation. Whilst this is true, there are 
multiple examples of samples being considered “different” by visual inspection 
but then appeared to be clonal by Bioanalyser analysis and the same ST-type by 
MLST. With the design of the study retaining those felt to be different by visual 
inspection, this would suggest that more isolates could have been excluded for 
subsequent further analysis. This may have reduced costs but also increased the 
risk of missing other shared strains. As a caveat to this, there is also evidence of 
strains appearing clonal by RAPD analysis, which then had different ST types by 
MLST, hence suggesting there remained a small chance of additional shared 
strains being missed during the RAPD process.  
The next technique, MLST, is considered a “Gold-Standard” strain typing 
technique.[353] It provides unambiguous data which can be compared to a 
substantial global database. The scheme’s principle involves the sequencing of 
highly conserved housekeeper genes, but therefore only a very small amount of 
the genome. Consequently, like RAPD, it does not provide sufficient resolution to 
discriminate closely-related strains. MLST is also considerably more expensive 
than RAPD. It is worth noting that there was complete concordance between the 
ST type as defined by MLST and that defined by WGS in those isolates which 
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underwent both techniques, suggesting that the highlighting of shared strains for 
WGS by MLST was an effective pipeline.  
The final technique we have used is WGS. This has the obvious appeal of a 
comprehensive review of the genome. The calculation of SNP difference reflects 
the genetic diversity between bacterial genomes, but its interpretation has the 
issues described above. We have looked to reduce these weaknesses through 
the prediction of hypermutators and the inclusion of unconnected publicly- 
available genomes. Whilst these approaches do not completely eradicate these 
issues, they add a level of analysis which has not been applied to similar work, 
and we believe is a major strength to this study. Whilst we were not able to include 
unconnected genomes for ST564, this is not a major issue as our results did not 
show an intermediate amount of genetic difference- the range that causes the 
greatest uncertainty in this type of analysis. WGS’s additional weaknesses as a 
technique for this sort of work include its lack of universal accessibility and that it 
requires more complexity and cost than RAPD or MLST.  
This work has obtained a cross-sectional review of PA epidemiology in a NCFB 
cohort with the added context of a parallel CF cohort and non-respiratory isolates 
from the same healthcare and geographical setting. Longitudinal analysis would 
be a valuable extension of this study and would give an insight into the chronicity 
and persistence of individual strains. It would also be important to assess for 
evidence of ST564 becoming more prevalent across the NCFB cohort. This, 
however, should not be performed too soon. The hospital attendance of patients 
with NCFB tends to be less frequent than those with CF and it may take a 
considerable amount of time for a strain to show increasing prevalence in the 
cohort. The absence of environmental PA data in this study may be seen as a 
limitation but the absence of a truly dominant strain means that it would be very 
unlikely to find a relevant hospital reservoir. In addition, the marked differences 
in Clone C prevalence across the respiratory cohorts, despite their sharing of 
facilities, argues against an environmental reservoir in the hospital. Our non-
respiratory samples do provide a comparator group to our respiratory cohorts, 
and the prominence of Clone C and PA14 does not point to a PA population 
structure out of keeping with previous data.[220]  
A further limitation is the identification of potential cross-infection events. Our 
review of this information could only include documented activity within the RD&E 
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hospital. Therefore there is the potential for cross-infection events to occur which 
would not be identified by this approach. This could include visits to community 
healthcare, attendance with a relative, picking up a prescription from the in-
hospital chemist, spending time in hospital amenities, or the sharing of public 
spaces. There may also have been further shared strains that were not identified 
within the patient cohort. This could have been for a multitude of reasons 
including, not all patients attending the department at a point when recruitment 
was possible, the patient not being able to produce a sample, the pathogen not 
being grown in the laboratory, and the strain being excluded by RAPD. 
Consequently there is a small possibility that the reported findings are an 
underrepresentation of the level of cross-infection occurring.  
Our findings in this study are consistent with previous work. The only similar 
NCFB UK study was performed in Newcastle where cross-infection may have 
taken place, but was believed to be rare.[131] Our study is an important addition 
to this work, not just by adding to the evidence-base, but also due to the difference 
in the set-up between sites. In the Newcastle study, patients with NCFB were 
managed on a separate site to the CF cohort, whilst our cohorts are managed on 
the same site and within the same department. A recent study performed a cross-
sectional genetic review of isolates of PA obtained through a multi-centre drug 
trial.[211] Due to the methodology and the multi-centre approach, this isn’t as 
relevant a publication for the specific question of cross-infection within NCFB 
cohorts. It did however show evidence of shared lineages within single centres 
and that isolates from the same sample could show greater diversity than the 
comparison of isolates from different patients. The inference of this is that cross-
infection could be occurring, which is again in keeping with our findings. 
It could be argued that if cross-infection is occurring then patients should be 
segregated. This may, however, not be the most pragmatic approach. The 
segregation of our CF cohort has logistical implications in terms of clinic capacity, 
time and space. If these were applied to NCFB clinics, the number of patients 
who could be seen per clinic would have to be reduced significantly. This would 
impact follow-up at the interval desired. Physiotherapy clinics and pulmonary 
rehabilitation courses would also be affected. From a patients perspective this 
may be highly frustrating, and also provide a negative psychological impact via 
segregation and the implication of being an infectious threat to others. Overall, 
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we believe that the negative impacts may outweigh the low risk of cross-infection. 
Some may argue that cohorts could be segregated by colonisation status, but this 
would not stop super-infection and patients will be infected with PA for a period 
of time before clinical investigation has detected it. We do not advocate a change 
in policy based on these results. Longitudinal data or evidence of cross-infection 
with other pathogens may however change opinion on this. Without a segregation 
policy it is clearly important that basic infection control measures should not be 
ignored.  
3.6 Conclusions 
Our study has shown evidence of likely but uncommon cross-infection between 
NCFB patients. At present, we believe the negative impacts that would be 
associated with implementing a segregated NCFB cohort (including reduced 
patients per clinic and reduced access to pulmonary rehabilitation courses) 
outweigh the low risk of cross-infection. However, with growing NCFB cohorts 
nationwide and cross-infection possible, ongoing longitudinal surveillance is 
clearly warranted.[20, 354, 355] 
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Chapter 4- Comparison of an in silico 
prediction model of hypermutability in 
Pseudomonas aeruginosa to a 
traditional hypermutator assay 
4.1 Abstract 
Introduction: The hypermutator phenotype of PA is well recognised in chronic 
lung disease. It results in a higher spontaneous mutation rate and is associated 
with antibiotic resistance. Interpretation of cross-infection studies with WGS 
require an appreciation of this phenotype when investigating beyond a short-term 
outbreak. In Chapter 3, we used a novel in silico prediction model to identify 
hypermutators. This was to aid our interpretation of the epidemiology of PA in 
cohorts with chronic infection and evidence of shared strains. Here we compare 
this in silico prediction model to the traditional culture-based method of identifying 
the hypermutator phenotype.   
Methods: Isolates which were predicted to be hypermutators by the in silico 
prediction model underwent traditional phenotypic assessment of 
hypermutability. Where available, examples of the same strains which were not 
predicted to be hypermutators were also included, alongside PAO1 as a control.    
Results:  Nine isolates predicted to be hypermutators and 5 isolates predicted not 
to be hypermutators (normomutators), underwent traditional phenotypic 
assessment of hypermutability. Isolates which were predicted to be 
hypermutators had a significantly higher actual mutation frequency when 
compared to both the predicted normomutators (p<0.00001) and PAO1 
(p=0.005). Seven out of 9 predicted hypermutators displayed phenotypic 
hypermutator behaviour. In contrast, none of the predicted normomutable 
isolates displayed hypermutator status.  
Conclusion: Our in silico prediction model displays compatibility with a traditional 
culture-based phenotypic assay for highlighting potential hypermutable isolates 
of PA. This highlights its usefulness in WGS cross-infection studies for chronic 
infection. 
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4.2 Introduction 
As already described in this thesis, PA has demonstrated its adaptability to a wide 
range of environments, including the airways of diseased lungs. An adaptive 
phenotype seen in this setting is that of the hypermutator where microorganisms 
display a higher spontaneous mutation rate. In PA this phenotype is rare in the 
environment and acute infection, but is more prevalent in chronic infection in the 
lungs. Previous data has suggested that 36-55% of CF patients may harbour this 
phenotype.[159, 345] This may even be an underestimation due to the significant 
PA divergence found in the lung and the observation that hypermutators can 
occur alongside normomutators.[356] A single sputum sample may not fully 
reveal this. Whilst studied in less detail, hypermutators have also been found in 
NCFB patients.[161] The hypermutator phenotype is thought to be due mainly to 
inactivation of the mismatch repair system (MRS) through loss of function of 
antimutator genes like mutS and mutL, but also through defects in the GO system 
which deals with error avoidance.[357, 358] 
Whilst a high mutation rate could be considered a disadvantage due to an 
increased risk in deleterious mutations, it may also have advantages in an airway 
environment, such as an association with biofilm growth.[359] A further 
association, and a major reason for the ongoing interest in this phenotype, is 
antibiotic resistance.[360-362] Patients with the chronically diseased airways of 
CF or NCFB are likely to have been subjected to a high historical usage of 
antibiotics. However, antibiotic resistance is thought to not solely be due to 
antibiotic use, and may instead arise as a consequence of hypermutability.[363] 
Furthermore, some studies have reported an association between clinically-
relevant markers of disease and a hypermutable state, though conflicting results 
exist, and confounders may explain these associations.[361, 364, 365] At present 
the investigation of hypermutator status has no place in standard clinical practice 
due to the uncertainties of its significance.[366] 
As WGS continues to become more accessible, hypermutator status may 
become important for a different reason. Among the many potential benefits of 
WGS, the use of the technique for cross-infection studies has been shown to be 
invaluable, both through our work described in Chapter 3, and others.[266, 367] 
In short-term outbreak studies, the mutation rate of microorganisms may not have 
much of an impact on interpretation of results. However in longer-term studies, 
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an appreciation of the mutation rate becomes highly relevant, particularly in cases 
where there is a reasonable amount of genetic difference but a prolonged period 
for that divergence to have occurred. Significantly different mutation rates have 
been reported for PA in chronic lung disease. The normal rate has been reported 
by some as 1-5.5 SNPs per year, whilst hypermutators have been reported with 
a rate of 100 SNPs per year.[154, 348-351] Consequently the potential range of 
difference in SNPs between two isolates involved in a cross-infection event 2 
years previous, may be very large. In cases where hypermutators are involved, 
the differences may be similar to those seen between seemingly unconnected 
strains. In Chapter 3 we used a novel in silico prediction model of hypermutator 
status to enhance our understanding of potential cross-infection in an 
epidemiological study of PA. This model predicted hypermutable isolates in 8 out 
of the 21 (38%) NCFB patients interrogated by WGS and 1 out of the 9 (11%) CF 
patients interrogated in this way. The pairwise comparisons of SNPs in these 
isolates were significantly greater than in those not predicted as having 
hypermutator status, suggesting an accuracy and relevancy to this output (see 
Figure 3.2 and Figure 3.3). 
The investigation for the presence of the hypermutator phenotype has 
traditionally been performed through the interrogation of PA growth on plates of 
culture media with and without rifampicin.[159] The frequency of mutants found 
on the rifampicin plates compared to the number of isolates found on plates 
without rifampicin allows the calculation of a quantifiable measurement known as 
the mutation frequency. The subsequent interpretation of this value has been 
variable, but often includes comparisons to the mutation frequency of PAO1 or a 
known hypermutator laboratory strain.[158, 159, 363, 368] Whilst straightforward, 
the technique is not rapid due to the requirement of time for growth, and the 
plating and subsequent counting of bacteria onto a large number of plates as 
triplicates are required to ensure robustness. As the novel in silico prediction 
model was integral to the investigation performed in Chapter 3, this chapter will 
compare the output from this model to the traditional culture-dependant 
technique.     
4.3 Methods 
A sub-set of isolates were chosen from the collection investigated in Chapter 3 to 
undergo further hypermutator assessment. The isolates which by in silico 
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prediction were described as hypermutators were all included as were examples 
of isolates of the same ST type which were not predicted as hypermutators by 
the model. Consequently, all isolates reviewed had undergone genotypic 
assessment by RAPD, MLST and WGS. Furthermore, all but one of these 
isolates had undergone further phenotypic assessment as part of an 
undergraduate student project which had included antibiotic resistance to 
ciprofloxacin, gentamicin and ceftazidime. These antibiotics are all clinically-
relevant for this cohort of patients.  
The hypermutator assay was performed as previously described (see Chapter 
2).[158] All batches included PAO1 to provide a batch-to-batch comparison.  
The primary assessment of hypermutability was the frequency in comparison to 
PAO1 within that batch. Those that were 20-fold greater or more were defined as 
strong hypermutators (SM); those 10-20 fold greater as weak hypermutators 
(WM), and others as normomutators (NM). This was an arbitrary definition for this 
study having taking into account alternative criteria and is referred to from here 
forth as M-status. Additional assessment of hypermutator status was also 
performed based on alternative criteria.[158, 159, 368] Clinical details for these 
patients had been obtained previously as part of the work involved for Chapter 3. 
The antibiotic resistance patterns from the undergraduate project were also 
reviewed. 
4.4 Results 
4.4.1 Samples Investigated 
In total 14 isolates underwent the Hypermutator assay, of which 9 were predicted 
to be hypermutators by the in silico prediction model. The 5 isolates which were 
not predicted to be hypermutators provided matches for ST17, ST27, ST235 and 
ST253. All ST252 isolates that had previously undergone WGS were predicted 
to be hypermutators and consequently no comparators were available for this 
strain. Of the 14 isolates, 11 originated from NCFB patients and 3 from CF 
patients. The duration of chronic infection in these patients are shown in Table 
4.1. A variety of mutations were seen which were predicted to have deleterious 
effects in MRS or GO systems, and these have previously been illustrated in 
Table 3.5. 
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 HMa  NMa  
Subjects 9 5 
NCFB 8 3 
Time since 1st PA isolate 
- Less than 1 year 
- 1-5 years 
- 5-9 years 
- More than 9 years 
 
0 
5 (55.6%) 
1 (11.1%) 
3 (33.3%) 
 
0 
1 (20%) 
0  
4 (80%) 
Table 4.1. Time since 1st documented PA-positive sputum culture aHM 
(Hypermutator) and NM (Normomutator) status are based on the in silico 
prediction. 
 
4.4.2 Variation in PAO1 Mutation Frequency  
Each batch of hypermutator assays performed contained no more than 4 isolates 
in order to maintain accuracy, and each batch contained a PAO1 control from the 
same master-strain stock. Consequently the same PAO1 master-strain was 
measured in 5 separate triplicates and provides insight into the consistency of the 
assay.  The mean mutation frequency was 3.48 x 10-8 (95 % Confidence interval 
(CI) 2.7 x 10-8- 4.28 x 10-8) with a standard deviation of 1.55 x 10-8. The within 
triplicate standard deviation ranged from 6.22 x 10-9 to 1.34 x 10-8 (mean within 
triplicate standard deviation of 1.04 x 10-8). As expected there was less variance 
within triplicates than across all samples and therefore the mutation frequency is 
most robustly assessed by comparison to the PAO1 triplicate result within the 
same batch. 
4.4.3 Mutation Frequencies  
Mutation frequencies calculated from the mean of the triplicates were obtained 
from all samples. One sample required prolonged incubation in order to grow 
sufficiently to record. The mean mutation frequency among all experiments on 
clinical samples was 1.87 x 10-6 (95% (CI) 1.85 x 10-6- 1.88 x 10-6).  The predicted 
hypermutators had significantly greater actual mutation frequencies as well as 
mutation frequencies compared to PAO1 (see Table 4.2).  
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 HMa NMa P valueb 
xPAO1c  126.49 1.41 0.005 
Mutation 
Frequency 
2.88 x 10-6 4.16 x 10-8 <0.00001 
Table 4.2 Comparison of mutation frequencies between predicted 
hypermutators and predicted normomutators aHM and NM status are based 
on the in silico prediction. bThe p values are calculated by Mann-Whitney Test. 
Values are displayed as means. cThe xPAO1 is calculated by the raw mutation 
frequency divided by the mutation frequency of PAO1 in that batch 
 
By our a priori definition of the hypermutator status phenotype, 7 out of 9 of those 
predicted to be hypermutators reached the criteria (5 were SMs and 2 WMs). 
None of those predicted to be normomutators displayed the hypermutator 
phenotype (sensitivity 100%; specificity 78%) (see Table 4.3 and Table 4.4). All 
predicted hypermutators had a higher frequency than PAO1. Two isolates did not 
meet our definition of a hypermutator for this assay. Both of these only had an 
R33H mutation in dnaQ and no other identified relevant mutations. Mutation 
frequencies were also compared to alternative criteria for defining the strength of 
the hypermutator phenotype (see Table 4.5). The greatest correlation appeared 
to be with the definition used by Kenna et al.[158]  
4.4.4 Antibiotic Resistance 
Antibiotic testing had been performed for 8 out of the 9 predicted hypermutators 
and all the predicted normomutators in the previous undergraduate study. No 
duplication of this testing has taken place. There was significant resistance to 
clinically-relevant antibiotics reported in this work (see Tables 4.6 and 4.7). No 
isolate was reported as being sensitive to all three antibiotics. The most marked 
observation was with ceftazidime, where 1 out of 5 of the predicted 
normomutators were resistant, whilst seven out of eight of the predicted 
hypermutators were (p= 0.015). The only predicted hypermutator not to be 
resistant contained the R33H mutation in dnaQ. A similar finding was found when 
defining the isolates by the hypermutator assay result. All 6 of the hypermutators 
which had sensitivity data were resistant to ceftazidime whilst only 2 out of the 7 
normomutators had were resistant (p=0.008).
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Table 4.3 Mutation frequencies and hypermutator status by various criteria for predicted hypermutators 
Sample (ST) Mutation Mean 
Mutation 
Frequency 
xPAO1 M-Status Status by 
Kenna et al 
[158] 
Status by 
Oliver et al 
[159] 
Status by 
Lutz et al 
[368] 
PIB26 (ST17) mutS- 
Frameshift 
5.78 x 10-7 14.5 WM WM NM SM 
PIB45 (ST27) mutS-V264E 5.59 x 10-6 140.25 SM SM HM SM 
PIB16 (ST17) mutS- L52P 
mutL- Q52X 
mutM- L342P 
5.09 x 10-7 36.82 SM WM HM SM 
PIB63 (ST253) mutS- 
Frameshift 
mutY- H72R 
9.21 x10-6 666.48 SM SM HM SM 
PIB58 (ST252) mutL- H469R 
dnaQ-R33H 
7.92 x 10-6 226.92 SM SM HM SM 
PIB67 (ST252) dnaQ- R33H 2.46 x 10-7 6.29 NM WM NM SM 
PIC30 (ST252) mutL- 
Frameshift 
dnaQ- R33H 
4.61 x 10-7 11.81 WM WM NM SM 
PIB01 (ST235) mutS- ΔL541-
S544 
1.27 x 10-6 32.57 SM SM HM SM 
PIB23 (ST252) dnaQ- R33H 1.3 x 10-7 2.78 NM NM NM WM 
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Sample Mean 
Mutation 
Frequency 
xPAO1 M-
Status 
Status 
by 
Kenna 
et al 
[158] 
Status 
by 
Oliver 
et al 
[159] 
Status 
by Lutz 
et al 
[368] 
PIB10.9 1.91 x 10-8 0.48 NM NM NM NM 
PIB22.6 4.2 x 10-8 3.04 NM NM NM WM 
PIB78.6 5.19 x 10-8 1.49 NM NM NM WM 
PIC07.9 3.24 x 10-8 0.69 NM NM NM WM 
PIC19.1 6.27 x 10-8 1.34 NM NM NM WM 
Table 4.4 Mutation frequencies and hypermutator status by various 
criteria for predicted normomutators 
 
 
Criteria Specificity Sensitivity 
M-Status 77.78% 100% 
Kenna et al [158] 88.89% 100% 
Oliver et al [159] 55.56% 100% 
Lutz et al [368] 100% 20% 
Table 4.5 Sensitivity and specificity for in silico predictions by various 
criteria 
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 HM  NM  
Isolates 8 5 
Ciprofloxacin 
- Sensitive 
- Intermediate 
- Resistant 
 
5 (62.5%)  
1 (12.5%) 
2 (25%) 
 
2 (40%) 
1 (20%) 
2 (40%)  
Ceftazidime 
- Sensitive 
- Resistant 
 
1 (12.5%) 
7 (87.5%) 
 
4 (80%) 
1 (20%) 
Gentamicin 
- Sensitive 
- Resistant 
 
1 (12.5%) 
7 (87.5%) 
 
0  
5 (100%) 
 
Table 4.6 Antibiotic resistance profiles for predicted hypermutators and 
predicted normomutators Results reported from previous undergraduate 
project 
 HM  NM  
Isolates 6 7 
Ciprofloxacin 
- Sensitive 
- Intermediate 
- Resistant 
 
1 (16.7%)  
1 (16.7%) 
4 (66.7%) 
 
3 (42.9%) 
1 (14.3%) 
2 (28.6%)  
Ceftazidime 
- Sensitive 
- Resistant 
 
0  
6 (100%) 
 
5 (71.4%) 
2 (28.6%) 
Gentamicin 
- Sensitive 
- Resistant 
 
1 (16.7%) 
5 (83.3%) 
 
0  
7 (100%) 
 
Table 4.7 Antibiotic resistance profiles for assay defined hypermutators 
and normomutators Results reported from previous undergraduate project 
 
4.5 Discussion 
In this chapter we have shown that those isolates predicted to be hypermutators 
by our in silico prediction model do indeed have a greater mutation frequency as 
determined by the traditional testing for the hypermutator phenotype. There was 
however large variability in the mutation frequencies observed among the 
predicted hypermutators, and by adopting different criteria some of these isolates 
would not be defined as phenotypic hypermutators. All isolates had originated 
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from patients who had been infected with PA for at least a year, and therefore the 
isolates were unlikely to represent acute infection.  
Our primary assessment was the comparison of mutation frequency to PAO1. A 
wide range of frequencies were seen, varying from a frequency of approximately 
half that of PAO1, though to a 666-fold increase. Whilst there are only small 
numbers available for comparison, there was no suggestion that hypermutator 
status correlated with ST type. There were four isolates belonging to ST252 which 
were predicted to be hypermutators and whilst two of them did not possess a 
mutation frequency greater than 10-fold that of PAO1, one ST252 isolate had a 
frequency which was over 200-fold the frequency of PAO1. What may be 
expected to be more relevant than ST type is the mutations noted during the in 
silico prediction. From the early literature into this topic, it has been made clear 
that mutS is a highly relevant gene.[357] Mutations were seen in mutS in 5 of the 
9 isolates and all but one were phenotypic hypermutators by all criteria detailed 
in Table 4.3 and all 5 were at least weak hypermutators by our criteria. Three 
isolates had mutations in mutL and just single isolates had mutations in either of 
the oxidized guanine (GO) system genes mutY and mutM. The isolate with the 
mutY mutation had the greatest mutation frequency, though it should be noted 
that there was also a mutL frameshift in this isolate. It is possible that a mutY 
mutation on its own may not have a large effect, but in combination with another 
mutation, may have led to a more dramatic change.[369] The other gene in which 
mutations were identified was dnaQ which is involved in proofreading activity and 
is also known as mutD. The same mutation (R33H) was found in all four of the 
ST252 isolates and no others. In two samples it was the only identified mutation 
of note, and these were the only two isolates which were not even weak 
hypermutators by our criteria (mutation frequencies PAO1 x 2.78 and PAO1 x 
6.29). This mutation on its own appears to have minimal mutator effect as defined 
by the hypermutator assay. The results from those that we did not predict to be 
hypermutators were as we would expect. None of the isolates reached criteria for 
hypermutator status by our criteria, or those described by Kenna et al or Oliver et 
al.[158, 159] This was not the case with the criteria by Lutz et al (Table 4.4), 
highlighting the discrepancies that exist between different hypermutator 
definitions.[368]  
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These discrepancies in definitions are worth considering. A 20-fold frequency in 
comparison to PAO1 was used to define hypermutator status in several 
studies.[159, 161] In the work by Kenna et al, whose methodology we have 
replicated, the definition of normomutable strains was based on the modal point 
of the distribution of mutation frequencies.[158] Three other categories were 
defined (hypomutators, weak and strong mutators), and those with a frequency 
20-fold greater were considered strong hypermutators. Consequently there were 
some which were considered weak hypermutators that had a frequency less than 
20-fold that of PAO1. To take this into account, we defined our categories with 
20-fold greater than PAO1 being noted as strong hypermutators and also noted 
those with frequencies 10-fold greater as weak hypermutators. Others have 
discriminated between strong and weak hypermutators with specific mutation 
frequency cut-offs.[368] In theory, it would be hoped that as the studies tend to 
have very similar protocols, including the same media and the same 
concentration of rifampicin in the media, that the mutation frequencies would be 
comparable. We have shown that even with the same master-strain and the 
assays being performed in the same laboratory by the same researcher, that 
variability is displayed. This is not an issue unique to ourselves, as this point was 
also made by Kenna et al.[158] It therefore seems logical that batch-to-batch 
variability should be considered in assessment of hypermutator status, rather 
than have specific mutation frequency cut-off points. As described above, a 
common option is an arbitrary threshold in relation to PAO1, however it is not 
clear what this should be.  
It is worth considering these results in the context of our pairwise comparison of 
SNPs in Chapter 3. Two ST17 isolates were included in this chapter (PIB16 and 
PIB26). The isolate PIB16 was more divergent from other ST17 isolates than 
PIB26, and had mutations in three genes, whilst PIB26 just had a frameshift in 
mutS. It may be expected therefore that PIB16 would have a higher mutation 
frequency, and indeed it did (PAO1 x 36.82 v PAO1 x 14.5). ST252 was the only 
other strain to have more than one predicted hypermutator. As mentioned above, 
2 of the 4 ST252 isolates did not meet our criteria for hypermutator status based 
on phenotype. These two had the least mean difference from other isolates of 
ST252. With regards to the two that were hypermutators, PIB58 had a far greater 
mutation frequency, though was less divergent from other isolates than PIC30. 
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This doesn’t not necessarily contradict our findings, as the origins of PIC30 may 
have been very different from the other ST252 isolates, and importantly isolates 
can switch their hypermutability. In a cross-sectional study it is impossible to know 
if an isolate has only recently obtained a hypermutable state. Duration of infection 
cannot be used as a surrogate of this as we can clearly see in our predicted 
normomutators that long-term infection does not necessary equate to a 
hypermutator phenotype.  
There was a large amount of antibiotic resistance noted in our isolates for 
ciprofloxacin, gentamicin and ceftazidime. Antibiotic resistance would be 
expected to some degree in hypermutators, but there was not a discernible 
difference from the resistance levels observed in normomutators for ciprofloxacin 
and gentamicin, albeit with very small numbers. There was however a statistically 
significant difference in rates of ceftazidime resistance in both predicted, and 
assay confirmed, hypermutators. All those which were resistant to ceftazidime 
were also resistant to gentamicin. This is of note as ceftazidime and gentamicin 
is a combination used for courses of IV antibiotics in patients with a history of PA, 
and is noted as common practice in national guidelines.[6] 
Taking things forward, a key question is why do we want to identify a 
microorganism as being a hypermutator? It has previously helped our 
understanding of adaptation to an environment, but as discussed above, at 
present there is no indication in clinical practice to investigate for this. If impacts 
on antibiotic resistance are of interest, then more direct measures would surely 
be of more relevance. However, identification of hypermutators should be of 
direct relevance to WGS-based cross-infection studies involving chronic 
infection. It is anticipated that the WGS method will become a gold-standard 
technique for this type of investigation. In a situation when WGS has already 
occurred, it would seem logical to then use information contained within the 
sequences to identify isolates that may accumulate SNPs at a higher rate- a 
potential modern way of defining a “Hypermutator”. This approach could evolve 
as WGS becomes more common and more longitudinal studies are performed. 
More genes may be revealed, and certain mutations may be identified as more 
or less important. The work in this chapter presents a starting point which even 
with small numbers, displays predictable differences between isolates.  
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There are clearly some weaknesses which should be noted. First of all, this study 
contains small numbers, though the hypermutator group did include every patient 
in whom we had predicted hypermutator status. Potential extensions of this work 
could include enlarging the investigation of those not predicted to be 
hypermutators. If we found isolates which displayed a hypermutator phenotype, 
then the WGS data could be re-examined for other mutations not previously 
identified. Further extensions could also include looking at multiple isolates from 
the same patient and investigating the heterogeneity of the potential 
hypermutator status and phenotype. With more resources, WGS on our large 
collection of isolates may provide greater insight into the accuracy of our in silico 
prediction model and the apparent significance of certain mutations. However, 
even with larger numbers the caveat of not knowing how long a microorganism 
has or has not been a hypermutator would prevent complete accuracy of 
interpretation. With this in mind, a study with the sequencing of longitudinal 
isolates with interrogation by this in silico prediction model and the hypermutator 
assay would improve understanding. A further weakness of this study is the 
hypermutator assay itself as it displays variability between batches. This was 
illustrated by the interrogation of PAO1 from the same stock across 5 batches. 
Our definition of hypermutator phenotype being based on comparison to PAO1 
within the same batch, should reduce this limitation. The marked difference in 
ceftazidime resistance was interesting to note but this was in the situation of low 
numbers and without replication performed of antibiotic sensitivity testing, which 
is a limitation of this finding. Significant resistance to this antibiotic in 
hypermutators is certainly consistent with recent work.[363] The fact that the one 
isolate which did not display resistance had the mutation with the weakest effect 
on hypermutator status, adds to the suggestion that further work would reveal 
mutations of less significance with regards to potentially useful markers such as 
antibiotic resistance and mutation frequency.  
4.6 Conclusions 
Interrogation of a sub-set of PA isolates which had undergone WGS, has 
supported the in silico prediction of hypermutator status which was used in 
Chapter 3. Despite small numbers, highly significant differences were seen 
between those predicted to be hypermutators and those which were not. Whilst 
the clinical application of testing for hypermutator status is unclear, this in silico 
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prediction model may be very useful for interpretation of cross-infection studies 
in the WGS-era. As more isolates of PA are analysed by WGS, the accuracy and 
relevance of this model can evolve. 
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Chapter 5- Culture-independent 
genotyping of Pseudomonas aeruginosa 
for cross-infection screening  
 
5.1 Abstract 
Introduction: Evidence has shown that cross-infection with PA occurs in CF and 
may occur in NCFB. Consequently, intermittent screening of cohorts is important. 
Current methods rely on cultivation of PA before employing a molecular technique 
such as MLST. This approach may be affected by false-negatives and bias 
towards faster growing strains when multiple strains are present. Culture-
independent approaches are developing in molecular microbiology, and we have 
compared the output from the traditional culture-dependent approach of MLST 
with a novel culture-independent approach in a CF cohort. 
Methods: Patients with CF who had previously isolated PA were prospectively 
recruited and submitted a sputum sample for investigation as part of our 
investigations described in Chapter 3. DNA was extracted from all sputum 
samples and genotyping by MLST was attempted. If PA had been cultivated, then 
DNA was extracted from isolates and genotyped by MLST as reported in Chapter 
3.  
Results: Thirty-two patients were recruited and sample processing by both 
approaches was performed on 31. Of these 31 sputum samples, PA was cultured 
from 22. Genotyping by MLST was achieved in 23 patients by the culture-
independent approach and 22 by the culture-dependent approach. In three 
instances genotyping was possible when culture did not isolate PA, and in 
another two instances genotyping was only successful via the culture-dependent 
approach. The culture-independent approach showed evidence of four strains 
being found in multiple patients (ST146- the Liverpool Epidemic Strain, ST217- 
the Manchester Epidemic Strain, ST27 and ST395) of which two were not 
revealed by the culture-dependent approach. From the 20 cases where 
genotyping results were obtained by both methods, there were exact matches for 
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130 of the 140 loci interrogated (92.86%). In 19 of these 20 patients, strains from 
the same clonal complex were revealed by both approaches.  
Conclusion: Genotyping for PA via a culture-independent technique is feasible 
and can reveal shared strains missed by culture-dependent techniques. There is 
strong agreement between the two approaches and the culture-independent 
approach offers results unbiased by culture. This approach has potential for 
cross-infection screening, including in those who only intermittently isolate PA. 
However, vigilance is required towards the impact of multiple strains within 
individual samples. 
5.2 Introduction 
As previously described in this thesis, cross-infection with PA is an important 
issue in CF. We have demonstrated highly likely cross-infection in a NCFB cohort 
and this has also been either reported or highlighted as a possibility by 
others.[131, 211, 355] Practical genotyping techniques are therefore important 
for centres to be able to screen for cross-infection in CF and NCFB, and 
potentially other respiratory diseases. 
As described in Chapter 3, we undertook an epidemiological review of PA in our 
NCFB and CF cohorts using three molecular techniques- namely RAPD, MLST 
and WGS. All three of these required the cultivation of PA on culture media from 
sputum samples. This first step provides a first potential limitation of this process 
as it is well-recognised that patients can intermittently isolate PA and at times this 
may be due to the technique not isolating PA, rather than PA being truly absent. 
In our study all patients recruited had previously isolated PA. We recruited 63 
NCFB patients but only obtained PA from 46. Of the 17 from whom we failed to 
obtain isolates, 12 isolated PA again after their recruitment. In our CF cohort we 
failed to obtain PA from 9 out of 31 and 5 re-isolated PA after their recruitment.  
If PA is isolated, a second issue is faced - of all the colonies on the plate how 
many and which ones will you investigate? It is recognised that multiple strains 
of PA can be found within a single sputum sample and therefore if just one colony 
is examined the presence of multiple strains will always be missed.[261] In 
addition, the isolate that you pick may not be the predominant, or the most 
important strain in the lung. In our work, ten isolates which were morphologically 
representative of those seen on the plate were picked for investigation. The 
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numbers of isolates picked in previous studies is highly variable but clearly the 
more isolates picked, the more accurate the representation you will have of the 
predominant strains.[131, 261] Also of note, PA can become visible on plates at 
different rates. Consequently there may be a bias towards fast-growing strains if 
there are multiple strains present.  
In recent years there have been many studies looking into the bacterial 
communities in the lungs and this has required the extraction of DNA directly from 
sputum samples to reveal the presence of bacteria which have not been cultured 
by standard techniques.[302] As would be expected, these studies have shown 
that PA can be detected by culture-independent techniques in samples of patients 
with chronic lung disease. With growing interest in culture-independent 
microbiological investigation, it is likely that the extraction of DNA will become a 
common starting point in standard diagnostic testing. This allows the potential for 
genotyping directly from sputum samples rather than requiring the initial step of 
culture. There has been a precedent for this with MLST having been applied 
directly to DNA from sputum for BCC genotyping,[370] however it has not been 
described in PA. If a similar approach was feasible for PA then the benefits would 
be multiple. The process would be quicker, less biased by culture and the colony 
picking process, and potentially allow the revealing of multiple strains. This could 
allow rapid and regular monitoring of a cohort for evidence of cross-infection. It 
has been shown that PA can be detected by molecular techniques, even in 
culture-negative samples.[318] Therefore this approach may allow strain typing 
of culture-negative samples. This may allow greater understanding of patients 
who intermittently isolate PA and also with regards to the cycle of seeming 
“eradication” followed by “re-infection”.  
Due to the above described issues, we have performed a study to look into the 
feasibility of applying the MLST scheme for PA directly from sputum samples. 
This has been performed alongside culture-dependent MLST to provide insight 
into the concordance of the output from these techniques. DNA from samples 
known to harbour different strains have also been artificially mixed in order to 
assess the impact of multiple strains on the techniques output. For the purposes 
of this thesis, the application of the MLST scheme for PA directly from sputum 
will be described as culture-independent MLST, whilst the traditional methods, as 
used in Chapter 3, will be described as culture-dependent MLST.  
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5.3 Methods 
For the CF patients investigated in Chapter 3, the sputum samples from which 
isolates originated were stored for investigation alongside the isolates 
themselves. Sputum samples were also stored from those who were recruited 
but whose investigation by culture methods did not reveal PA. The isolates were 
investigated as described in Chapter 3. The sputum samples subsequently 
underwent DNA extraction with the GeneJET Genomic DNA Purification Kit 
(ThermoFisher Scientific) as described in Chapter 2.2.3. MLST was performed 
on all sputum samples as described in Chapter 2.4. As an initial screen, PCR 
amplification was first performed for two loci (acsA and guaA), and checked for 
product by gel electrophoresis. If this was positive for both then the scheme was 
performed for the 5 remaining loci, if it was negative for both then the sample was 
identified as “MLST negative” for PA, and if one did not produce a band on 
electrophoresis then the process was repeated on the allele that did not produce 
a band. In no circumstances did the repeat PCR fail to produce product if one loci 
had been positive in the first round.  
To enable appreciation of the impact of multiple strains within individual sputum 
samples, the DNA extracted from two samples known to harbour different strains 
were mixed into five aliquots with DNA based ratios of 9:1; 7:3; 1:1, 3:7 and 1:9 
for each sample. These mixtures then underwent the amplification and 
sequencing process for the trpE gene. This was also done with DNA extracted 
from bacterial culture for the same previously identified alleles. The two chosen 
were based on two samples with a large number of nucleotide differences within 
the trpE locus as revealed by the investigations described in Chapter 3 from 
culture, and from DNA extracted from sputum in this chapter.  
5.4 Results 
5.4.1 Culture-independent MLST Results 
Sputum samples were collected from 31 CF patients who had previously grown 
PA. One other patient was recruited, however the sample was not collected. In 
22 instances PA was isolated from the sample and 10 representative isolates 
from that sample were stored. The results of these isolates have been described 
in Chapter 3. DNA was successfully extracted from all of the sputum samples, 
with DNA yields ranging from 1.1-76 µg. MLST was attempted on all 31 samples 
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and successfully provided a result in 23 (74.19%). This compares to 22 by 
culture-dependent MLST (71%). Of the eight in whom culture-independent MLST 
did not reveal PA, 6 did not isolate PA on culture. Culture-independent MLST 
allowed genotyping in three instances where the sputum sample had been 
reported as culture-negative by the clinical laboratory (see Table 5.1). 
From the 23 sputum samples from which results were obtained by culture-
independent MLST, only 17 distinct concatenated sequences were obtained. In 
total there were 4 concatenated sequences which were found in multiple patients. 
These shared genotypes were ST27 and ST146 from 3 patients, and ST217 and 
ST395 from 2 patients.  
5.4.2 Concordance Between Culture-dependent and Culture-independent 
MLST 
Overall there were 20 samples with paired MLST results from both the culture-
dependent and the culture-independent technique. Therefore the sequences of 
140 alleles could be compared as the MLST scheme sequences 7 housekeeper 
genes. For the purposes of this comparison, the ST-type from the sample 
representative of the more abundant RAPD profile was chosen (see methods 
section in Chapter 3). From the comparison of these 140 alleles, there was an 
exact sequence match in 130 cases (92.86%). When assessing from a sample 
perspective, 16 out of the 20 had an identical concatenated sequence by both 
techniques and a further 3 were identified as the same clonal complex (defined 
as having exact matches for 6 out of the 7 alleles). In two of these three cases 
there was just one nucleotide difference between the samples, whilst in the other 
there were 6 nucleotides different. In the one case where the results did not 
identify the same clonal complex, the culture-dependent technique identified 
ST195 and the culture-independent technique identified ST217. These two ST 
types have differences in all 7 alleles and 53 nucleotide differences across their 
concatenated sequence (see Table 5.1). The investigations in Chapter 3 had not 
shown any indication of multiple strains in this sample. There was no evidence of 
ST195 in any other samples however, as previously reported, ST217 was present 
in a sample from another patient. 
By the culture-dependent method there had previously been evidence of shared 
strains with ST146 and ST27. However, by the culture-independent method there 
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was also evidence of ST217 and ST395 in multiple patients. Potentially the most 
significant finding from the discrepancies between the two techniques is the 
revealing of previous missed known transmissible strain (see Table 5.1). MES 
was reported in two patients by this technique whilst the LES was found in a 
patient who was not related to the siblings described in Chapter 3 who harboured 
this strain. 
Patient Culture-
dependent 
Culture-
independent 
Relevant notes 
PIC09 ST235 No exact match Difference of 1 
nucleotide. Same 
clonal complex. 
PIC13 No exact match ST217/MES Difference of 1 
nucleotide. Same 
clonal complex. 
PIC16 Culture-negative No exact match  
PIC17 ST379 Negative  
PIC25 No exact match ST1717 Difference of 6 
nucleotides. Same 
clonal complex. 
PIC27 Culture-negative ST146/LES Shared stain not 
revealed by culture-
dependent MLST 
PIC28 No exact match Negative  
PIC29 Culture-negative ST395 Shared stain not 
revealed by culture-
dependent MLST 
PIC32 ST195 ST217/MES Difference of 53 
nucleotides. Shared 
stain not revealed by 
culture-dependent 
MLST 
Table 5.1 Discrepancies between culture-dependent and culture-
independent MLST Samples listed as “no exact match” did not have an exact 
match on the MLST database. 
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5.4.3 Mixed Samples and the Presence of Multiple Strains 
As described in Chapter 3, one patient showed evidence of multiple strains by 
RAPD and MLST. With regards to the RAPD profiles, 9 out of the 10 had been 
the same and the MLST result for a representative of this prevalent profile was 
ST146/LES. When the other RAPD profile was assessed by MLST, it did not have 
an exact match but was closely related to ST146/LES. Unsurprisingly when the 
matched sputum sample was interrogated by culture-independent MLST, the 
result was ST146/LES. At the ppsA allele, where the isolates obtained from the 
sputum sample differed by 3 nucleotides, the trace from the culture-independent 
MLST was examined at these positions of difference. No evidence of the second 
strain was seen by this examination.    
The extracted DNA from two sputum samples was combined into 5 different 
mixes. The combinations in these mixes was based on total DNA in ratios of 9:1, 
7:3, 1:1, 3:7 and 1:9. The sequences for the two samples at the trpE allele were 
previously identified as trpE 7 and trpE 47, which differ by 13 nucleotides. In the 
5 mixtures, those with at least 50% of the mixture being from the sample identified 
as trpE 7, there was no bi-directional disagreement and the consensus sequence 
was trpE 7. In neither of the other two mixtures was the allele identified as trpE 
47 and bidirectional disagreement was seen. The sequence with the most 
bidirectional disagreement was the mixture with 30% from the trpE 7 sample, 
where the resulting consensus sequence harboured a mix of nucleotides from 
both trpE alleles. Examining the traces at these points of disagreement suggests 
the presence of multiple strains (as displayed in Figure 5.1). 
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Figure 5.1 Multiple traces on sequencing data from DNA mixed from two 
sputum samples Traces taken from the Forward sequence of a mixture 
containing 30% of DNA from a sample identified as trpE 7 and 70% from a sample 
identified as trpE 47. Bi-directional disagreement occurred at position 189 and 
192. For trpE 7 the sequence would be GGCGGG whilst for trpE 47 it is GTCGAG  
 
The same experiment was performed on DNA extracted from culture for the same 
alleles so that the sequences should have been pure from each strain. In this 
instance, the consensus sequences were reported as trpE 7 when its proportion 
in the mix was 90%, 70%, 50% and 30%. For the mixture with 10% DNA from a 
trpE 7 sample and 90% DNA from a trpE 47 sample, there were multiple 
instances of bidirectional disagreement. Again, on examining the trace, there was 
evidence of multiple traces compatible with the known constituent sequences 
(see Figure 5.2). 
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Figure 5.2 Multiple traces on sequencing data from DNA mixed from culture  
The trace displays the suggestion of multiple traces at positions 336, 339 and 
342, from a mixed sample of  10% from trpE 7 sample and 90% trpE 47 sample. 
Bidirectional disagreement occurred at positions 336 and 342, and the 
sequences for the allele also differ at position 339. The sequence for trpE 47 
would have been TACGCTGT, whilst for trpE 7 is would have been CACTCTAT 
 
One patient showed evidence of a completely different strain by culture-
dependent and culture-independent MLST with reported results of ST195 and 
ST217 respectively. When looking at the sequences derived from culture-
independent MLST, there was occasional evidence of disagreement between 
forward and reverse sequences and assessment of traces did show evidence of 
multiple traces (see Figure 5.3) suggesting possible multiple strains. 
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Figure 5.3 Multiple traces from sample with conflicting results Multiple traces 
seen at various points including positions 139, 223 and 230 
5.5 Discussion 
In this chapter we have applied culture-independent MLST to a cohort of CF 
patients who have previously isolated PA. This has demonstrated the presence 
of renowned transmissible strains which were not reported by traditional MLST. 
It has also highlighted the potential presence and issues of multiple strains when 
investigating by these techniques. 
One of our aims in this study was to investigate the feasibility of this novel 
technique of culture-independent genotyping of PA. This was with consideration 
of this being a technique that could be used for epidemiological studies of PA in 
clinical cohorts. We have demonstrated that this is possible and can provide 
genotyping data in the globally recognisable format of MLST. In this particular 
cohort it has shown evidence of shared strains between patients. When this 
cohort was studied by culture-dependent methods two shared strains were found- 
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namely ST146/LES and ST27. By the culture-independent method described 
here, these shared strains were again found in the same patients, with the 
addition of ST146/LES being found in one other. This therefore could represent 
missed epidemiological data of key importance and be evidence of breaches in 
infection control. In this instance review of clinical notes suggests that this is 
unlikely to be the case. The patient was already colonised with PA before they 
transferred from a CF unit in another part of the country to our care. In addition, 
before the patients care was transferred, their PA had been genotyped and 
reported as LES.     
In addition to ST27 and ST146/LES, two other shared strains were revealed by 
this method - ST217 and ST395. ST217 is also known as the Manchester 
Epidemic Strain (MES) and has been reported as a transmissible strain 
associated with increased healthcare burden.[198, 229] MES was not reported in 
Chapter 3, as one of the patients who has displayed this had a sequence with a 
slight difference by the culture-dependent technique (differing at a single locus) 
whilst the other patient had a completely different strain reported by the culture-
dependent approach. ST395 was reported in Chapter 3 in one CF patient and 3 
NCFB patients. It is not currently recognised as a transmissible strain. By the 
culture-independent approach, it was again found in the same CF patient, but 
also in one other despite being culture-negative. This ability to generate 
genotyping data from culture-negative samples is potentially very useful. This is 
because the intermittent isolation of PA in culture can mean that false-negative 
culture results may result in missed shared strains. In addition, being able to 
perform repeated genotyping on consecutive samples could give insight into the 
effects of attempted eradication regimes and whether later re-isolation is with a 
new strain or not. It should however be noted, that there were two episodes when 
PA was grown on a plate but not found by this technique. A possible explanation 
may be that the amount of DNA in the sample which was from PA may be very 
small. Previous 16S rRNA sequencing data has shown that samples can be 
culture-positive for PA despite having an exceedingly low relative 
abundance.[133]  
With culture-independent MLST for PA not previously described, and the 
recognised potential for the presence of multiple strains in CF, it was important 
to perform a pairwise comparison of the output to the traditional approach. With 
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the traditional approach, MLST is performed on DNA originating from a single 
colony and therefore should be a pure sample. If the presence of multiple strains 
in samples was having a major impact on the consensus readings from the 
sequencing data, then it may be expected that there would be poor concordance 
between the two results. However, this has not been the case and concordance 
was very high between the samples, even when the traces may suggest multiple 
strains. In all but one case where data was available by both approaches, there 
was an exact match for at least 6 of out 7 of the loci sequenced. In one sample 
(PIC32) there was no match for any of the loci. However on examining the traces, 
there did appear to be the presence of multiple traces. Consequently a plausible 
explanation is that multiple strains were present in the same sample and that the 
faster growing strain was picked from plates for the culture-dependent approach, 
but on the basis of total DNA a different strain predominated. This then begs the 
question, which is the better approach? We picked multiple isolates from our 
patients in order to reduce multiple strains going unobserved, however in patient 
PIC32 we appear to have missed multiple strains. However via the culture-
independent approach whilst we got just one result, there was the observation of 
the likely presence of multiple strains. To give further perspective on this issue 
we mixed samples to provide insight into the impact this can have on results. 
In Chapter 3 we found evidence of multiple strains in one patient, however by the 
culture-independent approach we just picked up what we believed to be the most 
abundant strain (based on RAPD profiles and targeted MLST). When we mixed 
the DNA from two sputum samples that were known to harbour different strains, 
we observed inconsistencies in the MLST output as the ratios changed. A 
potential flaw of this experiment was that whilst a total DNA content was known, 
it was conceivable that one sample had a high relative abundance of PA, whilst 
the other had a low relative abundance, consequently distorting the ratios. We 
therefore repeated this process using a mixture of DNA extracted from pure 
cultures rather than sputum. Again inconsistent outputs were observed as the 
ratios of the DNA samples changed. A few important points need to be taken from 
these experiments. Firstly, the use of a different alignment sequence can bias 
towards a certain result if there are disagreements between the bidirectional 
sequencing. This was noticeable in some of the mixed experiments. Secondly, if 
the consensus results contain sections from more than one strain, then the 
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process may generate a hybrid sequence that is in not actually present within the 
sample. If this was a common issue then we would not see the high level of 
agreement that we saw between the two approaches. It does however highlight 
an occasional limitation of the technique. The other limitation of culture-
independent MLST is the inability to identify specific strains when the presence 
of multiple strains is suspected. We can collect evidence of the presence of 
multiple strains via this culture-independent approach by viewing traces and 
noticing bidirectional disagreement in sequences but this does not allow 
identification of what the other strains are. If there are two traces or more, then it 
is unclear which alleles the differences at different positions come from, except 
in the circumstance where there is just a single nucleotide different throughout 
the entire concatenated sequence. Even then doubts remain, as the commercial 
sequencing company reports that the multiple traces seen can just be noise 
rather than definite multiple sequences (this is from personal correspondence 
with the sequencing company). This limitation must be put into context however. 
We picked multiple colonies in order to get an appreciation of the multiple strains 
present but this culture-dependent approach failed to detect multiple strains in 
samples such as PIC32.  
On the basis of the above findings, it could be argued that a dual approach should 
be taken for extensive epidemiological reviews of PA in respiratory cohorts. By 
the dual approach you may pick up evidence of multiple strains as in PIC32, 
including the faster growers and the most predominant strain by total DNA. Due 
to the occasional issues of multiple strains giving seemingly false MLST results, 
if confirmation of shared strains was required, the culture-dependent approach 
would be essential and it may take multiple sputum samples and picking of a 
significant number of colonies to prove this. The use of two typing techniques is 
common in epidemiological reviews to ensure robustness of findings, and indeed 
in our work we have used three techniques. Consequently it should not be seen 
as a failing to use the two techniques. If rather than an extensive epidemiology 
review, a screening process was wanted, then culture-independent MLST may 
have its place as a first line investigation. By this approach two loci could be 
screened and if there is a match between samples for one of these, then a 
cascade approach could be taken with sequencing the other loci until all 7 loci 
are sequenced or differences at greater than one loci is seen. Culture-dependent 
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MLST could then be performed in cases where shared strains needed to be 
proved and where WGS may be wanted, or in cases where there was the 
suggestion of multiple strains by either sequence or trace examination. A further 
place for culture-independent MLST would be for monitoring and understanding 
the process of attempting to eradicate PA. As previously mentioned, patients can 
isolate PA intermittently and can seemingly “self-clear”. Relapse after attempts of 
eradication is also recognised with some questioning if true eradication ever truly 
occurred. By performing intermittent culture-independent genotyping, 
assessment of strain persistence could be better understood, even in culture-
negative samples. It should however be noted that as culture-independent 
methods do not measure viability, a lag period may exist when PA is still detected 
despite no longer being viable.  
Whilst culture-independent identification of strains has been performed before, 
as far as we are aware this represents the first time it has been reported for 
PA.[370, 371] This is clearly a real strength of this study, as is the pairwise 
comparison with the culture-dependent approach. A limitation is the size of the 
collection. If a larger collection was examined, more instances of multiple strains 
giving conflicting results may have occurred. It is also of potential significance 
that this was performed exclusively in CF patients. It is possible that in other 
diseases, the relative abundance of PA may be lower and consequently only a 
small amount of PA DNA is present following extraction. The methods described 
here could be used in other diseased populations to investigate this further.  
5.6 Conclusion 
We have demonstrated the feasibility of genotyping of PA on DNA extracted 
directly from sputum. This has shown high concordance with culture-dependent 
approaches and has also revealed transmissible strains in culture-negative 
samples which were missed by the traditional approach. The approach can 
highlight potential situations of multiple strains in a specimen but it should be 
noted that this can on occasion negatively affect the result by creating a hybrid 
sequence that fails to match any individual alleles present. This novel approach 
offers potential for rapid screening of a cohort, as part of an epidemiological 
review, and the investigation of intermittent infection. 
133 
 
Chapter 6- Utilising RISA for 
interrogating bacterial communities of 
the bronchiectatic lung 
6.1 Abstract 
Introduction: A cornerstone of the management of the chronic suppurative lung 
diseases is the understanding and treatment of acute exacerbations and chronic 
infection. These decisions are often based on pathogens identified by traditional 
culture-based methods. Culture-independent techniques have however revealed 
that the bacterial communities of the lungs are complex and have far greater 
diversity than that reported by culture-based methods. These methods have 
suggested associations between ecological measures of a bacterial community 
and disease severity in multiple diseases, however there are inconsistencies in 
conditions such as NCFB. Whilst 16S rRNA sequencing has been the gold-
standard technique for examining these communities, it is not accessible in 
everyday clinical care. In this chapter, we investigate the utility of an alternative 
cheaper microbial community profiling technique (RISA), and examine the 
relationship between the bacterial community and patient characteristics in a 
NCFB cohort, and a comparator CF cohort. 
Methods: Sputum samples were prospectively collected from patients with NCFB 
or CF when they were submitting sputum samples as part of their standard clinical 
management, as well as relevant clinical details and patient characteristics. 
Following DNA extraction, RISA was performed on all submitted samples. 
Investigation into the output from RISA was performed by cluster analysis and 
the assessment of ecological measures of the bacterial communities in relation 
to patient characteristics. 
Results: 208 sputum samples were submitted from 99 patients with NCFB and 
51 patients with CF. RISA analysis was successfully performed on all samples 
and revealed a wide range of community complexity. Comparison between the 
two diseases suggested that our CF patients had more complex bacterial 
communities. In NCFB, cluster analysis revealed groups with potentially 
significant characteristics, such as reduced diversity and evenness. Increased 
134 
 
community complexity was associated with a low exacerbation phenotype in 
NCFB, and a positive correlation was seen between community richness and lung 
function. A relationship was not found between disease severity (as measured by 
the Bronchiectasis Severity Index) and ecological measures of the bacterial 
community.  In the CF cohort, a positive correlation was seen between lung 
function and both community richness and diversity.   
Conclusion: RISA offers a potential alternative to 16S rRNA sequencing, and as 
an adjunct to traditional culture, for characterising of bacterial communities in 
chronic suppurative lung disease. In our NCFB and CF cohorts it has revealed 
associations with clinically-relevant markers, such as lung function and 
exacerbation phenotype. It now requires validation of its output by 16S rRNA 
sequencing.  
6.2 Introduction 
CF and NCFB are chronic suppurative lung diseases whose clinical courses are 
believed to be heavily influenced by the management of both their chronic 
infections and their acute exacerbations. The cornerstone of managing chronic 
infection and exacerbations is antimicrobial therapy. In the acute setting this is 
often with 2-week courses of antibiotics via the oral or intra-venous (IV) route. 
Chronic infection is often managed with prophylactic oral or inhaled antibiotics.  
In current practice, traditional culture techniques are applied to sputum and other 
respiratory samples to identify potential pathogens. This information is then used 
to guide decision-making with regards to antimicrobial therapy. This process 
tends to lead to PA and SA being common targets in CF, and PA and HI in NCFB. 
Other pathogens which are observed and targeted, though less frequently, 
include Streptococcus pneumoniae (SPn), Moraxella catarrhalis (MC), 
Stenotrophomonas maltophilia (SMalt), species of the BCC, and NTMs. 
Over the last decade, research using culture-independent molecular techniques 
has illustrated that there are far more complex bacterial communities in diseased 
lungs than is revealed by culture.[302] It has also been established that the 
healthy lung is not sterile.[301] Investigation of different disease states has shown 
disease-specific patterns. CF has understandably been subject to considerable 
interest, and it appears that there is an association between bacterial 
communities lacking diversity and disease severity.[133] In end-stage disease 
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the lung may be dominated by a single pathogen such as PA.[372] This concept 
of reduced diversity and disease severity is not limited to CF, or even the lung, 
with evidence of reduced diversity in other pathological conditions such as 
inflammatory bowel disease.[373] There have also been studies into NCFB 
cohorts. Studies by Rogers et al on a RCT cohort have suggested associations 
between diversity and lung function, and richness and several disease 
markers.[321, 323] However, this has not been a universal finding and other 
studies on unselected cohorts have not found such a correlation.[271, 319] Of 
note, these studies contained samples collected before the trio of RCTs which 
have led to chronic macrolide therapy being standard care for those regularly 
suffering from exacerbations.[38, 51, 52] Also the studies were performed without 
comparison with a validated severity index (the Bronchiectasis Severity Index 
(BSI)), which is now available and gives a score between 0-21.[40] The 
relationship between bacterial community composition and disease severity 
remains unresolved. 
With clinicians basing management on traditional culture methods, a 
microbiological technique that is limited in the detail it reveals, it would seem likely 
that a technique providing more detail of the bacterial community would be 
desirable.  The main culture-independent technique currently used in the 
research community is 16S rRNA sequencing. Despite reducing costs of 
sequencing, it clearly remains far more expensive and time consuming than 
traditional culture. In addition, it requires significant bioinformatic processing. A 
further reason that it is not used in standard NHS practice is that we do not know 
what the results actually mean for the clinical management of a patient. It would 
consequently be appealing for a technique to be available that could quickly and 
cheaply provide information beyond what is provided by culture, which could be 
of benefit in understanding the microbial communities of the lung, and could 
subsequently guide management strategies. Such a method would allow large 
clinical studies into bacterial communities and the impacts of therapies at a more 
affordable cost. This would then also be potentially usable in daily clinical practice 
to help personalise treatment in an evidence-based manner. 
Ribosomal Intergenic Spacer Analysis (RISA) is a simple and cheap microbial 
profiling technique which has been used predominantly in environmental 
sampling.[288, 290, 291, 374] It has been suggested that RISA can discriminate 
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at the species level in most cases and has shown a degree of consistency with 
pyrosequencing in environmental work.[287, 291, 375] The technique involves 
PCR amplification of the intergenic spacer region between the 16S and 23S 
subunits. It has recently been applied to CF cohorts with the suggestion of 
potential benefit in the management of CF and other conditions including 
NCFB.[133, 270] However, its use has not been described in a NCFB cohort at 
present. Other community fingerprinting techniques exist and have been used for 
studies of the diseased lung such as T-RFLP, however RISA has demonstrated 
greater sensitivity and resolution in environmental work.[284, 291] Consequently, 
in this study we have collected sputum samples and clinical data from NCFB 
patients to examine the utility of RISA as a technique to be used in clinical 
practice, and the relationships between microbial profiles and disease severity. 
In parallel, we have applied RISA to samples from our CF cohort as a comparator 
group. In this chapter we will describe our cohorts, the output obtained by RISA 
interrogation, and insights into bacterial communities alongside disease and 
patient characteristics. In the subsequent chapter we will compare its output to 
16S rRNA sequencing in a subset of NCFB patients. 
6.3 Methods 
Patients were recruited prospectively if they were submitting a sputum sample as 
part of their routine care. Patients were eligible for recruitment if they had a 
confirmed diagnosis of CF, or radiologically-defined bronchiectasis and a 
consistent clinical presentation in the absence of CF. Up to three samples per 
patient could be included and recruitment could take place irrelevant of 
exacerbation status, though this was noted at recruitment. The “exacerbation” 
state was defined by a patient currently taking an acute course of antibiotics due 
to respiratory symptoms, or if antibiotics were prescribed to them at that clinical 
consultation due to a change in respiratory symptoms. If the sample was 
submitted within 2 weeks of an exacerbation it was defined as “post-
exacerbation”, whilst beyond 2 weeks was classified as “stable”. At the point of 
recruitment, clinical details were recorded and a sample sent to the local 
microbiology laboratory for standard processing. Samples were only included in 
this study if they were available at the consultation. This was to prevent the 
situation where samples produced at home are then submitted at the local health-
centre before transfer to the hospital laboratory. In this scenario, samples can be 
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awaiting courier pick up for variable periods of time and potentially stored at a 
variety of temperatures. By just interrogating samples submitted immediately we 
could guarantee minimal delay in transfer to the laboratory.  
In the NHS laboratory an aliquot was taken for our investigation, with the 
remainder used for standard microbiological testing. Consequently all samples 
had a culture result reported by the laboratory. Once the aliquots were transferred 
to the University laboratory, they underwent DNA extraction and subsequent 
RISA analysis as described in Chapter 2. In addition, aliquots of Mucolyse were 
also obtained from the laboratory and 500µl were subjected to the DNA extraction 
process with each of the 5 batches of the DNA extraction kit and reagents used.  
The ecological measures of diversity, evenness and richness were estimated by 
using the concentration of the bands and numbers of band on the bioanalyser 
output as a surrogate for species abundance and presence.[291] The estimates 
of these ecological measures by RISA are referred to in this thesis as e-Diversity, 
e-Evenness and e-Richness. This is to distinguish the results from the 
subsequent output from 16S rRNA sequencing described later in this thesis. 
Statistical testing was performed in GraphPad Prism 7.03. For the purposes of 
statistical testing, all variables were assessed for normality by histogram 
observation. Of note, e-Diversity and e-Evenness were not consider to have a 
normal distribution for the purposes of analysis. 
6.4 Results 
6.4.1 The NCFB Cohort 
As would be expected by the epidemiology of the conditions, the NCFB cohort 
was the larger of the two. In total 102 patients without CF were recruited, however 
three were subsequently excluded. One patient on re-review of radiological 
investigation did not have definite NCFB, one patient’s sputum sample was lost, 
and from one patient the laboratory were unable to process the sample due to 
insurmountable adherence to the sputum pot. From the remaining 99 patients, 
123 samples were submitted, of which 98 were taken in the stable state. A wide 
range of disease severity was seen, with BSI scores ranging from 1-18. With 
regards to categories, 21.2% were “Mild” (BSI = 0-4,), 44.4% were “Moderate” 
(BSI = 5-8) and the remaining 34.3% were “Severe” (BSI greater than 8). The 
main clinical details at recruitment are displayed in Table 6.1. All the BSI 
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components either showed significant differences between the BSI categories or 
a trend towards, with the exception of radiological severity (Chi-square= 1.603, 
p= 0.4487). There was no significant difference in the use of prophylactic 
antibiotics between the different BSI categories. 
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 Mild  
(n=21) 
Moderate 
(n=44) 
Severe 
(n=34) 
Overall 
(n=99) 
Age, years 
(Range) 
56.86  
(31-69) 
66.23 
(17-85) 
69.82 
(35-88) 
65.47 
(17-88) 
BSI 
(Range) 
2.71 
(1-4) 
6.5 
(5-8) 
11.29 
(9-18) 
7.34 
(1-18) 
%Female 66.67% 72.73% 52.94% 64.65% 
Aetiology 
- Idiopathic 
- Asthma 
- Post-
infective 
- Other 
 
14.28% 
38.09% 
 
14.28% 
33.33% 
 
40.91% 
13.64% 
 
18.18% 
27.27% 
 
38.24% 
11.76% 
 
14.71% 
35.29% 
 
34.34% 
18.18% 
 
16.16% 
31.31% 
FEV1 %predicted 
(Range) 
84.86% 
(33-116%) 
72.05% 
(30-108%) 
55.09% 
(23-96%) 
69.94% 
(23-116%) 
Colonised at 
recruitmenta 
- Any 
- PA 
- HI 
 
 
9.52% 
0 
9.52% 
 
 
31.82% 
13.64% 
13.64% 
 
 
70.58% 
41.18% 
26.47% 
 
 
40.40% 
20.20% 
17.17% 
BMI 25.68 
(4.22) 
25.97 
(6.35) 
23.54 
(4.44) 
25.07 
(5.45) 
Exacerbations in 
last 12 monthsb 
1.71 
(1.93) 
3.55 
(2.57) 
4.32 
(3.69) 
3.42 
(0.97) 
MRC Dyspnoea 
score 
2 
(0.69) 
2.25 
(0.88) 
2.85 
(1.06) 
2.4 
(0.97) 
In-patient hospital 
days in last 2 years  
0 0.43 
(2.2) 
4.44 
(8.9) 
1.59 
(5.66) 
3 or more lobes 
affected/cystic 
changes on CT 
57.14% 45.45% 58.82% 52.5% 
Antibiotic 
Prophylaxis  
- Any 
 
 
61.9% 
 
 
47.72% 
 
 
47.06% 
 
 
50.5% 
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- Oral 
- Inhaled 
42.86% 
19.05% 
43.18% 
18.18% 
35.29% 
20.59% 
40.4% 
19.2% 
Any IV antibiotics 
in last 12 months 
0 4.55% 26.47% 11.11% 
<10 pack year 
smoking historyc 
90.48% 72.73% 64.71% 73.7% 
Table 6.1 Baseline demographics of NCFB cohort at recruitment. The data 
in this table are presented as mean values or percentages of that group. In those 
continuous measures where range is not of specific interest, standard deviations 
are reported alongside the mean value. aColonisation was defined by the isolation 
of a pathogen twice in a twelve month period and at least three months apart. 
bExacerbations were by patient recall of a change in respiratory symptoms which 
lead to a course of antibiotic treatment. cA pack year is the smoking of 20 
cigarettes a day for a year. The figure was recorded as reported by the patient. 
6.4.2 The CF Cohort 
In the CF cohort, 51 patients were recruited, of whom 28 handed in multiple 
samples. Overall 85 samples were submitted and 53 of these were taken from a 
patient in a stable state. A wide range of ages (17-65 years) and lung function 
(26-113% predicted) were seen. The main baseline demographics are shown in 
Table 6.2. 
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Age, years  
(Range) 
32.80  
(17-65) 
%Female 50.98%  
Mutations: 
- F508del homozygous 
- F508del heterozygous 
- Other 
 
39.22% 
52.94% 
7.84% 
FEV1 %predicted  
(Range) 
61.86%  
(26-113%) 
BMI 23.62 
(3.84) 
MRC Dyspnoea score 1.9 
(0.95) 
Antibiotic Prophylaxis 
- Any 
- Oral 
- Inhaled 
 
90.2% 
80.39% 
66.67% 
Any IV Antibiotics in last 12 
months 
52.94% 
 
Table 6.2 Baseline demographics of CF cohort at recruitment Values are 
reported as means or as a percentage of the cohort. For continuous data, if the 
range is not considered to be of specific interest, then a standard deviation is 
reported. FEV1 %predicted and BMI values were available for 50 out of the 51 
patients.  
6.4.3 Culture Results 
All sputum samples underwent standard microbiological assessment at our NHS 
laboratory. Samples are not routinely tested for acid-fast bacilli in order to detect 
TB or NTM but are requested intermittently for a variety of reasons including 
clinical suspicion, part of a CF annual review, or before consideration of 
commencing a prophylactic antibiotic such as azithromycin. Consequently the 
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lack of samples positive for an NTM should not be compared directly to other 
pathogens such as PA.  
In the NCFB cohort the most frequently isolated pathogen was HI, both overall 
and when looking at just one result per patient (as assessed by the first sample). 
As would be expected, PA had a very similar prevalence, and these two 
pathogens accounted for approximately three-quarters of cultured pathogens 
(see Table 6.3). Of note a large number of samples did not reveal bacterial 
pathogens (43.09%). 
Bacteria All 
samples 
(n=123) 
Baseline 
samples 
(n=99) 
Stable 
 
(n=98) 
Post-
exacerbation 
(n=4) 
Exacerbation 
 
(n=21) 
PA 25 19 19 1 5 
HI 26 22 23 1 2 
SA 7 5 6  1 
Coliform 3 3 2  1 
SPn 3 3 3   
Klebsiella 
pneumoniae 
2 2 1  1 
MC 2 2 2   
Serratia 
marcescens 
2 1 2   
SMalt 2 1 2   
Burkholderia 
multivorans 
1 1 1   
Proteus sp 1 1  1  
Culture-
Negative 
53 43 42 1 10 
Table 6.3 Culture results for NCFB cohort From some samples multiple 
pathogens were isolated. A sample was called “Culture-negative” if a potential 
bacterial pathogen was not isolated from the sample. 
Traditionally PA has been seen as a more significant pathogen than HI and 
colonisation with it results in 2 more points in the BSI than other potentially 
pathogenic organisms. Consequently, it may be expected that those isolating PA 
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at baseline would have a higher BSI than those isolating HI. This was the case, 
however this difference did not reach statistical significance (though it did if 
colonisation status was considered). The mean difference in the BSI score 
between those who isolated PA at baseline and those who isolated HI was only 
2.01 (see Table 6.4). Of interest, in those who isolated HI rather than PA, a worse 
exacerbator phenotype was seen (see Table 6.4). The patients who isolated HI 
had significantly less prophylactic therapy or IV antibiotics in the preceding 12 
months. When patients were assessed on the basis of colonisation status rather 
than baseline culture result, the difference in exacerbator phenotype between HI 
and PA no longer reached statistical significance and the difference in oral 
prophylaxis no longer persisted (see Table A6.1). 
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 PA 
 
(n=19) 
HI 
 
(n=22) 
Other 
 
(n=15) 
Culture-
negative 
(n=43) 
P Value 
(PA vs. HI) 
Agea 65.79 
(11.51) 
62.68 
(18.11) 
63 
(13.06) 
67.63 
(11.81) 
0.5335 
BSIa 9.37 
(4.5) 
7.36 
(2.76) 
5.87 
(3.38) 
6.95 
(3.28) 
0.0967 
FEV1 
%predicteda 
66.58 
(24.54) 
61.77 
(21.77) 
73.27 
(24.1) 
72.14 
(20.72) 
0.5208 
Exacerbator 
phenotypeb,c 
- High 
- Medium 
- Low 
 
 
10.53% 
47.37% 
42.11% 
 
 
50% 
31.82% 
18.18% 
 
 
40% 
40% 
20% 
 
 
46.51% 
30.23% 
23.26% 
0.0220d 
 
0.0068 
0.3087 
0.0931 
Oral 
antibiotic 
prophylaxisb 
63.16% 27.27% 26.67% 41.86% 0.0296 
Inhaled 
antibiotic 
prophylaxisb 
31.58% 0 13.33% 25.58% 0.0060 
Received IV 
antibiotics in 
last 12 
monthsb 
31.58% 0 13.33% 9.3% 0.0060 
Table 6.4 Clinical measures for different baseline culture results in the 
NCFB cohort Data is presented with mean values and standard deviations, or 
percentage of the group. Statistical testing was by at-test, or bChi-squared test. 
cExacerbator phenotype was described as “High”- greater than 3 exacerbations 
in preceding 12 months; “Medium”- 2 or 3 exacerbations in preceding 12 months; 
“Low”- 0 or 1 exacerbations in preceding 12 months. dChi-squared test from 3x2 
contingency table. 
 
In the CF cohort the culture results were again dominated by just two pathogens, 
but in this group it was PA and SA (see Table 6.5). There was a noticeable 
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amount of co-infection with both of these pathogens which needs to be taken into 
account when reviewing results alongside clinical detail (see Table 6.6). 
Statistical analysis may be further limited due to small sub-groups. However, in 
the absence of SA, there is a trend to suggest PA may be seen in the more 
severely diseased patient and those with PA and SA appear to be in-between 
those just isolating PA or SA with regards to lung function and IV antibiotic 
requirement (see Table 6.6). The above reservations with regards to small groups 
and the impact of co-infection should be remembered though. 
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Bacteria All 
samples 
(n=85) 
Baseline 
samples 
(n=51) 
Stable 
 
(n=53) 
Post- 
exacerbation 
(n=3) 
Exacerbation 
 
(n=29) 
PA 45 24 28 1 16 
SA 32 21 22  10 
Achromobacter 
sp 
4 3 1  3 
Burkholderia 
vietamensis 
4 1 4   
Burkholderia 
multivorans 
3 2 2 1  
Burkholderia 
gladioli 
2 1   2 
HI 2 2 2   
Proteus 
mirabilis 
2 1 1  1 
SMalt 2 2   2 
Achromobacter 
xylosoxidans 
1    1 
 
Acinetobacter 
baumanni 
1 1 1   
Acinetobacter 
haemolyticus 
1 1   1 
Coliform 1 1 1   
Not processed  1    1 
Culture-
negative 
14 11 11 1 2 
Table 6.5 Culture results from CF patients From some sputum samples 
multiple pathogens were isolated. A sample was called “Culture-negative” if a 
potential bacterial pathogen was not isolated from the sample. 
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 PA  
 
(n=12) 
SA  
 
(n=9) 
PA+SA  
 
(n=12) 
Others 
 
(n=7) 
Culture-
negative 
(n=11) 
P 
Value 
Age, yearsa  35.25 
(11.45) 
35.44 
(15.12) 
30.42 
(10.52) 
29.43 
(7.58) 
32.73 
(9.31) 
0.7250 
%femaleb 50% 66.67% 33.33% 57.14% 54.55% 0.3776 
FEV1 
%predicteda 
52.36 
(10.46) 
69.22% 
(18.20) 
64.42% 
(20.58) 
50.71% 
(18.89) 
67.27% 
(21.18) 
0.1371 
Oral 
prophylaxisb 
75% 77.78% 91.97% 85.71% 72.73% 0.7791 
Inhaled 
prophylaxisb 
66.67% 44.44% 100% 71.43% 63.64% 0.0722 
IV days in last 
12 monthsc 
11.5 
(0-29.75) 
0 
(0-12) 
0.5 
(0-25.75) 
28 
(0-64) 
0 
(0-14) 
0.2467 
Table 6.6 Baseline culture results and clinical characteristics of CF cohort 
Data is present either as a mean value with standard deviation, median with a 
range, or as a percentage of the group. Statistical analysis performed by at-test, 
bChi-squared test, or cMann-Whitney. 
 
6.4.4 RISA Profiles 
Following DNA extraction from all 208 samples and 5 negative controls, RISA 
was performed with PCR amplification of all samples. We were able to obtain 
observable DNA fragments which were seen on both standard gel 
electrophoresis and via the bioanalyser for all the clinical samples. In total, 1258 
bands were observed. No PCR product was detected for any of the negative 
controls. Over 95% of bands had a length between 400-1200 bp with many 
samples yielding bands in the region of 530 to 570 bp (see Figure 6.1).  Cluster 
analysis with the creation of a dendrogram for all samples displayed significant 
diversity among the samples studied (see Figure 6.2).From this dendrogram 
potentially significant bands were identifiable as being of high intensity with 
values around 530, 560 and 750 bp. The bioanalyser output quantified the band 
intensity by concentration. When the bands with the highest concentration within 
each sample were reviewed, the prevalent bands were around 530-570 bp and 
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750-770 bp (see Figure 6.3). Previously performed unpublished in silico 
predictions by collaborators, suggests that the prominent bands in the 530-570 
bp region may be due to Streptococcus and that the 750-770 bp region may be 
dominated by PA and HI. 
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Fig 6.1 Frequency distribution data of all bands between 400-1200 bp 
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Fig 6.2 Dendrogram of RISA fragments from all clinical samples 
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Figure 6.3 Frequency distribution data of the dominant band in each 
sample 
6.4.5 Ecological Measures from RISA Profiles Between Cohorts 
The ecological measures of diversity, evenness and richness were all estimated 
from the bioanalyser data output. Comparisons were made between the two 
patient cohorts with the baseline sample included for analysis. By all measures 
the NCFB cohort appeared less complex (see Figures 6.4, 6.5 and 6.6). This 
analysis included samples in various clinical states. We have also performed 
comparison of these ecological measures by just looking at the first available 
sample from a patient in the stable state. This reduced the numbers available in 
the analysis but still showed statistically a significantly less complex community 
in the NCFB cohort (see Table 6.7). Comparisons of samples from the same 
patient in both the stable and exacerbation state was only available for 18 
patients. However, from these small numbers there was no clear difference in the 
ecological measures between these states (see Table 6.8). 
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Figure 6.4 Comparison of e-Diversity between NCFB and CF Median values 
were 1.43 for NCFB and 1.71 for CF. The p value as calculated by Mann-Whitney 
test was 0.0009. The bars represent the median and the interquartile range. 
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Figure 6.5 Comparison of e-Evenness between NCFB and CF Median 
values were 0.84 for NCFB and 0.89 for CF. The p value as calculated by 
Mann-Whitney test was 0.0096. The bars represent the median and the 
interquartile range. 
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Figure 6.6 Comparison of e-Richness between NCFB and CF Mean values 
were 5.65 for NCFB and 6.83 for CF. The p value as calculated by unpaired t-test 
was 0.0063. The bars represent the mean and the standard deviation. 
 
 
 
 
 
NCFB  
(n=85) 
CF  
(n=39) 
P Value 
e-Diversity 1.51 1.71 0.0064 
e-Evenness 0.84 0.91 0.0015 
e-Richness 5.79 7.05 0.0136 
Table 6.7 Comparison of ecological measures in stable NCFB and CF 
patients Includes 1st stable sample per patients available. Comparison was 
performed by Mann-Whitney test for e-Diversity and e-Evenness with values 
reported as medians. e-Richness is reported as a median and statistical 
comparison was performed by the unpaired t-test. 
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 Stable Exacerbation P Value 
e-Diversity 1.56 1.57 0.8317 
e-Evenness 0.87 0.88 0.3982 
e-Richness 6.5 5.78 0.3231 
Table 6.8 Comparison of ecological measures in the stable and 
exacerbation state from both cohorts Wilcox matched pairs signed rank test 
performed for comparison of e-Diversity and e-Evenness with medians reported. 
Paired t-test was performed for comparisons of e-Richness and mean values 
reported 
 
6.4.6 RISA in the NCFB Cohort 
When cluster analysis was performed on the baseline samples from the NCFB 
cohort, the dendrogram divided into three main clusters (Groups A-C) and a small 
disparate group (Group D) (see Figure 6.7). When compared to culture results, 
Group A had a high proportion of culture-negative samples (16/22) and Group C 
had a high proportion of H. influenzae culture-positive samples (14/25). Reduced 
e-Diversity and e-Evenness were present in Group C. Group B featured two 
dominant bands around 530 and 560bps, which based on previous in silico 
predictions may be representative of Streptococcus. Two samples were culture-
positive for MC and these two clustered right next to each other in Group C with 
a highly similar dominant band. Details of the comparison of the Groups created 
through cluster analysis are presented in Table 6.9. 
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Figure 6.7 Dendrogram of baseline samples from NCFB cohort The red 
circle indicates typical bands around 530 and 560 bps. The blue box highlights 
the two patterns of the two samples positive for Moraxella catarrhalis clustering 
next to each other.   
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 Group A 
(n=22) 
Group B 
(n=46) 
Group C 
(n=25) 
Group D 
(n=6) 
P<0.05 
Agea 65.73 
(13.91) 
69.11 
(10.06) 
60.28 
(15.95) 
58.33 
(17.75) 
0.0374 
B v C 
BSIa 7.59 
(4.15) 
7.24 
(3.21) 
7.2 
(3.69) 
7.83 
(4.22) 
 
FEV1 
%predicteda 
69.91 
(24.5) 
71.54 
(21.92) 
65.52 
(22.18) 
59.67 
(19.48) 
 
Oral 
Prophylaxisb 
36.36% 41.3% 
 
40% 50%  
Inhaled 
prophylaxisb 
31.82% 13.04% 24% 0%  
PA-positiveb 9.09% 23.91% 12% 50%  
HI-positiveb 0 15.22% 56% 16.67% <0.0001 
Culture-
negativeb 
72.73% 47.83% 16% 16.67% 0.0006 
High 
exacerbatorsb 
(>3) 
36.36% 41.3% 40% 33.33%  
Medium 
exacerbatorsb 
(2-3) 
40.91% 32.61% 36% 33.33%  
Low 
exacarbatorsb 
(0-1) 
22.73% 26.09% 
 
24% 33.33%  
e-Diversityc 1.26 
(0.64-1.9) 
1.58 
(1.13-
1.83) 
0.94 
(0.63-
1.54) 
1.33 
(0.9-1.85) 
0.0171 
B v C 
e-Evennessc 0.93  
(0.89-
0.97) 
0.85 
(0.76-
0.89) 
0.62 
(0.56-
0.78) 
0.76 
(0.65-
0.87) 
<0.0001 
A v B 
A v C 
B v C 
e-Richnessa 4.82 
(3.04) 
6.24 
(2.51) 
5.12 
(2.12) 
6.33 
(2.36) 
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Table 6.9 Comparison of cluster analysis groups in the NCFB cohort 
Statistical analysis by aANOVA or bChi-squared test or cKrusal-Wallis. Values are 
quoted as means with standard deviations, or percentages of their group, or 
medians with IQR. The “P<0.05” column highlights statistically significant results, 
and if by ANOVA or Krusal-Wallis, then which groups differ significantly. 
As discussed above, the NCFB cohort appears to have less complex bacterial 
communities than those of the CF cohort. We have interrogated potential factors 
for this to seek an indication of association. Of note there was a positive 
correlation between age and e-Diversity and e-Evenness, and between FEV1 and 
e-Richness, and a negative correlation between exacerbations and e-Diversity 
(see Table A6.2). When looking at the culture results, there is a suggestion that 
HI-positive samples are less complex that those of PA, with a statistically 
significant difference in e-Evenness (p=0.0064) and trending towards it for e-
Diversity (p=0.1645) (see Table A6.3). This is in keeping with Group C on the 
dendrogram. In the samples where a pathogen was isolated from the laboratory, 
a statistically significant reduced e-Evenness score was seen (p=0.0262) (see 
Table A6.4). When assessing categorical factors such as antibiotic burden, 
gender  or  home environment (urban and rural setting and the ownership of 
animals), no significant relationships were seen with ecological measures except 
urban living having higher e-Diversity and e-Richness scores than rural living (p 
values of 0.0294 and 0.0098 respectively (see Table A6.5)). 
Of particular interest, and relevance to patients, there were significant differences 
in exacerbation phenotype and ecological measures. The patients classified as 
having a low exacerbation phenotype (as defined by an either 0 or 1 
exacerbations in the last 12 months) had higher e-Diversity and e-Richness and 
a trend towards more e-Evenness (see Table 6.10). 
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Exacerbator Phenotype 
 High 
(n=39) 
Medium 
(n=35) 
Low 
(n=25) 
P Value 
e-Diversity 1.29 
(0.68-1.62) 
1.22 
(0.69-1.68) 
1.65 
(1.15-1.96) 
0.0201 
e-Evenness 0.77 
(0.68-0.88) 
0.84 
(0.65-0.91) 
0.88 
(0.8-0.91) 
0.1826 
e-Richness 5.54 
(2.63) 
4.97 
(2.54) 
6.76 
(2.35) 
0.0313 
Table 6.10 Comparison of exacerbation phenotypes Statistical analysis is 
performed by Krusal- Wallis test when e-Diversity or e-Evenness is involved 
with median values reported, or by ANOVA for e-Richness with mean values 
reported 
6.4.7 RISA in the CF Cohort 
Cluster analysis was also performed for the CF cohort (see Figure 6.8). Of note, 
it did not fall into as tight clusters as the NCFB cohort and consequently a useful 
comparison of clusters could not be performed. Ecological measures were again 
calculated from the bioanalyser output and compared to patient characteristics 
and clinical data. With regards to continuous data, no significant association was 
found between age and BMI, and any ecological measures (see Table A6.6). 
There was however a positive correlation found between lung function and e-
Diversity and e-Richness (see Figure 6.9, Figure 6.10 and Table A6.6).  
The ecological measures were also compared to different culture results with 
significant findings with regards to all measures. Those who isolated PA or did 
not isolate a pathogen appeared to have the least complex communities (see 
Table 6.11). The samples which did not isolate any pathogens had lower e-
Diversity (p=0.0182) and lower e-Richness (p=0.0350), than those who isolated 
pathogens (see Table A6.7). As with the NCFB cohort, other factors such as 
gender, antibiotic burden and environment were assessed, but no associations 
were noted (see TableA6.8). As well as antibiotic prophylaxis, this also applied to 
IV antibiotics in the last 12 months (see Table 6.12). 
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Figure 6.8 Dendrogram of baseline samples from CF cohort 
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Figure 6.9 Comparison of e-Diversity and FEV1 %predicted in CF cohort 
Assessed by linear regression. P=0.0216 and R2=0.1052 
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Figure 6.10 Comparison of e-Richness and FEV1% predicted in CF cohort 
Assessed by linear regression. P=0.0111 and R2=0.1269 
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 PA 
 
(n=12) 
SA 
 
(n=9) 
PA+SA 
 
(n=12) 
Other 
 
(n=7) 
Culture-
negative 
(n=11) 
P Value 
e-
Diversity 
1.48 
(1.14-
1.73) 
1.91 
(1.63-
2.09) 
1.9 
(1.65-
2.04) 
1.62 
(1.41-
1.99) 
 
1.48 
(1.07-
1.74) 
0.0056 
e-
Evenness 
0.86 
(0.71-
0.9) 
0.92 
(0.85-
0.94) 
0.92 
(0.85-
0.92) 
0.86 
(0.79-
0.91) 
0.89 
(0.73-
0.9) 
0.0168  
e-
Richness 
5.5 
(2.29) 
8.11 
(2.13) 
8.08 
(1.93) 
7.57 
(2.06) 
5.55 
(1.44) 
0.0043 
Table 6.11 Comparison of CF culture result and ecological measures 
Calculations involving e-Diversity and e-Evenness are performed by Krusal-
Wallis test and values reported as medians with IQRs. Calculations involving e-
Richness were performed by ANOVA with values reported as means with 
standard deviations. “Other” refers to culture positive samples which did not 
isolate PA or SA. Multiple comparisons for e-Diversity revealed a statistically 
significant difference in the comparison of PA+SA v Other. Multiple comparisons 
for e-Richness revealed a statistically significant difference in the comparison of 
PA v PA+SA and PA+SA v Culture-negative. 
 >14days 
(n=13) 
1-14days 
(n=14) 
No IVs 
(n=24) 
P Value  
e-Diversity 1.62 
(1.3-1.88) 
1.62 
(1.35-1.9) 
1.76 
(1.33-1.99) 
0.6197 
e-Evenness 0.87 
(0.84-0.92) 
0.9 
(0.79-0.92) 
0.89 
(0.81-0.92) 
0.9916 
e-Richness 6.62 
(1.94) 
6.57 
(2.58) 
7.17 
(2.34) 
0.6940 
Table 6.12 Comparison of IV antibiotic days in preceding 12 months and 
ecological measures in CF cohort Calculations involving e-Diversity and e-
Evenness are performed by Krusal-Wallis test and values reported as medians 
with IQRs. Calculations involving e-Richness were performed by ANOVA with 
values reported as means with standard deviations 
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6.5  Discussion 
In this chapter we have successfully performed microbial profiling with the RISA 
technique on NCFB and CF cohorts. This has demonstrated an output of 
potentially clinically-relevant information in relation to markers of disease severity 
such as lung function and the exacerbator phenotype, as well as clustering 
samples into potentially useful categories such as low diversity communities. It 
has also given insight into the comparison of bacterial communities in the lungs 
of those with NCFB and CF and the position of their traditional pathogens- namely 
PA, HI and SA, within their communities. 
When considering our dataset it should be noted that the cohorts involved in this 
study are fairly typical of what may be expected in other centres around the UK. 
In the NCFB cohort there was a predominance of females and a typical mean 
age. As is often the case, a significant proportion of the cohort did not have a 
clear aetiology for their NCFB. Interestingly there appeared to be a higher rate of 
asthma as an aetiology in the mild category. Conceivably some of these patients 
only remain under out-patient follow-up because of their concurrent asthma, and 
otherwise they would have been discharged from follow-up with their mild NCFB. 
There was a wide range of severity, with the majority either having moderate or 
severe disease. Microbiological data was also typical, with PA and HI the most 
prominent pathogens by the traditional culture approach. However, there 
appeared to be a suggestion of HI-positive cultures being seen in patients with 
higher exacerbation rates than those with PA-positive cultures. PA is usually 
considered to be the more pathogenic of these two prominent microorganisms 
and is traditionally associated with more severe disease. Those with PA did have 
a higher severity score, but it should be considered that the difference of 
approximately 2 points between these sub-groups is the same as that awarded 
to patients colonised with PA. There could be a couple of explanations for this 
observations. It is plausible that certain strains of a generally less pathogenic 
organism, may have greater pathogenicity than strains of another more notorious 
microorganisms. A relatively benign local PA population may have less impact on 
exacerbations than a more pathogenic HI population. Another explanation maybe 
that those with PA receive better treatment. This may in part be due to greater 
vigilance with PA, but also available therapies may be more effective for PA. For 
example, macrolides have been shown to be more effective in those with PA, and 
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the use of inhaled colistin in those who are compliant is effective.[52, 120] In our 
cohort, those with PA received significantly more prophylactic antibiotic which 
may explain this finding.  
In the CF cohort there was a predominance of the main mutation - F508del as 
would be expected. There was also a wide range of disease severity, varying 
from patients listed for transplant, through to those with supra-normal lung 
function. Traditional microbiological techniques revealed PA and SA to be the 
main pathogens grown on culture. Consequently we have studied two cohorts 
with characteristics and microbiological status which will be comparable to many 
others. 
Following DNA extraction of sputum from these cohorts, RISA profiles were 
successfully obtained from all samples. Of note, no RISA profiles could be 
generated from accompanying negative controls. This is very important, as 
sensitive molecule techniques such as 16S rRNA sequencing, can amplify DNA 
when processing negative control samples. When samples were viewed together 
via cluster analysis there were clearly some dominant bands. RISA cannot be 
used to formally identify the presence of pathogens by bands but our 
collaborators (E. Mahenthiralingam and M. Bull, Cardiff University) have an 
unpublished database of ITS band sizes. This allows us to speculate that 
prominent microorganisms in our communities may be PA, HI, SA and various 
Streptococcal species. However, this database highlights why RISA cannot be 
used primarily as a pathogen identification tool, as the band size for HI and PA 
can be very close. The bioanalyser has an error margin of +/- 5% and 
consequently two bands which appear identical could be either PA or HI. Indeed 
in our dendrograms, examples can be highlighted where a PA-positive sample is 
between two very similar HI samples. Others have also noted issues with close 
band lengths.[292] In addition, our collaborators database and other published 
work has shown how the same species can have more than one band 
length.[376] These are major limitations, though for other pathogens, RISA may 
give an indication of a likely pathogen which may direct towards more targeted 
investigation for that microorganism. For example, the two samples positive for 
MC both had a dominant bands around 800 bp (797 bp and 805 bp). Three out 
of the four samples positive for SMalt had a dominant band around 820bp (819-
821 bp) and the other sample’s second most prominent band was 823 bp.  
164 
 
Whilst RISA has limitations as a pathogen identification tool, what it does provide 
is a visual and quantifiable assessment of the bacterial community. For example, 
the image of a single dense band suggests a community overwhelmingly 
dominated by a single pathogen. The bioanalyser output allows quantification of 
this through band counting and giving a concentration for the band. These outputs 
can then be used to calculate estimates of ecological measures such as diversity, 
evenness and richness. These are the ecological measures which have 
commonly been used in investigation of the bacterial communities of the lung and 
have shown associations with clinically significant markers and phenotypes.[133, 
286, 321] Whilst these ecological measures are inter-linked in their calculations, 
they do provide different descriptions of the community. Richness is the most 
straightforward and is a count of the number of taxa (whether defined by species, 
genera, OTU or other criteria). Evenness takes into account how equal the 
abundance is of the taxa that make up that community. Diversity takes into 
account both the richness and the evenness of that community. Whilst these 
metrics may all point in the same direction when describing how complex a 
community is, this is not always the case. For example, a community with just two 
species with similar relative abundance will have a low richness but a high level 
of evenness. Another community with 10 species may have a greater richness, 
but if this community is dominated by one species then the evenness may be very 
low and the diversity less than other communities with similar richness.  
Ecological estimates in our cohorts suggest that our NCFB bacterial communities 
are less complex than our CF bacterial communities by all measures. The 
statistical significance of all of these measures gives strong confidence in this 
observation, as does the persistence after removal of non-stable state samples. 
In previous studies the diseases have not been directly compared as they have 
here, and this finding is both interesting and novel, and well worth considering 
the reasons why. The expectation may have been for the opposite. CF is often 
seen as a more severe disease and the situation of the lung being dominated by 
a single pathogen in late-stage disease is well described.[286, 329, 372] 
However, with improvements in management and increasing life expectancy, 
patients are transferring from paediatric to adult care further away from the end-
points of lung transplantation or death. In fact a recently published paper 
assessing three transitioning groups found the greatest diversity in the group who 
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had most recently transitioned.[377] Within our CF cohort there is a great range 
of disease severity and a significant proportion have well-maintained lung 
function. We have shown an association between lung function and estimates of 
diversity and richness, so whilst the lack of complexity of end-stage CF patients 
may hold true, this is not the picture for the whole cohort. Another reason why the 
CF cohort may have been expected to have less complex communities is the 
antibiotic burden that these patients endure. A higher proportion of CF patients 
are on prophylactic antibiotics and have had courses of IV antibiotics in the last 
12 months. It would therefore be expected that this would have an impact on their 
communities. However, neither the usage of prophylactic antibiotics nor the 
burden of IV antibiotic therapy was associated with a difference in any ecological 
measures in either cohort. On the face of it, this may be counter-intuitive, but this 
may not be a great surprise. Some previous work has demonstrated remarkable 
resilience of the bacterial communities of the diseased lung in the face of 
antibiotics.[324] The technique may also play a part. A technique with a lower 
sensitivity than 16S rRNA sequencing might not show the impact on less 
prominent bacteria which also contribute to the community. The lack of bands 
generated by negative control samples may highlight the lower sensitivity of 
RISA, and this reduced sensitivity compared to 16S rRNA sequencing has been 
previously recognised.[292] 
If we think about why NCFB lungs may have less complex communities, then age 
would be a potential factor. The NCFB cohort is clearly markedly older and if 
diversity reduced with age, then this may be the explanation. However our data 
suggests an increase in diversity with age in NCFB. This is surprising as work in 
CF cohorts has suggested a trend of decreasing diversity with age.[312] This may 
in some ways be a quirk of sampling an unselected everyday NHS cohort. For a 
younger patient to be seen in clinic regularly they are likely to have significant 
disease, whilst those who have exceeded life expectancy may have milder 
disease as suggested by their longevity. The answer to why our NCFB bacterial 
community appears less complex may be at least partially explained by looking 
directly at the bacteria rather than focusing on exogenous reasons. In the NCFB 
cohort those who isolated HI appeared to have less complex communities than 
those with PA. We saw no evidence of co-infection with PA and HI, and this is 
not a novel observation.[270, 271] In the CF lung however, instead of HI, SA is 
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the other main pathogen seen. Unlike HI, SA appears to be associated with more 
complex communities than patients with PA. In addition, co-infection with SA and 
PA was common and appeared to be associated with a more complex 
community. It would thus seem plausible that a contributor to our observation is 
that HI dominates a community more than SA, and HI is seen far more in NCFB 
whilst SA is seen far more in CF. It is worth noting that statistically significant 
differences in the ecological measures persisted when the numbers assessed 
were reduced by just looking at samples taken in the stable state. Whether or not 
studies of bacterial communities in the lungs should just be performed on stable 
state samples are unclear. Whilst it may seem that by doing so will give a fairer 
representation, some studies have shown that very little change occurs during 
exacerbations and acute antibiotic therapy, though this is not universal.[319, 324, 
378] Combining our two cohorts allowed comparison of 18 patients from whom 
we had obtained samples in both the stable and the exacerbation state, and in 
these patients we did not see a significant change in any of the ecological 
measures.  
One of our primary aims in this study was to investigate the microbial profiles 
generated by RISA and their associations with clinical characteristics and disease 
severity. The main focus has been on NCFB due to the size of the cohort and 
due to the disease having not previously been investigated by this technique. The 
use of cluster analysis on the NCFB cohort sorted samples into groups with 
certain characteristics. For example, Group C had less complex communities 
whilst Group B profiles were dominated by a couple of bands with lengths around 
530 and 560 bp. By in silico prediction this may represent Streptococcus. Other 
work has highlighted that Streptococcus is often not reported by traditional 
culture.[314] Interestingly, there was no discernible difference between the 
groups with regards to disease severity as defined by the Bronchiectasis Severity 
Index. There was also no significant difference with others simple markers of 
severity such as lung function and exacerbation rate. It may be seen as a 
limitation that RISA cannot highlight disease severity by cluster analysis, but there 
should not be a need for this as clinical assessment should be able to do this. 
The fact that it does not distinguish disease severity may in fact be a significant 
advantage. It would seem plausible that two patients with similar disease severity 
but very different microbial communities may benefit differently from the same 
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prophylactic therapy. Consequently, for drug trials, RISA may provide simple sub-
group analysis for little added cost in patients without discernible clinical 
differences. If certain sub-groups benefitted more, it would be a technique that 
could easily be incorporated into the planning of long-term therapies in standard 
clinical care. 
As well as the creation of dendrograms, the output from RISA has allowed us to 
describe communities with estimates of diversity, evenness and richness. These 
descriptions could be an adjunct to traditional culture to help provide a more 
detailed overview of the patient’s bacterial community. For example, rather than 
a sample simply being reported as HI-positive, a report of HI-positive within a 
community of high richness, low evenness and moderate diversity, may be more 
helpful. As our understanding of the importance of the microbiota increases, this 
simple addition to clinical reports may aid the managing clinician and therefore 
the patient.  
For RISA, or an alternative technique, to be really useful the ecological measures 
need to mean something with regards to the impact of the disease on the patient. 
We have not demonstrated an association with disease severity as defined by 
the BSI. However, there does need to be some caution not to over-interpret this 
result. The BSI is a scoring system which provides clinicians an overview of 
disease severity and researchers a quantifiable measure. It does award a 
significant number of points for being colonised by PA and being elderly. To 
illustrate this impact, if you are 80 years old and have isolated PA in sputum twice 
in the last 12 months, you would be categorised as severe even if you had no 
other markers of disease. There is a suggestion in our data that PA may not be 
behaving more pathogenically than HI in our local cohort, and Devon does have 
a large geriatric population. The BSI also awards points for hospital admissions. 
This often occurs when a patient requires IV antibiotics. We provide a home IV 
service which tends to be used more by younger patients who self-administer 
their own drugs. Consequently a patient may have had courses of IV antibiotics 
without being admitted to hospital. This may reduce the score in some of our 
younger patients and hence distort their reported severity. For many patients, 
rather than a score, what matters to them is their frequent symptoms including 
exacerbations and breathlessness. In our cohort, patients with low exacerbation 
rates had more diverse and richer communities, whilst lung function was 
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associated with a richer community. These findings clearly do not show 
causation, though the concept of a more complex community being less 
susceptible to exacerbations is appealing and greater investigation is warranted.  
Beyond lung function and exacerbation rates, other results of note in the NCFB 
cohort included the observation of reduced evenness in culture-positive samples 
and less complex communities in rural dwellers. The reduced evenness in 
culture-positive samples is logical and implies that the more prominent a 
pathogen is in a community, the more likely it will reveal itself when that 
community is used to inoculate agar plates. The reduced complexity of those in 
rural areas (defined as not living in a town or city) is interesting. It is not 
mechanistically clear why this is the case, as the opposite may have been 
expected. We have not recorded duration of living in that setting or where the 
patient was brought up as a child, and consequently this result may not be a 
reflection on the rural environment. 
The CF cohort was also analysed on its own, however its smaller size needs to 
be considered when assessing results. The cluster analysis did not display 
multiple distinct clusters of significant size like in the NCFB cohort. This may 
suggest some greater heterogeneity of CF bacterial communities which should 
be expected in the cohort with the greater complexity of its communities. Of note, 
reduced diversity and richness was associated with worse lung function, whilst 
evenness was not. This is very similar to the results seen in our NCFB cohort and 
compatible with previous work when FEV1 was used as a primary marker of 
disease severity.[133] Clearly causation cannot be claimed, but it would seem 
plausible that airflow obstruction could impact on the clearance of respiratory 
secretions and accompanying microbiota, and that certain communities with 
reduced diversity and richness may cause further airway damaged and 
worsening airflow. There has been work which raises the possibility of differential 
airway remodelling according to the bacteria present in the airway via  matrix 
metalloproteinases.[379] When looking at culture results and ecological 
measures, less complex communities were seen for PA-positive samples and 
culture-negative samples, and reduced diversity in PA-positive samples has been 
observed before.[270] The culture-negative group is also of interest and can pose 
significant challenges in clinical decision-making due to the lack of a pathogen to 
target. The ecological pattern seen in our CF cohort is the opposite of our NCFB 
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cohort and may represent a different threat in CF where difficult to culture 
pathogens may dominate communities.[133] Another consideration in these 
patients may be the impact of fungal disease, which is not investigated by the 
RISA technique. The final point to highlight in the CF cohort is the lack of impact 
of antibiotic burden on community measures. The literature is mixed on the 
impact of antibiotics and ecological measures. Significant resilience in the 
microbial community can be seen, whilst there is also the suggestion that 
antibiotics drive loss of diversity in CF.[314, 315, 319, 329, 377] These concepts 
do challenge previously held views on what we are achieving, or looking to 
achieve, with antimicrobial therapy and the management of chronic lung disease. 
The concept of germ theory appears too simplistic in chronic infection of the lung. 
Consequently the concept of looking to kill one pathogen may also be flawed.  
There is no previous work looking at bacterial communities in NCFB by RISA, 
however if RISA is a useful technique, then we would expect some similar 
findings to those seen in studies using the gold-standard technique of 16S rRNA 
sequencing. The previous findings in NCFB are mixed, and consequently it is 
unsurprising that some of our results are in keeping with some of the literature. 
Work by Rogers et al on a cohort from an RCT assessing long-term macrolides, 
reported a positive correlation between diversity and FEV1.[321] Whilst we did 
not quite reach statistically significance for this, we did see a trend towards, and 
we did find a positive correlation between FEV1 and richness which was also 
found by Rogers et al. However, reviews of unselected cohorts of NCFB at 
centres in London and the North-East of England failed to show an association 
between FEV1 and diversity.[271, 319] Previous studies had not compared 
ecological measures to the BSI. In the CF cohort the findings of FEV1 correlating 
to ecological measures has been consistently found.[133, 377] However, the 
seeming lack of impact of antibiotic prophylaxis on ecological measures in both 
cohorts is at odds with some previous work in both diseases.[314, 319]. As 
discussed previously, this may be due to a lack of sensitivity in the technique, the 
stability of the community or a combination of both.  
With regards to the CF cohort itself, it is difficult to make direct comparisons with 
the most relevant work of Flight et al that also used RISA.[133] Many of their 
conclusions were based on the accompanying 16S rRNA sequencing data which 
we do not have. Their cluster analysis contained 9 more patients than ours and 
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divided into two large clusters. Our cluster analysis was performed in the same 
way and with collaboration with the same team, and yet if we divide our cluster 
analysis at the same level of similarity, we have 6 different clusters with only one 
of them containing more than 5 samples. The only clear difference between the 
process used by Flight et al and ours is the technique used for extraction of DNA. 
As we used mechanical disruption as part of our protocol, this may have changed 
the type of species extracted and hence lead to less tight clustering. The other 
difference of note was in the pathogens cultured. For example, we saw more SA 
and they found more BCC. This would very much be expected to influence the 
output.  
There are several strengths to highlight in both this study and the technique 
described. In the current literature there is no current description of bacterial 
communities in NCFB in a cohort of this size. In addition, none of the preceding 
work takes into account the BSI or provides direct comparison to a CF cohort. 
This is also the first study to describe RISA profiles in a NCFB cohort. The 
technique has shown itself to be easy to perform and analyse. It has also been 
performed at a fraction of the cost and bioinformatics processing of 16S rRNA 
sequencing. This makes it a realistic technique in day-to-day clinical practice. Its 
limitations however must be noted. The 5% error margins of the bioanalyser and 
the small difference in band length among different potential pathogens means 
this cannot be used for diagnostic identification. In addition, there is no previous 
data to validate its estimates of ecological measures alongside the gold-standard 
technique, however we have performed this comparison and describe it in the 
next chapter. The likely reduced sensitivity compared to 16S rRNA sequencing 
increases the chances of samples having only a single band seen. A single value 
results in an e-Diversity and e-Evenness scores of 0. Whilst these samples are 
likely to have low diversity and evenness, using other more sensitive techniques, 
the values may well not be that low. For the purposes of this study, the non-
parametric distribution means that the statistical tests are unlikely to be affected, 
and if the question asked is whether or not the sample has low diversity or 
evenness, then again this is not a significant issue. Limitations in this study 
beyond the technique include the sample size and the lack of longitudinal 
samples and clinical follow-up. However, as an initial step this study 
demonstrates what RISA is capable of and the feasibility of its use in larger 
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longitudinal trials. Additional limitations include the focus exclusively on bacteria. 
The impacts of fungi and viruses are beyond the scope of this work and neither 
RISA nor 16S rRNA sequencing can provide insight beyond bacteria. It may be 
that for better understanding of the microbiome that parallel investigations are 
required which take into account the virome and the mycobiome. 
When considering the role of RISA in the future, it is important to remind 
ourselves where our understanding is at the moment. Research so far has 
highlighted associations between communities and patient phenotypes in chronic 
suppurative lung disease, other lung pathologies and in other organs. This has 
not however led beyond hypotheses of the importance of these observations. To 
move the field forward, the inclusion of microbial community assessment in large 
longitudinal clinical trials is essential. This may then give understanding into the 
real-world significance of these findings and which therapies should be 
administered to patients with different bacterial communities. For this to be done 
on a large scale in clinical trials, and then be used in subsequent clinical practice, 
the technique should ideally be simple, quick and cheap. RISA offers these 
attributes and therefore whilst it has clear limitations, it should be considered as 
a technique to take the field forward.  
6.6 Conclusion 
In this chapter we have described and shown the utility of RISA in a NCFB cohort 
and an accompanying CF cohort. The technique has allowed estimates of 
ecological measures of the bacterial community and has suggested a greater 
community complexity in the CF lung than in NCFB. It has also highlighted 
associations between community measures and clinically-important markers 
such as exacerbator phenotype in NCFB and lung function in NCFB and CF. 
RISA holds potential as an adjunct to traditional culture and stratifying patients 
for future trials and therapies. However, it needs validation of its output by 16S 
rRNA sequencing and this is the focus of the next chapter. 
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Chapter 7- Microbiota characterisation 
of a bronchiectasis cohort by 16S rRNA 
sequencing with comparison to RISA 
analysis 
7.1 Abstract 
Introduction: It has become clear that human lungs contain far more complex 
bacterial communities than previously appreciated. However, the clinical 
significance of these communities in NCFB is unclear, as is the best approach to 
practically measure them. In this chapter we look into the bacterial communities 
and patient characteristics, and compare community measures by a gold-
standard technique (16S rRNA sequencing) to a cheaper and easier technique 
(RISA). 
Methods: A subgroup of samples from the NCFB cohort described in Chapter 6 
underwent interrogation by 16S rRNA sequencing. This technique was used to 
identify the genera making up these communities and to investigate for 
associations with patient characteristics. Comparisons were made with the 
ecological measures estimated by RISA and the sample characteristics proposed 
via cluster analysis. 
Results: Seventy-two samples from 68 patients underwent interrogation by 16S 
rRNA sequencing. The most common genera by mean relative abundance were 
Streptococcus, Haemophilus and Pseudomonas, and these genera were the 
most prevalent in over 80% of samples. Those with Streptococcus as the most 
prevalent genera had greater community complexity than those with 
Haemophilus or Pseudomonas as the most prevalent. Whilst community 
measures did not reveal an association with disease severity as such (as defined 
by the BSI), there was a negative correlation between exacerbation frequency 
and diversity and evenness. Similarly, there was a positive correlation between 
exacerbation frequency and Haemophilus abundance. This analysis 
demonstrated a correlation between communities profiles as described by 16S 
rRNA sequencing and RISA. 
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Conclusion: In our cohort 16S rRNA sequencing has revealed complex 
communities which may have an impact on exacerbation frequency in NCFB. We 
have shown that RISA provides useful insight into the ecological characteristics 
of a bacterial community and may have utility in widespread routine use as a 
surrogate for 16S rRNA sequencing.   
7.2 Introduction 
In this thesis we have described and shown how molecular techniques reveal far 
greater detail and insight into the microbiology of the bronchiectatic lung found in 
CF and NCFB patients. An important concept in this field has been the realisation 
that the healthy lung is not sterile and in fact contains complex polymicrobial 
communities. A principle technique used in recent years has been 16S rRNA 
sequencing. This essentially allows a listing of bacteria and their relative 
abundance. From this, calculations of ecological measures are made such as 
diversity, evenness and richness. These measures appear to be associated with 
clinically significant markers in diseases both in and outside the lung. In asthma, 
bronchial hyper-responsiveness has been shown to be associated with bacterial 
diversity, and increased bacterial diversity is possibly protective against asthma 
development.[380, 381] In COPD, airflow obstruction has been associated with 
reduced diversity.[382] In CF, a loss of diversity has been associated with disease 
severity and less complex communities with quicker decline in lung function.[314, 
316] In the gut, reduced diversity has been identified in inflammatory bowel 
disease.[373] 
In NCFB the message is muddier. One of the earlier prominent works suggested 
a stable microbiome despite antimicrobial treatment.[324] Subsequent work by 
Rogers et al then suggested that bacterial diversity correlated with lung function 
and that patients’ risk for exacerbation could be stratified by their bacterial 
community.[321, 323] However, there has been other work which has not linked 
clinical characteristics and disease severity with the microbial community 
measures.[271, 319, 324] Importantly, none of these studies have looked at using 
the Bronchiectasis Severity Index (BSI) to compare the community to the disease 
severity. Whilst it is unclear, it would seem likely that different bacterial 
communities are likely to behave differently, and also respond differently to both 
the host immune response and therapies like antibiotics. Consequently better 
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understanding of the association between disease, therapy and the bacteria 
communities in the lung environment is likely to be useful.  
If appreciation of the bacterial community’s ecological structure does indeed turn 
out to be useful with regard to the management of NCFB or other conditions, then 
a rapid, cheap and accessible test would have large appeal for everyday 
healthcare. Despite the falling costs of sequencing, 16S rRNA sequencing still 
has a significant cost and complexity, and requires significant bioinformatics 
processing before even considering its clinical significance. In Chapter 6 we have 
described RISA, a cheap and accessible profiling technique that allowed us to 
estimate the ecological measures of diversity, evenness and richness.  
In the context of the above issues, we have conducted a study investigating the 
microbiota of NCFB patients in relation to potential influencing factors such as 
their disease severity, their previous therapy and their environment. The 
molecular investigation has been performed on samples which had previously 
undergone RISA, and a further aim of this chapter is to compare the information 
gleaned from that technique with the view of validating it as an appropriate 
method. 
7.3 Methods 
A subset of samples from those investigated in Chapter 6 were sent for 16S rRNA 
amplicon sequencing with the ESS, as described in Chapter 2. The samples were 
chosen exclusively from the NCFB cohort. The first stable sample available from 
each patient was submitted if available, resulting in 85 samples being submitted. 
Five negative controls were also submitted, generated by performing the DNA 
extraction process on Mucolyse from the NHS microbiology laboratory, which had 
not been mixed with sputum (this process was done once from each of the five 
batches of the DNA extraction kit used). In addition, DNA was extracted from one 
aliquot of the DES used to dilute samples for submission. Finally, a further five 
culture-negative samples were submitted in order to fill a 96-well plate for 
sequencing. Following sequencing, any sequence which had at least 10% of its 
reads in the negative controls was excluded from downstream bioinformatics 
analysis by the Sequencing Service.  In addition, one sample was missed off the 
sequencing run and seventeen were removed from final analysis due to low 
concentrations of DNA after initial amplification, and hence preventing confidence 
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that all samples had been treated equally. This left 68 stable samples and a 
further 4 others.   
7.4 Results 
7.4.1 Sequencing Output and Read Removal 
In total 90 clinical samples and 6 negative controls were submitted for 16S rRNA 
sequencing with the ESS. One sample was left off (due to laboratory error) and 
the remaining 95 underwent sequencing. From these, 8447 different sequences 
were obtained - of which 141 were only found in negative controls and 4 were 
found in all negative controls. These 4 sequences were identified at genus level 
as Delftia, Achromobacter, Ralstonia, and Propionibacterium. Sequences were 
removed when greater than 10% of the total reads came from the 6 negative 
controls. This left 8177 sequences. For 17 samples there was un-recordable 
quantity of DNA at a point in the process, and these samples had a higher 
proportion of contaminant reads. To ensure confidence in our results, these were 
removed from further analysis leaving 72 samples available for analysis. From 
these 72 samples, there were 7289 different sequences and 482 when collapsed 
to genus level for the purposes of taxonomic binning.  
The bioinformatics pipeline DADA2, gave reported resolution to sequence level 
rather than OTUs, with the next level of differentiation at genus level. It was 
debated which taxonomic level would be used for the primary analysis of the 
ecological measures of diversity, evenness and richness. These measures were 
calculated by both methods and showed very high concordance (see Figures 7.1, 
7.2 and 7.3). Due to such high concordance, it was felt that either could be used. 
We chose the taxa of genus due to issues with accurate species-level 
identification for many sequences. For example, one sequence identified as 
Burkholderia ambifaria / anthina / arboris / cenocepacia / cepacia / contaminans 
/ diffusa / glumae / lata / metallica / multivorans / plantarii / pyrrocinia / sp / stabilis 
/ vietnamiensis. 
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Figure 7.1 Diversity calculated at sequence and genera level Analysis 
performed by linear regression. P<0.001 and R2= 0.8539. 
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Figure 7.2 Evenness calculated at sequence and genera level Analysis 
performed by linear regression. P<0.0001 and R2= 0.7255. 
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Figure 7.3 Richness calculated at sequence and genera level Analysis 
performed by linear regression. P<0.0001 and R2= 0.6178. 
 
7.4.2 Comparison of 16S rRNA Sequencing Subgroup to Original Cohort 
The samples were selected for 16S rRNA sequencing by the first stable sample 
available for each patient. A further 4 additional samples were also investigated 
and came from patients who were already included. These additional samples 
are only included for comparison between techniques (e.g. comparing ecological 
measures generated by RISA and 16S rRNA sequencing). For all other analysis, 
the 68 stable samples with just one per patient are used. There were no 
significant differences found between the overall cohort which were described in 
Chapter 6 and the subset assessed here (see Table 7.1). 
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 Total Cohort Subset P Value 
No 99 68  
Age, yrs.a 
(Range) 
65.5 
(17-88) 
66 
(17-88) 
0.8198 
BSIa 
(Range) 
7.3 
(1-18) 
7.3 
(2-18) 
0.9714 
%Femaleb 64.65 67.65 0.6878 
FEV1 
%predicteda 
(Range) 
68.94 
(23-116) 
68.87 
(25-116) 
0.9840 
Colonised at 
Recruitmentb 
- Any 
- PA 
- HI 
 
 
41.41% 
20.20% 
17.17% 
 
 
39.71% 
20.59% 
17.58% 
 
 
0.8253 
0.9514 
0.9365 
BMIa 25.07 
(5.45) 
25.58 
(5.87) 
0.5700 
Exacerbations 
in last 12 
monthsc 
3.42 
(3.06) 
3.34 
(3.05) 
0.9235 
MRC Dyspnoea 
scorea 
2.404 
(0.97) 
2.426 
(0.98) 
0.8808 
Antibiotic 
Prophylaxisb  
- Any 
- Oral 
- Inhaled 
 
 
50.51% 
40.40% 
19.19% 
 
 
44.12% 
36.76% 
16.18% 
 
 
0.4349 
0.7469 
0.6850 
<10 pack year 
smoking 
historyb 
73.74% 72.06% 0.8600 
Table 7.1 Comparison of demographics of NCFB cohort initially recruited 
and the subgroup that underwent 16S rRNA sequencing The data in this table 
is presented as mean values or percentages of that group. In those continuous 
measures where range is not of specific interest, standard deviations are reported 
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alongside the mean value. Statistical comparison was performed by aunpaired t-
test, bChi-squared or cMann-Whitney test. 
7.4.3 Relative Abundances of Genera and Ecological Measures 
From the total reads within each sample, relative abundances were calculated. 
When the mean relative abundance was calculated from the 68 samples at 
genera level, only three were over 10%, namely Streptococcus (27.49%), 
Haemophilus (21.88%) and Pseudomonas (10.94%). The 15 most abundant 
general are shown in Figure 7.4.  
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Figure 7.4 Mean relative abundance by genera in NCFB cohort 
 
There was highly variable abundances of some genera across the samples as 
highlighted by Haemophilus and Pseudomonas having noticeably lower median 
values (4.22% and less than 0.01% respectively) than their mean value. 
Streptococcus had a similar median value (24.81%) to its mean value, 
demonstrating it’s more consistent presence across communities. When 
assessing genera by frequency of being the most prominent genera within a given 
sample, these same three genera were the most prominent, and between them 
were the most prominent in 82.35% of all samples (see Fig 7.5). 
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Figure 7.5 Proportion of communities dominated by each genera 
The ecological measures of diversity, evenness and richness were compared 
between samples dominated by each of the three main genera and the others. A 
genera was considered to dominate a sample if it was the most prevalent. 
ANOVA assessment revealed a significant difference in diversity (p< 0.0001). 
This was due to differences between the Streptococcus-dominated and the 
Haemophilus-dominated samples, and between the Streptococcus-dominated 
and the Pseudomonas-dominated samples. In both instances Streptococcus-
dominated samples had a higher diversity score (see Fig 7.6). The same pattern 
was also seen with regards to evenness, with Streptococcus-dominated samples 
being more even than Haemophilus - (p<0.0001) and Pseudomonas - (p=0.0151) 
dominated samples (see Fig 7.7). With regards to richness, there was a slightly 
different pattern, though again significant differences where seen by ANOVA. 
These were due to differences between Haemophilus-dominated samples and 
samples dominated by Streptococcus (p=0.0004), and between Haemophilus-
dominated and those dominated by a bacteria other than Streptococcus or 
Pseudomonas (p=0.0002) (see Figure 7.8).   
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Figure 7.6 Diversity depending on the dominant genera Bars represent the 
mean with standard deviations. 
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Figure 7.7 Evenness depending on the dominant genera Bars represent the 
mean with standard deviations. 
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Figure 7.8 Richness depending on the dominant genera Bars represent the 
mean with standard deviations. 
 
The above measures suggest that when either Haemophilus or Pseudomonas is 
the most prominent genus, the communities appear less complex than those 
dominated by Streptococcus. In order to investigate further, correlations were 
assessed between the presence of these three genera and the presence of other 
common genera found. As would be expected of Haemophilus and 
Pseudomonas (given their domination of less complex communities), no positive 
correlations were seen between the presence of either of these genera and the 
presence of other genera. Indeed, multiple negative correlations were seen. For 
Haemophilus, these negative correlation were seen with Pseudomonas, 
Actinomyces, Rothia, Veillonella, Prevotella and Streptococcus, whilst for 
Pseudomonas, the negative correlations were seen with Veillonella, 
Streptococcus and Haemophilus. On the other hand, Streptoccocus actually had 
positive correlation with Rothia and Veillonella. Other positive correlations were 
observed between other genera, as listed in Table 7.2.   
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Genera Positive Correlates 
Streptococcus Rothia  
Veillonella 
Actinomyces Veillonella  
Prevotella, 
Rothia Streptococcus 
Veillonella Prevotella 
Streptococcus  
Actinomyces 
Prevotella Actinomyces 
Veillonella 
 
Table 7.2 Positive correlations found between the relative abundances of 
the common genera 
7.4.4 Comparison of Traditional Culture and 16S rRNA Sequencing 
Results 
Comparisons were made between the culture results and 16S rRNA sequencing 
results from the 72 samples that had undergone both techniques. Of these 72 
samples, 39 isolated potential pathogens and are referred to as culture-positive 
samples, whilst 33 did not and are referred to as culture-negative samples. When 
looking at results at this initial sub-division, there were clear differences in 
community complexity and composition. Culture-negative samples were 
significantly more complex when assessed by the measures of diversity 
(p=0.0026), evenness (p=0.0046) and richness (p=0.0082) (see Table 7.3). 
When looking at samples which were culture-positive for HI or PA, there was a 
trend towards lower diversity and evenness in the HI-positive samples, without 
quite reaching statistical significance. When reviewing composition with regards 
to mean relative abundance, there appears to be a higher abundance of 
Haemophilus and Pseudomonas in culture-positive samples (see Figure 7.9), 
although these do not reach statistical significance. There were however 
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significantly higher relative abundance of Streptococcus, Actinomyces, Neisseria, 
Rothia and Prevotella in the culture-negative samples. 
 Culture-
positive 
Culture-
negative 
P= 
Diversity 1.20 1.70 0.0026 
Evenness 0.28 0.39 0.0046 
Richness 67.54 80.85 0.0082 
 
Table 7.3 Ecological measures of culture-positive and culture-negative 
samples Comparison of measures was performed by the unpaired t-test. 
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Figure 7.9 Mean relative abundance of genera in culture-positive and 
culture-negative samples 
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The genus with the highest mean relative abundance in culture-negative samples 
was Streptococcus, as opposed to Haemophilus in the culture-positive samples. 
When assessing the most prominent genus in culture-negative samples, 
Streptococcus was the most prominent in 22 of the 33 samples (66.67%). As well 
as these 22 samples, a further 10 culture-positive samples had Streptococcus as 
the most prominent genus. However, in these 10 samples, Streptococcus was 
not isolated at all by traditional culture. Instead, Haemophilus influenzae, 
Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiella pneumoniae, and 
Stenotrophomonas maltophilia were isolated from these 10 samples. By 16S 
rRNA sequencing, Haemophilus was the most common genera in 15.15% of the 
culture-negative samples and 30.2% of the culture-positive samples. Of the 12 
culture-positive samples in which Haemophilus was deemed the most abundant 
genus, 11 isolated HI and one isolated Streptococcus pneumoniae. 
Pseudomonas was the most prominent genera in 3.03% of culture-negative 
samples and 23.08% of the culture-positive samples. In these culture-positive 
samples, all of them isolate PA and one also isolated SA. The pathogens isolated 
by culture when a certain genera is deemed the most prevalent by 16S rRNA 
sequencing, are listed in Table 7.4. 
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Dominant 
Genera/Culture 
Result 
BMV HI KP MC PA SA SerM Smalt Spn Culture-
Negative 
Streptococcus  4 1  3 1  1  22 
Haemophilus  11       1 5 
Pseudomonas     9 1    1 
Actinomyces          2 
Burkholderia 1 1         
Moraxella    2       
Neisseria          2 
Staphyloccocus  1    2     
Corynebacterium       1    
Enterococcus          1 
Stenotrophomonas        1   
Total 1 17 1 2 12 4 1 2 1 33 
 
Table 7.4 Culture results when a certain genera is most prevalent BMV- 
Burkholderia multivorans, HI- Haemophilus influenza, KP- Klebsiella 
pneumoniae, MC- Moraxella catarrhalis, PA- Pseudomonas aeruginosa, SA- 
Staphylococcus aureus, SerM- Serratia marcescens, Smalt- Stenotrophomonas 
maltophilia, Spn- Streptococcus pneumoniae. 
 
Whilst the bioinformatic pipeline attempted to provide species level identification, 
such results tended to be ambiguous (only 12% of sequences detected had an 
unambiguous identification). Klebsiella pneumoniae was the only pathogen 
isolated by culture that was not identifiable by the accompanying 16S rRNA 
sequencing data. There was wide range of relative abundances seen for the 
genera of the pathogens identified by culture (Table 7.5). Of note, a sample had 
1% abundance for Staphylococcus but was reported by culture as positive for SA 
and Candida. The only other genera to have less than 10% relative abundance 
but to be isolated by culture was Pseudomonas (see Table 7.5). When looking at 
culture-negative samples, there were examples of high relative abundance of the 
important genera of Pseudomonas and Haemophilus. One sample was 93.33% 
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Pseudomonas (of which at least 99.99% of the Pseudomonas reads were 
identified as PA), yet did not isolate PA. Twelve samples had a relative 
abundance of Haemophilus above 10% without isolating a Haemophilus species, 
including a sample with 67% relative abundance of Haemophilus (of which at 
least 66.34%% of the Haemophilus reads were identified as Haemophilus 
influenzae). Other noteworthy findings included the near complete dominance of 
Moraxella in the two samples which isolated it (both greater than 96% relative 
abundance), whilst it’s relative abundance was never above 0.38% in any other 
sample. Also of note, the technique was able to report a relative abundance of 
Staphylococcus of 74.71% in a sample. This is noteworthy due to concerns with 
16S rRNA sequencing not picking up SA.[280, 319]   
 
Culture N= Lowest 
abundance 
(genera) 
Highest 
abundance 
(genera) 
BMV 1 41.89% 41.89% 
HI 17 23.66% 99.66% 
KP 1 0 0 
MC 2 96.12% 96.32% 
PA 12 9.47% 99.78% 
SA 4 1% 74.71% 
SerM 1 19.9% 19.9% 
SMalt 2 24.55% 40.56% 
SPn 1 18.46% 18.46% 
 
Table 7.5 Range of relative abundance of relevant genera in culture-positive 
samples BMV- Burkholderia multivorans, HI- Haemophilus influenza, KP- 
Klebsiella pneumoniae, MC- Moraxella catarrhalis, PA- Pseudomonas 
aeruginosa, SA- Staphylococcus aureus, SerM- Serratia marcescens, Smalt- 
Stenotrophomonas maltophilia, Spn- Streptococcus pneumoniae. 
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7.4.5 Patient Characteristics and Ecological Measures 
Patient characteristics were assessed alongside ecological measures as 
determined by 16S rRNA sequencing. For each characteristic, comparisons were 
made with diversity, evenness and richness. No significant correlations were 
found for multiple factors including age, BMI and FEV1, and urban or rural living.  
Disease severity as defined by the Bronchiectasis Severity Index (BSI) was 
assessed in two ways: (1) comparison between the BSI total score and the 
ecological measures, and (2) comparison between the categories generated by 
the BSI (i.e. mild, moderate and severe) and the ecological measures. No 
significant associations were found by either approach. 
Patients were grouped by exacerbator phenotype (low, medium or high,  as 
described in Chapter 6) based on their exacerbation frequency of the last 12 
months. Whilst RISA-based ecological measures correlated with exacerbator 
phenotype (Chapter 6), equivalent 16S rRNA-based ecological measures did not. 
However, if the actual number of patient-reported exacerbations was compared 
to 16S rRNA-based diversity and evenness, then a significant correlation was 
seen (p= 0.0085; R2= 0.1003 and p= 0.0075; R2= 0.1035) (see Figures A7.1 and 
A7.2). There was one significant outlier with regards to reported exacerbations, 
and the correlation by evenness remained even after removing this patient.   
The relative abundance of the 10 most common genera were compared against 
multiple clinical and patient characteristics. There was a positive correlation with 
age with regards to the Streptococcus genera (p= 0.0202; R2= 0.07901), but a 
negative correlation with Staphylococcus (p=0.0137; R2= 0.08851). As would be 
expected there was a positive correlation between Pseudomonas abundance and 
disease severity as defined by the BSI (see Figures A7.3). There was also a 
positive correlation between exacerbation frequency and abundance of 
Haemophilus, but not Pseudomonas.  
Additional comparisons were made between patient therapies and ecological 
characteristics. There was a trend towards greater diversity and evenness in 
those not on inhaled corticosteroid, but this did not quite meet statistical 
significance. No significant associations were made between PPI usage, oral 
antibiotic prophylaxis or nebulised prophylaxis. 
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7.4.6 Comparison of RISA Output to 16S rRNA Sequencing Data 
In chapter 6, cluster analyses were performed on the output provided by RISA. 
The baseline samples for the NCFB cohort divided into four clusters of varying 
size. Of these samples, 65 underwent 16S rRNA sequencing and this allowed 
insight into the characteristics of these previously described groups.  
One of the RISA groups (Group C), appeared to have reduced diversity and 
evenness on the basis of the RISA analysis. This finding was supported by 16S 
rRNA sequencing data (see Figs 7.10 and 7.11). In addition, when using culture 
results, Group C had a higher proportion of Haemophilus influenzae. This was 
also found to be consistent with 16S rRNA sequencing data as 9 out of the 17 
samples were dominated by Haemophilus. This compared to only 6 samples 
being dominated by Haemophilus out of the remaining 48 samples clustered into 
other groups. When assessing Haemophilus with a relative abundance criteria 
rather than a community dominance view point, there was a significant difference 
between the RISA groups due to the high abundance in Group C and the low 
abundance in Group B. Whilst the levels of abundance were also low in the other 
two RISA groups, they did not reach significance (likely due to low numbers).  
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Figure 7.10 Comparison of 16S rRNA-based diversity of each RISA group 
Comparison were performed by ANOVA. Significant difference between A-C 
(p=0.0013) and between B-C (p=0.0008). Bars represent the mean value and 
standards deviation. 
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Figure 7.11 Comparison of 16S rRNA-based evenness of each RISA group 
Comparison were performed by ANOVA. Significant difference between A-C 
(p=0.0016) and between B-C (p=0.0005). Bars represent the mean value and 
standards deviation. 
 
The largest group in the RISA analysis was Group B. This group had a large 
proportion of culture-negative samples and prediction based on RISA fragment 
lengths had suggested that this group may be dominated by Streptococcus. This 
again appeared to be consistent with the 16S rRNA analysis. Out of the 35 
samples from Group B which underwent 16S sequencing, 23 were dominated by 
Streptococcus. Only 6 samples out a possible 30 were dominated by 
Streptococcus and clustered into the other RISA groups. 
The estimated ecological markers of diversity, evenness and richness obtained 
from RISA were compared to the values generated by 16S rRNA sequencing. 
These comparisons were done using the values obtained by sequence, genera, 
and also looking at only the genera with a relative abundance over 1% (“1% 
genera”). Significant association was seen for all comparisons except richness 
by genera (see Table 7.6). 
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 Diversity  
(genera) 
Diversity 
(sequence) 
Diversity  
(1% genera) 
p= <0.0001 <0.0001 <0.0001 
R2= 0.32 0.3539 0.3282 
 Evenness 
(genera) 
Evenness 
(sequence) 
Evenness  
(1% genera) 
p= <0.0001 <0.0001 <0.0001 
R2= 0.3418 0.3627 0.3767 
 Richness 
(genera) 
Richness 
(sequence) 
Richness  
(1% genera) 
p= 0.1815 0.0012 <0.0001 
R2= 0.02536 0.1404 0.1928 
 
Table 7.6 Association between ecological measures estimated by RISA 
and calculated by 16S rRNA sequencing. The values are generated by linear 
regression.  
7.5 Discussion 
In this chapter I have examined the microbiota in a cohort of bronchiectasis 
patients with the use of 16S rRNA sequencing technology. This has provided 
insight into the bacteria present in a NCFB cohort from a region of the UK not 
previously investigated by culture-independent techniques. This has allowed 
comparison between bacterial communities and patient characteristics - an area 
of some conflicting evidence. It has also allowed comparison with a simpler and 
cheaper technique described in Chapter 6, namely RISA. 
As part of the work in Chapter 6, samples were collected from both NCFB and 
CF patients with multiple samples from some patients. Whilst all samples were 
able to undergo RISA, it was not feasible for all samples to be interrogated by 
16S rRNA sequencing. Due to capacity on a single run being 96 (and this being 
a feasible number), this number of samples were included. In order to obtain 
negative controls from all 5 batches of kit used for DNA extraction, and from the 
diluent used to standardise the samples, 6 of the 96 wells were used for these 
negative controls. It was decided to only use NCFB samples to maximise the 
opportunity for clinical correlates in this condition, whilst still enabling comparison 
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to RISA. There are suggestions from the literature that the microbial communities 
in several lung diseases can be relatively stable despite exacerbations and 
antimicrobial therapy.[324, 378] However for consistency we aimed to target 
samples obtained only in the stable state. We had samples from 85 
bronchiectasis patients which met this requirement. A further 5 samples were 
submitted which were taken from a non-stable state. This was to utilise space on 
the sequencing run and provide added data for the comparison with RISA. For a 
proportion of samples, insufficient DNA was measurable during the sequencing 
process to allow confidence in a consistent process across all samples. 
Consequently these samples were excluded from final analysis. These samples 
had more overlap with the communities seen in the negative controls and this 
added to our justification for omitting these samples. Comparisons were made of 
the patient demographics in the subgroup of 68 patients undergoing 16S rRNA 
sequencing analysis, and the 99 patient who underwent RISA interrogation. No 
significant differences were found, providing confidence that our subgroup was 
an accurate representation of our overall NCFB cohort.  
In previous microbiota analysis, the taxonomic identification is often expressed in 
OTUs. This is based on similarity of sequence and equates roughly to genus level 
identification. The DADA2 pipeline used herein offers the potential for species 
levels identification instead of OTUs as well as genera level identification, and 
can report ecological measures at a sequence or genera level.[341] In order to 
calculate ecological markers, it had to be decided what level of identification we 
would work at. Comparisons were made between the measures calculated at 
genera and sequence level identification. These showed very close correlation, 
and hence we concluded them to be good surrogates of each other. Whilst 
species-level identification was possible for some samples, in other samples the 
genera was reported with multiple possibilities at species level. Consequently it 
was not possible to perform useful ecological analysis at species level. Due to 
genera having recognisable names to work with, this was the measure chosen 
instead of sequence level.  
Of the 482 different genera identified, there were 3 genera which combined to 
make up over half the mean relative abundance - namely Streptococcus, 
Haemophilus and Pseudomonas. More strikingly, over 80% of samples had one 
of these three as the most abundant genus. These findings are not out of keeping 
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with other UK NCFB cohorts. Data from a tertiary centre in London had these 
three as the most abundant genera, and Belfast data highlighted them as being 
the dominant bacteria in samples from NCFB patients.[319, 324] Work from the 
North East of England identified three main families within their NCFB cohort- 
Pseudomonadaceae (majority likely to be PA), Pasteurellaceae (majority likely to 
be HI), and Streptococcaceae.[271]. This does highlight that despite the inherent 
bias of traditional culture, the same common potential pathogens are suggested 
by both techniques. The results do however appear quite different from a recently 
published group described by Byun et al.[383]. The most striking difference is 
their significantly lower abundance of Streptococcus. There is also a noticeably 
larger abundance of Haemophilus, Pseudomonas, Moraxella and Prevotella, and 
less Neisseria, Rothia and Veillonella. When considering these differences it is 
worth noting that samples were obtained by bronchoscopy, there was an 
exacerbation and stable group, and only 14 patient were included. The patients 
were also from South Korea and consequently conceivably surrounded by 
different bacterial communities and treatment strategies. In addition, a different 
DNA extraction kit was used to those used in the UK, and it is conceivable 
different extraction processes may have yielded different results.  
An observation from our data when considering the three main genera is the 
variable abundance. This is neatly illustrated by the median abundance for 
Haemophilus and particularly Pseudomonas being so much lower than the mean 
values. This is driven by the large dominance that these genera display in some 
patients. This feeds into the hypothesis that these bacteria are “aggressors” that 
dominate the microbial community in the lung at the exclusion of others. It would 
also be consistent with the concept of HI and PA being significant pathogens in 
this disease process. No positive correlations were found between Haemophilus 
or Pseudomonas and other genera, whilst there was a positive correlation 
between the abundance of Streptococcus and Rothia, and Veillonella. The 
concept of positive and negative relationships in the bacterial community is not 
new.[271, 321, 322] When we looked at the ecological markers of diversity, 
evenness and richness, significant differences were seen. These again illustrated 
the domination over a community that Haemophilus and Pseudomonas could 
have as opposed to Streptococcus. The comparison of culture-negative and 
culture-positive samples, revealed greater complexity in culture-negative 
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samples. This finding is likely to be interconnected with the samples dominated 
by Streptococcus being more complex and culture-negative samples often having 
Streptococcus as the prevalent genus. This data as a whole could point to a 
concept of Streptococcus as a community “stabiliser”, and its near absence in the 
South Korean cohort may explain the predominance of certain pathogens.  
A concern of culture techniques is their seeming inability to identify a pathogen 
when a patient appears to be suffering from symptoms which are believed to be 
of bacterial aetiology. It is consequently of interest to examine the correlation of 
culture-positive results to 16S rRNA sequencing data, and to assess what is 
present in culture-negative samples. Whilst the overall picture suggests that 
Pseudomonas and Haemophilus are deemed prevalent by both culture-
dependent and culture-independent methods, sequencing data from culture-
negative samples shows that PA and HI may not be isolated on plates even when 
sequencing data suggests otherwise. One sample was almost completely 
dominated by PA when the sequencing data was analysed to species level, and 
yet was culture-negative. Five samples were dominated by Haemophilus by 
sequencing and yet were culture-negative in the NHS laboratory. In one instance 
the sequencing data reported a relative abundance of 67% (of which at least 66% 
was HI) without a pathogen being found. Beyond these examples, the main 
finding in culture-negative samples was the general abundance of Streptococcus. 
In two-thirds of these samples, Streptococcus was the dominant genus. Other 
genera which dominated a small number of samples were Actinomyces, 
Neisseria and Enterococcus.   
In this cohort there were 9 different pathogens revealed by culture. Unremarkable 
findings were seen for samples positive for Burkholderia multivorans, 
Stenotrophomonas maltophilia, Serratia marcescens and Streptococcus 
pneumoniae. In these cases, relative abundances of the relevant genera ranged 
from 18.46% to 41.89%. For one pathogen, Klebsiella pneumoniae, no evidence 
of presence was found on sequencing data despite a positive culture. There are 
two plausible explanations here - either the culture result is a false-positive, or 
the culture-independent process has failed to either successfully extract the DNA 
from this organism, or to identify the DNA sequence. One pathogen which 
historically has been felt to be over-represented by culture or under-represented 
by 16S rRNA sequencing is SA. In one SA-positive sample, we found a relative 
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abundance of 74.71%. This is reassuring as it illustrates that our methods were 
able to successfully extract and sequence Staphylococcus. One sample which 
was positive for SA by culture revealed only 1% relative abundance by 16S rRNA 
sequencing. These results may suggest that laboratory culture techniques are 
very effective for isolating SA from sputum, even when it is present in low 
abundance. After Staphylococcus, Pseudomonas had the next lowest relative 
abundance despite a positive culture result with under 10% in one instance. At 
the other end of the scale, Pseudomonas and Haemophilus had examples of 
relative abundance over 99% in culture-positive samples. Moraxella catarrhalis 
is the other pathogen that was revealed by culture. It is notable that in the two 
samples which were positive for this pathogen, the relative abundance was above 
96% in both. Although based on only two samples, it suggests that Moraxella may 
be able to dominate a community like other more prevalent pathogens such as 
Haemophilus and Pseudomonas. Moraxella has shown capacity to reduce 
community diversity in other disease processes such as COPD.[378] 
When comparing the culture results to sequencing data, it is important to 
remember what the results actually mean. Culture results indicate whether or not 
a bacterial species which is considered a putative pathogen in a specific disease 
process, has been isolated and identified in a deliberately biased environment. 
Sequencing data, when reported as relative abundance, just reports the presence 
of DNA of that taxa as a percentage of the total bacterial DNA found. It does not 
identify either total amount (bacterial load) or actual viable bacteria. A degree of 
caution must therefore be applied. For instance, two samples may have a relative 
abundance of Haemophilus of 20% and one may be culture-positive for HI whilst 
the other does not isolate a pathogen. This may not represent inconsistency of 
the culture technique, as the culture-negative sample may have little viable HI 
(for example, due to a very recent course of antibiotics) and a low bacterial load. 
In chronic suppurative lung diseases such as NCFB and CF, issues with sputum 
clearance from diseased airways is a common problem. These patient are also 
commonly on prophylactic antibiotics, which may include inhaled antibiotics 
delivered directly to the bacterial communities. It could be hypothesized that in 
patients with significant disease burden (illustrated by poor airway clearance and 
high antimicrobial intake), the contribution of non-viable bacteria to the relative 
abundance could be high. As previously mentioned, attempts have been made 
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to just measure viable cells, however this is not common practice.[283] With 
regards to issues with the use of relative abundance, it is possible to perform 
quantitative PCR to give you a total abundance. Whilst this is likely to be more 
useful when comparing a sputum culture result to sequencing data from DNA 
extracted from the same samples, limitations remain. A sputum sample is only 
going to be a small component of what is present in the lung. Denser sputum may 
be harder to clear from the lung for sampling, and may contain a different bacterial 
load. Therefore even if qPCR were to be employed, it may not be a true 
representation of the total abundance of bacteria in the lung.   
A key interest with regards to the data arising from 16S rRNA sequencing is what 
its clinical relevance is, and what factors may influence the communities. As 
previously discussed in this thesis, the preceding work in this field has been partly 
inconsistent.[271, 319, 321, 323, 324] Also, whilst previous work has attempted 
to seek associations between bacterial communities and clinical severity, none 
previously had use of the BSI as a measure of disease severity. One of our aims 
was to take the opportunity to use the BSI alongside ecological measures of the 
bacterial communities. In light of the previous work in NCFB and other disease 
processes, the influence PA colonisation has on the BSI score, and also the 
impact Pseudomonas seems to have on community complexity, it may have been 
expected that an association would be seen between disease severity (as 
quantified by the BSI) and the community measures. However, this was not the 
case. Similarly, community measures did not correlate with FEV1, which has 
previously been used as a surrogate for disease severity. This was out of keeping 
with some but not all previous work.[319, 321] 
Exacerbations are events that patients are acutely aware of, and the 
understanding of them and subsequent management is very important for 
patients.[37] In this subgroup, there appeared to be an association between 
patient-reported exacerbations and reduced diversity and evenness. There was 
a significant outlier with regards to patient-reported exacerbations. If this patient 
was removed then the association with evenness only remained and when 
grouping patient by exacerbations frequency (low, medium and high), no 
association was seen. This differed from our RISA analysis. This may in part be 
due to smaller numbers, but also that the greater sensitivity of16S rRNA 
sequencing data may result in measures being affected by irrelevant 
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contributions. It should also be noted that exacerbation frequency was based on 
the patient’s recall and consequently potentially subject to bias, inaccuracy, or 
variability due to local prescribing. In addition, there are likely to be several 
different types of exacerbation phenotype and severity in bronchiectasis, and the 
community complexity may play a role. A recent COPD study suggested 
dysbiosis was associated with worse exacerbation severity and also with an 
eosinophilic process.[378] Other associations noted were a positive correlation 
between Streptococcus genus and age, a negative correlation between 
Staphylococcus and age, and a positive correlation between Pseudomonas 
abundance and BSI. 
It is worth pausing to consider the significance of these findings. Whilst early work 
suggested a link between disease severity and communities, this has not been a 
consistent finding.[271, 319, 321, 323, 324] An appealing hypothesis is that a 
community dominated by a pathogen (and with a low diversity, evenness and 
richness) will be a pathology-causing entity leading to disease progression.[322, 
384, 385] This could lead to the formulation of strategies aimed at altering 
communities in the lung to prevent disease progression. The success of faecal 
transplant in the bowel gives a precedent for potential benefit when the bacteria 
community is altered. Alternatively, a community of low complexity may appear 
in severe disease due to the toll of disease, recurrent therapies and time. 
However, this is not what we have found. The lack of correlation with markers of 
community complexity and the BSI is possibly surprising for many reasons. The 
BSI includes additional points for colonisation with PA, and unsurprisingly we 
observed a correlation between Pseudomonas abundance and BSI. We have 
seen less complex communities in those that are dominated by Pseudomonas 
compared to those dominated by Streptococcus. Haemophilus dominance was 
also associated with reduced community complexity, and Haemophilus 
abundance was also associated with exacerbation frequency (which is also a 
parameter that contributes to the BSI). Taking all this into account, an association 
may have been expected. However, a counterbalance to these factors is the 
contribution that greater age makes to the BSI. Interestingly, there was a positive 
correlation between age and Streptococcus abundance. There appears to be 
greater complexity in the Streptococcus samples and consequently, this may be 
having an impact on this interpretation. As discussed in Chapter 6, the 
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investigation of an unselected District General disease-specific cohort may be 
subject to certain quirks. For example, younger patients who are actually seen by 
the bronchiectasis service may have more aggressive disease which has led to 
them being referred at a younger age. Also, by performing a cross-sectional 
study, patients may be at different stages of the establishment of their 
maintenance therapy. For example some may have only been recently referred 
and may not have established airway clearance techniques, undergone 
pulmonary rehabilitation, become established on prophylactic therapy, 
undergone a full eradication course for PA, etc.   
The observation of reduced complexity being associated with exacerbations 
allows for the continuation of the concept of dysbiosis causing susceptibility to 
these episodes. It could be the case that whilst the impact of exacerbations may 
have an impact on disease state, it may be over many years, and consequently 
a cross-sectional study may not bear out this impact. It may also be that the size 
of this study, and others, has not been large enough for significant associations 
to be clearly identified. It was interesting to note that Haemophilus was the only 
genus whose abundance was associated with exacerbation frequency. 
Traditionally, PA has been seen as the principle pathogen in this disease process. 
As mentioned elsewhere in this thesis, it is plausible that due to the attention 
given to PA, we may be better at treating patients with this pathogen. Outcomes 
may therefore be better, despite those patients harbouring a potentially more 
pathogenic organism.  
When considering the importance of the polymicrobial community and NCFB, it 
should also be considered that the reason that there has not been a consistent 
finding of reduced community complexity and disease severity is that it does not 
exist. It may well be that the balance and structure of the community is not as 
significant as other considerations such as the behavioural capacity of the genes 
present. For example, the switching on of virulence factors may be more 
important than the evenness of a community and could explain why large 
changes in communities might not be seen during exacerbation.  
Another reason for performing 16S rRNA sequencing on these samples was to 
allow comparison to our RISA data. The cluster analysis of RISA band patterns 
had created groups of which the characteristics had been speculated. These 
included lower complexity samples, high abundance of Haemophilus, and high 
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abundance of Streptococcus. These findings have been supported by our 16S 
rRNA sequencing data. However, it should be noted that the dominant 
characteristic of a sample did not ensure clustering to a specific group. For 
example, not all samples dominated by Streptococcus were in the same group. 
In Chapter 6 we also used RISA data to estimate our ecological measures. We 
compared these estimates to those recorded by 16S rRNA sequencing. For all 
three measures, positive correlations were seen, however the association was 
noticeably stronger for evenness and diversity than for richness. The lower 
concordance of richness is less of a concern as this is the least sophisticated of 
the measures, and probably least likely to be clinically relevant. 
Potentially of more use practically is the ability of RISA to identify samples as 
either low or high diversity, evenness or richness. It is debatable what the criteria 
for “low” or “high” should be. However the correlation seen between RISA and 
16S rRNA sequencing suggests that with larger data sets, useful parameters 
could be obtained. We hypothesised that as RISA is believed to be a less 
sensitive technique, that concordance may be better when discarding genera with 
less than 1% relative abundance from the 16S rRNA sequencing data. There was 
a suggestion from our results that this may be the case with diversity and richness 
but not evenness.  
With 16S rRNA sequencing considered the gold-standard, our findings provide 
encouragement for the output from RISA. Whilst it does not provide a perfect 
correlation of ecological measures and does not allow for confident taxonomic 
identification, it clearly provides a meaningful measure of the community. A 
similar message also appeared between the two techniques - namely a 
suggestion of less exacerbations with more complex samples. There have been 
other studies comparing RISA and sequencing data, both in the environment and 
the lung.[133, 287] As evidence and use increases, RISA may develop utility in 
clinical practice. 
There are various strengths and weaknesses of this work to comment on. This 
work has provided taxonomic identification and ecological measures of the 
communities found in an unselected bronchiectasis cohort. This has been done 
with highly detailed clinical correlates and hence adds to our understanding of 
the bacteria present in patients with bronchiectasis. The gold-standard technique 
has been used for this process, allowing comparison with RISA - an older 
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technique that has not been extensively used for interrogation of clinical samples. 
It has also used a pipeline not previously reported in lung studies, and this has 
allowed some greater identification to species level.  
However, it should be noted that the gold-standard process is not perfect. Whilst 
we were able to process all the RISA samples, we were not confident enough 
with the consistency of some of our samples to report all of them by 16S rRNA 
sequencing. In addition there is the potential issue of contamination. As 
mentioned multiple times in this thesis, the molecular techniques I have used deal 
with DNA and not necessarily the DNA of viable bacteria. An environment may 
be sterile as the bacteria have been killed as part of a rigorous sterilising process, 
but this does not mean that the DNA of the dead bacteria may not be amplifiable 
and therefore detectable. There are multiple possible sources for this, including 
the DNA extraction kits.[282] To ensure rigor, I extracted DNA from negative 
controls from each of the 5 batches of DNA extraction kit used. These were 
sequenced, as was the DES used to dilute samples. This revealed that bacterial 
DNA was indeed detectable within these negative controls. This is an undeniable 
limitation, and is likely to be more of an issue with low biomass samples. Whilst 
a database of likely local contaminants and kit-specific contaminants can be 
collated, the fact that common contaminants such as Ralstonia have also been 
cultured from sputum in certain circumstances can provide uncertainty.[386] This 
highlights the potential importance of culture and how culture-dependent and 
culture-independent methods may complement each other. If a sample isolates 
a given species by culture that is also detectable by molecular analyses, then this 
is almost certainly accurate. A further issue is the reporting of relative abundance. 
It may be that bacterial load is more important than relative abundance. Whilst it 
is possible to do qPCR to give a better idea of this, you are still only getting a 
surrogate of the overall lung. It is very likely that the bacterial load in one sputum 
sample will be different to another. For example, the first cough of the day in a 
bronchiectasis patient may be very different to one later in the day. Hydration 
state may also influence the amount coughed up, as may the inhalation of 
therapies into the lung such as antibiotics or hypertonic saline. Also, sputum 
originating from one area of the lung may have a different biomass than another 
geographical region. Furthermore, our current use of antibiotic therapy does not 
take into account bacterial load as such, but merely the likely (or identified) 
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pathogen. Consequently, trying to measure total abundance rather than relative 
abundance, is not without significant limitations as well.  
A further issue with 16S rRNA sequencing is the time and cost of the process. 
Whilst costs are undeniably falling, the process requires an intricate multi-step 
process likely to include multiple professionals. This may well not be feasible in 
day-to-day clinical practice.  
It is worth commenting on the bronchiectasis cohort studied and the collection of 
data from them. The patients were recruited from routine clinical practice. They 
clearly needed to be able to produce a sputum sample. They are therefore 
representative of the patient from whom we use microbiological testing to drive 
management. Demographically they are also in keeping with other studied 
cohorts. As a cohort they are likely to be sicker than total population that have 
bronchiectasis and the likelihood of being recruited would be based on the need 
for healthcare interaction during the recruitment period. Overall, we can be 
confident that they are representative of those we treat in day-to-day practice. 
With regards to their clinical details, we can have high confidence of the accuracy 
of nearly all the data collected. The exacerbation rate however is possibly the 
measurement with the lowest accuracy. In this study it was based on patient 
reported exacerbation rate. This is obviously at risk of recall bias. There is also 
the issue of what actually constitutes an exacerbation. We considered the use of 
acute antibiotics for a change in respiratory symptoms to constitute an 
exacerbation. However, the threshold for antibiotic prescribing will vary from 
clinician to clinician. The only way around this is for a prospective study with 
protocol-defined exacerbations being recorded. This was not possible for this 
study design.  
When assessing the outcomes of the chapter, it is clear that the bacterial 
communities of bronchiectasis patients are highly variable. It is also clear that 
culture can reveal the likely major pathogens, though they can be present in high 
relative abundance and yet not be isolated by culture. It seems likely that a single 
culture-negative sample cannot be taken as conclusive evidence that a previous 
pathogen is now eradicated. In a world where culture-independent techniques 
have not found their niche in everyday healthcare, culture still has an important 
place though. It remains unclear the exact significance of the bacterial community 
to the disease process, and mechanistic and prospective work is likely to be 
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required to answer this. It is also plausible that true understanding will be far more 
complex and require the additional understanding of the interactions of the 
bacterial community with: viruses and fungi; the host immune system; and the 
behaviour of the bacteria as displayed by virulence factors and resistance 
mechanisms. An understanding of such a complex environment currently seems 
a way off in the research world and consequently even further away in a resource-
stretched healthcare setting such as the NHS.  
This brings us along to the potential role and significance for RISA. In this chapter 
we have shown, that whilst not perfect, it provides reasonable correlation with 
16S rRNA sequencing for ecological characteristics. By providing this at a fraction 
of the cost, complexity and time, RISA potentially represents a clinically-useful 
technique. Clearly for this to be the case, an appreciation of what it means for 
management is key. This will only be revealed by its prospective use in clinical 
trials. RISA is clearly more feasible than 16S rRNA sequencing to be used in a 
very large clinical trial of a therapy- for example prophylactic antibiotics, to identify 
subgroups who may respond to a therapy.  
As our understanding of the microbiome and relevant techniques evolve, it may 
be the case that we see a hierarchy of investigations depending on the clinical 
situation. It is likely that culture will retain its place as a first line investigation and 
provide evidence of a viable pathogen. In clinical circumstances where an 
isolated bacteria is believed to be the important pathogen in a process, further 
techniques (including culture-independent techniques) may then be used to look 
at virulence factors, resistance genes etc. This is already being used in the 
management of TB with sequencing for rifampicin resistance.[268] An overview 
of the bacterial community may be relevant for more chronic management, such 
as prophylactic antibiotics or consideration of pathogen eradication regimes. This 
potentially could include RISA. In circumstances where culture has not revealed 
a significant pathogen, 16S rRNA sequencing may come into its own by also 
providing taxonomic identification alongside community characteristics. 
Metagenomics and metabolomics may be further levels of investigation in the 
future, however these may remain prohibitive from day-to-day clinical care for 
longer. These may eventually be reserved as an investigation for when patients 
are not responding to standard therapy as prescribed on the basis of clinical 
history, examination, and simpler microbiological tests. 
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7.6 Conclusion 
In summary we have demonstrated complex bacterial communities in the 
bronchiectatic lung. The predominant genera are not out of keeping with 
traditional culture results, though high abundance of a particular genus does not 
always translate to culture-positive samples. Whilst we have not found an 
association between community characteristics and the BSI or FEV1, there 
appears to be an association between exacerbation frequency and less complex 
communities. Finally, RISA has been shown to provide an appreciation of 
potentially relevant ecological markers, and may therefore have a role in the 
investigation and management of chronic respiratory disease.  
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Chapter 8- Summary and Discussion 
In the thesis, I have used both culture-dependent and culture-independent 
techniques to investigate PA and the wider bacterial community within the 
bronchiectatic lung. This has been performed prospectively with the use of 
samples submitted by patients with NCFB and CF as part of their ongoing care 
at the Royal Devon & Exeter Hospital. In this final, Chapter I shall describe how I 
have addressed the aims which were set out in Chapter 1 of this thesis, highlight 
novel and important findings, and discuss potential areas for future research, 
before a final conclusion. 
8.1 To Perform an Epidemiological Review of PA in NCFB Utilising a 
Variety of Genotyping Techniques to Investigate the Likelihood of Cross-
infection With PA 
As illustrated throughout this thesis, PA is both a common and highly important 
pathogen in NCFB.[40, 43, 44, 48, 107, 108, 110, 111, 113-115] Despite its status 
in NCFB, there is little known about the epidemiology of PA in this condition.[131, 
210, 211] This is in contrast to CF where epidemiological studies of PA led to 
concerns of cross-infection with clinically significant strains.[185-188, 192, 194-
199, 232] Cross-infection is taken very seriously in the CF community and this 
data has in part led to the widespread practice of segregation of patients.[95, 179] 
The risk of cross-infection with PA is unknown in NCFB, though there is some 
evidence suggesting occurrence.[131, 211] 
In Chapter 3, I described the largest single-centre epidemiological review of PA 
in a NCFB cohort. This has been robustly performed due to a few key aspects of 
study design. Importantly 10 representative isolates per sample were used. This 
was done to reduce the risk of underestimating multiple strains within a sample. 
Previous work in CF and NCFB has illustrated the potential for multiple strains of 
a pathogen to be present within a single sample.[211, 261] The study was 
performed via the use of three genotyping techniques. These techniques included 
a rapid screening technique (RAPD), the highly portable MLST, and the higher 
resolution analysis of WGS. From the WGS data, in silico prediction of 
hypermutator status was performed to aid interpretation of differences between 
isolates. Interpretation of WGS data was also aided by the incorporation of 
publicly-available genomes into our analysis. In addition, to provide greater 
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context to the findings of the study, epidemiological analysis was also performed 
on both the local CF cohort and also on non-respiratory clinical samples. These 
are not aspects of any previous epidemiological study of PA in either CF or NCFB.   
Due to its portability, MLST is the easiest method to describe the PA strains found 
in our NCFB cohort. Via MLST, 35 different sequence types were revealed and 5 
were shared between patients. The most abundant strain was ST17, which is 
better known as Clone C. Clone C is a globally abundant strain which has been 
found in clinical and environmental sources over a prolonged period of time.[214, 
217, 218, 220-223] It was also found in our non-respiratory samples and it should 
not be seen as surprising that it was prevalent in a NCFB cohort. Further 
investigation was performed on this strain with the interrogation of three isolates 
per NCFB patient by WGS. The demonstration of greater between-patient 
diversity than within-patient diversity, alongside the comparisons with 
unconnected publicly-available genomes and the background abundance, 
provided confidence that cross-infection was unlikely to have occurred with Clone 
C. 
The epidemiological review revealed evidence of highly likely cross-infection with 
ST564, with three patients harbouring isolates that were genetically very similar. 
This is the most robust published data which suggests cross-infection in 
NCFB.[355] ST564 is a rarely reported strain and based on our clinical 
attendance records, may have super-infected a patient. Due to its small numbers, 
we are currently unable to comment on the clinical significance of this strain. It 
will be important to repeat this study in the future to see if we see evidence of 
increasing prevalence in the cohort, and if in large enough numbers, any 
suggestion of clinical impact. It is possible that there are other cases of cross-
infection within this cohort, however we do not have sufficient evidence to state 
this. One factor that may well contribute to the uncertainty is that of hypermutable 
isolates. Unlike previous work, we have looked to address this issue, and have 
shown greater genetic diversity when predicted hypermutators are involved in 
pair-wise comparison. One of our other concerns was the potential for cross-
infection between CF and NCFB patients. While these cohorts are seen in out-
patients at separate times, they do use the same facilities and they do share 
healthcare professional such as physiotherapists, specialist nurses and doctors. 
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Pleasingly, there was no evidence of cross-infection between these cohorts or 
within the CF cohort, with the exception of two family members. 
This chapter has achieved the aim of performing an epidemiological review of PA 
and is the largest of its kind in NCFB. It has provided the most robust evidence 
yet of cross-infection within a NCFB cohort, albeit rare. It has also highlighted the 
difficulties of performing a cross-infection study in a chronic disease cohort, even 
with the use of WGS. A principle issue is the interpretation of the genetic diversity 
between samples as seen in WGS. Despite this high level of robustness, cross-
infection can only be considered as a likelihood and longitudinal data is required 
to further our understanding of the risk in this cohort. 
8.2 To Gain Insight into the Prevalence of Hypermutable PA in NCFB and 
its Impact on WGS-based Studies Addressing Cross-infection 
As highlighted above, WGS data in an epidemiological study can reveal wide-
ranging levels of genetic difference. There are many reasons why two isolates 
may display a certain level of difference and one of these is hypermutation. 
Hypermutators are found in chronic lung disease and can indeed be 
common.[159, 161] In our epidemiological review we performed a previously 
undescribed in silico prediction of hypermutator status. We also performed a 
traditional hypermutator assay to ensure the reliability of this in silico prediction. 
As part of the epidemiological review performed in Chapter 3, isolates from 31 
patients underwent WGS. Of these, 22 were from NCFB patients and 9 from CF 
patients. By the in silico prediction 8 NCFB patients were predicted to have 
hypermutable PA and 1 CF isolate was predicted to be a hypermutator. This 
highlighted that hypermutable PA is not uncommon in NCFB. We also showed in 
Chapter 3 that those that were predicted to be hypermutators had significantly 
greater genetic difference when compared to other examples of the same strain. 
In addition, the results of the traditional hypermutator assay revealed a high 
frequency of the hypermutator phenotype amongst those isolates that were 
predicted to be hypermutators by the in silico approach, providing further 
confidence in this prediction model. Consequently, this prediction model appears 
to be highly relevant to the assessment of WGS output in the context of a cross-
infection study. 
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We have clearly shown that hypermutators are not uncommon in PA found in 
NCFB patients. We have also demonstrated that in silico prediction of 
hypermutators from WGS data aids interpretation of results by facilitating the SNP 
differences to be put into relevant context and promoting the rational 
consideration of the likelihood of cross-infection. This common phenotype must 
now be taken into account in future cross-infection studies into chronic respiratory 
disease using WGS. Our testing of the model against the traditional technique 
has supported its use, however an interrogation of a larger collection of 
sequenced isolates may enable the refining of this model. 
8.3 To Test the Utility of a Novel Culture-independent Genotyping 
Technique for PA 
In recent times, the advances of molecular microbiology have resulted in the 
development of culture-independent techniques. These have revealed how 
traditional culture does not tell the full story and how samples may not grow 
certain pathogens even when culture-independent techniques reveal the 
presence of their DNA.[281] Consequently, when performing prospective cross-
infection studies on samples, shared strains may potentially be missed if they do 
not grow on a plate. It is also recognised that not all pathogens will grow at the 
same rate on a plate, and that multiple strains can occur in a sample.[211, 261] 
When picking isolates off a plate, there may well be a bias towards those that are 
faster growing rather than the most important or abundant. With the increasing 
use of culture-independent techniques in research, DNA is increasingly extracted 
from sputum samples. Considering these factors, we have looked to see if it was 
possible to perform MLST on DNA extracted from sputum for PA, and if so, how 
it compared to the traditional method. 
The results described in Chapter 5 show that it is indeed possible to perform 
MLST without the need for culturing the bacteria. We showed that genotyping 
data could be obtained from culture-negative samples, however there was the 
occasional example of not being able to obtain genotyping data despite a sample 
being culture-positive. By the culture-independent technique we found evidence 
of transmissible strains which were not revealed by the culture-dependent 
method. Whilst in our cohort this does not seem to have masked likely cross-
infection, this does highlight the possibility of it being missed.  
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A potential concern with this technique is that the presence of multiple strains in 
a single sample may yield ambiguous sequence reads. This does not seem to be 
a common problem as there was very high concordance between the culture-
dependent and culture-independent approaches. However, when artificially 
mixing DNA from different pure cultures in different ratios, outputs could be 
generated suggesting the presence of an MLST allele sequence which was not 
there. This limitation has to be acknowledged if using this technique and 
consequently we would recommend not using this as the only genotyping 
technique in a comprehensive epidemiological review. Despite this limitation, this 
technique could have a very useful role, either alongside a culture-dependent 
process or as a screening tool. As previously mentioned, longitudinal data in 
cross-infection studies is highly desirable, though often not performed. It is also 
unclear at what interval this should be done. By performing screening in a few 
loci in a cohort, a quick appreciation of changing epidemiology or the increasing 
presence of a particularly strain may be revealed, subsequently guiding the timing 
for an in-depth epidemiological review.    
This study has achieved the aim of testing the utility of a culture-independent 
genotyping technique with the novel use of the MLST scheme for PA on sputum 
samples. As well as demonstrating the feasibility of this, we have also shown the 
potential benefits and suggested a place in clinical practice.  
8.4 To Investigate the Relationship Between Disease Severity and the 
Bacterial Community Composition in NCFB 
Our current understanding and management of NCFB has been based around 
the use of traditional culture methods. Via these techniques, a single pathogen is 
often reported. Data accumulated with the use of these processes has led to our 
view of PA as the most important pathogen in NCFB.[110] The development of 
culture-independent techniques has shown that these techniques do not reveal 
the significant complexity contained within the lung.  
In Chapters 6 and 7 we looked into the communities in the bronchiectatic lung 
with the aim of investigating the relationship between community composition and 
disease severity. This was performed by two techniques- RISA and 16S rRNA 
sequencing. We are not aware of any previous work examining bacterial 
communities in NCFB by RISA, and via this technique we also examined our local 
CF community. Interestingly, the NCFB communities appeared less complex. 
210 
 
This is a novel finding, and unexpected. There has previously been an 
appreciation of PA dominating communities in both conditions, and as a result 
decreasing diversity and evenness. In CF the other main pathogen is SA, while 
in NCFB it is HI. Samples which were culture-positive for HI seemed to have lower 
complexity than those positive for SA. Consequently, in NCFB, both the main 
pathogens appear to have a large impact on community complexity, and hence 
may explain the lower overall complexity.   
Previous work, both into NCFB and in other diseases, suggested that less 
complex communities may be associated with more severe disease.[133, 321] 
To our knowledge, we have undertaken the first study of whether the composition 
of these communities correlates with the BSI - a validated severity index for 
NCFB. Whilst we expected a relationship between the BSI and the communities, 
this was not found by either RISA or 16S rRNA sequencing. This could be for 
multiple reasons, including the possibility that there is not a link between disease 
severity and community complexity. Alternatively, it could be due to certain quirks 
of the index, and from collecting samples from an unselected cohort. Whilst there 
was no correlation with the BSI, we did observe associations between the 
communities and the clinical status of the patient. There was an inverse 
relationship between exacerbation frequency and complexity by both techniques, 
whilst RISA also showed a positive correlation between community richness and 
lung function.  
Due to these findings, it remains plausible that there is a relationship between the 
complexity of the bacterial community and the clinical condition of the patient, 
even if this is not borne out by comparisons with the BSI. It is important to note 
that even if there is a relationship, this does not mean that a low complex 
community is necessarily more pathogenic, or makes patients more susceptible 
to exacerbations. Even if this is the case, it is likely to just be a component. Other 
components may include the viral and fungal communities, the collection of 
resistance genes in the community, and the specific strains of bacteria and their 
pathogenicity. This does not however mean that the community complexity may 
not be very important. In many disease processes, successful management 
includes targeting various components, and NCFB is likely to be no different.  
When considering the pathogens dominating the community and disease 
severity, it was interesting to note the comparisons between HI and PA. By RISA, 
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samples which were positive for HI had less complexity, and by 16S rRNA 
sequencing there was a trend for samples where Haemophilus was the most 
prevalent genera to be less complex. Also of note there was an association 
between Haemophilus and exacerbations. This raises the possibility in our 
cohort, that HI may have the potential to dominate communities more than PA, 
and be associated with more exacerbations.  
In these chapters we have achieved our aim of investigating relationships 
between bacterial communities and disease severity. The issue is not clear cut, 
and this may be due to there being far more to it than mere community structure. 
However, there is enough to suggest that it remains an approach of potential 
interest when considering our investigation and management of a patient with 
NCFB. 
8.5 To Test the Clinical Utility of RISA as a Cheaper and Quicker 
Alternative to 16S rRNA Sequencing 
A novel approach in the thesis has been to use RISA to investigate the wider 
bacterial community in the bronchiectatic lung. In Chapter 6 we used it to 
investigate both our NCFB and CF cohorts. In the following chapter we compared 
its output to the gold-standard technique of 16S rRNA sequencing in our NCFB 
cohort. As we now appreciate some of the limitations of traditional culture 
techniques, there is an obvious appeal to try and bring culture-independent 
techniques into everyday clinical practice. However, various considerations need 
to be made beyond what is simply the “best” test. Ideally a test will provide a 
clinician with a rapid and easily interpretable result with relevance to the treatment 
decisions. In a resource-limited environment like the NHS, the cost of the test will 
also be a consideration. While sequencing costs are falling and technologies 
evolving, the technique of 16S rRNA sequencing still comes at a significant cost 
in terms of finance, time and complexity. Consequently an alternative which could 
be incorporated into everyday clinical care would be appealing. 
With this in mind, we have used RISA alongside 16S rRNA sequencing. It has 
been a cheaper, quicker and easier technique to perform. It has also required 
less external expertise to perform and produces outputs from. Furthermore, it has 
shown consistency with the gold-standard technique with regards to various 
measures, but also in showing trends with regards to relevant data. 
Consequently, it retains appeal as a potential tool. However, it has two clear 
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limitations - one shared with 16S rRNA sequencing (the current lack of 
understanding of the clinical relevance of the output), and the other not (a lack of 
capacity for pathogen identification).  
As with 16S rRNA sequencing, at present we do not know how data derived from 
RISA can impact clinical decision-making. For this to change, we need 
prospective longitudinal clinical trials. These could give us insight into how a 
certain intervention in the face of different community characteristics can 
influence clinical outcome. These trials will clearly be difficult and expensive to 
run. RISA would both reduce the cost of the trial, but also allow subsequent 
integration into cash-strapped clinical settings to aid decision-making, in a way 
that 16S rRNA sequencing would not.  
The clear difference between 16S rRNA sequencing and RISA is that RISA does 
not provide pathogen identification. This is an obvious limitation, however this 
does not need to be insurmountable when considering a place for RISA in clinical 
practice. There are putative band lengths which have been calculated and 
consequently candidate pathogens can be listed. For example, we were able to 
correctly predict the strong presence of Streptococcus in samples. In many 
cases, the use of concurrent culture techniques may provide evidence of a viable 
pathogen. If not, the extracted DNA could be used either for pathogen-specific 
PCR or (in cases of ongoing uncertainty) 16S rRNA sequencing.  
In this thesis we have started to explore the utility of RISA and have demonstrated 
potential for its use in the clinical setting. It is conceivable that in the future, 
clinicians may have a variety of tests available to them of varying complexities 
and costs. For different clinical questions and problems, different tests may be 
appropriate, and RISA may sit within this suite. 
8.6 Areas for Future Research 
There is clearly scope for further research to be performed around the areas 
covered in this thesis. Recently the topic of cross-infection has gained attention 
in the NCFB community.[131, 211, 354, 355] At present there is no high quality 
longitudinal data and there is no evidence beyond PA. Consequently there is 
significant scope for future research into this area, and given the prominence we 
have displayed of Haemophilus and Streptococcus, these are logical targets for 
investigation. 
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Future studies into cross-infection are likely to include sequencing techniques. It 
is consequently critical to gain a better understanding of what constitutes a 
significant genetic difference between samples. While this is far more straight-
forward in real-time outbreaks, this is very challenging in complex bacterial 
communities which have evolved over time. In this thesis we have attempted to 
gain an understanding of the impact of hypermutable strains on the genetic 
difference seen between samples by using an in silico prediction model. As more 
WGS data is generated from isolates, a better insight into the impact of certain 
mutations will be gained. In addition, longitudinal studies will give a greater 
understanding of the persistence or switching to a hypermutable state. Additional 
research will also aid a better understanding of the typical range of genetic 
divergence within a sputum sample. With these aspects better studied, greater 
context can be given to the differences seen between isolates.  
Large scale cross-infections studies are time-consuming and costly. It is also 
unclear at what interval to perform them. There is consequently an appeal in 
performing a simpler screening test to give an indication of when to perform the 
follow-up study. We have shown the potential of MLST applied directly to DNA 
extracted from sputum. This has now been shown to be possible for both PA and 
BCC.[370] It would be expected that this would be possible for other important 
pathogens. Consequently, future research should look into the utility of rapid 
screening for evidence of putative transmissible strains in a variety of pathogens 
before embarking on large prospective studies. 
It is very likely that there will be a large amount of culture-independent research 
into the lung microbiome. It would probably be most useful for this to be directed 
in two very different directions. There is the need for high quality studies with 
sophisticated techniques to further our understanding of the micro-organisms in 
the lung. However, there will come a time when culture-independent techniques 
will have to be integrated into clinical trials in a format which will be permissible 
to everyday clinical care. Without this, it is very difficult to see how the 
management of patients can move forward. A possible future research project 
would involve the use of RISA in a clinical trial involving an intervention and 
assess if its outputs can help personalised management.  
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8.7 Conclusion 
In this thesis with have used molecular techniques to provide better insight into 
PA and the wider bacterial community within the bronchiectatic lung. We have 
found evidence of cross-infection in NCFB cohorts through an in-depth 
epidemiological study involving multiple genotyping techniques and with 
comparison to both CF and non-respiratory isolates. We have proposed an in 
silico prediction model for hypermutators to better assess WGS data and we have 
demonstrated a potential screening test for cross-infection in a cohort. For the 
wider bacterial community we have observed characteristics associated with 
clinically important markers and performed an alternative community assessment 
to the usual 16S rRNA sequencing approach. It is to be expected that culture-
independent techniques will become increasing important, and the challenge now 
is how best to start utilising them for patient benefit.  
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Appendices 
 PA 
Colonised 
(n=20) 
HI 
Colonised 
(n=17) 
Colonised 
by Other 
(n=4) 
Not 
Colonised 
(n=58) 
P Value 
PA v HI  
Agea 66.3 
(11.43) 
60.82 
(16.82) 
69 
(10.77) 
66.31 
(13.38) 
0.2621 
BSIa 10.6 
(3.38) 
7.53 
(3.13) 
7.5 
(2.18) 
6.16 
(3) 
0.0154 
FEV1 
%predicteda 
62.65 
(22.03) 
59.88 
(21.1) 
83.25 
(26.45) 
72.78 
(21.61) 
0.7080 
Exacerbator 
Phenotypeb,c 
- high 
- medium 
- low 
 
 
20% 
55% 
25% 
 
 
41.18% 
47.06% 
11.76% 
 
 
100% 
0 
0 
 
 
41.38% 
27.59% 
31.03% 
0.3089d 
Oral 
antibiotic 
prophylaxisb 
55% 35.29% 25% 37.93% 0.3248 
Inhaled 
antibiotic 
prophylaxisb 
40% 0 50% 15.52% 0.0039 
 
Received IV 
antibiotics in 
last 12 
monthsb 
30% 5.88% 0 6.9 0.0975 
 
Table A6.1 Clinical measures for different baseline colonisation status- 
NCFB Data is presented with mean values with standard deviations or 
percentage of cohort. Statistical testing was by at-test, or bChi- squared test. 
cExacerbator phenotype was described as “High”- greater than 3 exacarbations 
in preceding 12 months; “Medium”- 2 or 3 exacerbations in preceding 12 
months; “Low”- 0 or 1 exacerbations in preceding 12 months. dChi-squared test 
from 3x2 contingency table. 
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  P Value R2 
Age 
- e-Diversity 
- e-Evenness 
- e-Richness 
 
0.0402 
0.0243 
0.2064 
 
0.04269 
0.05119 
0.01641 
BSI 
- e-Diversity 
- e-Evenness 
- e-Richness 
 
0.8741 
0.1312 
0.9334 
 
0.0002603 
0.02333 
7.246e-005 
FEV1 %predicted 
- e-Diversity 
- e-Evenness 
- e-Richness 
 
0.0929 
0.4233 
0.0390 
 
0.02884 
0.006622 
0.04321 
Exacerbations 
- e-Diversity 
- e-Evenness 
- e-Richness 
 
0.0373 
0.0538 
0.0989 
 
0.04396 
0.03781 
0.02782 
   
BMI 
- e-Diversity 
- e-Evenness 
- e-Richness 
 
0.6603 
0.5562 
0.6618 
 
0.002 
0.003582 
0.001981 
Table A6.2 Comparison of ecological measures and continuous data by 
linear regression for the NCFB cohort  
 
 
 PA HI Others P Value 
e-Diversity 1.68 1.13 1.44 0.1645 
e-Evenness 0.86 0.66 0.86 0.0064 
e-Richness 6.32 5.68 5.5 0.4357 
Table A6.3 Comparison of ecological measures and culture results in 
NCFB cohort Statistical analysis was performed by Krusal-Wallis test for e-
Diversity and e-Evenness and by ANOVA for e-Richness. 
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 Culture-positive Culture-negative P Value 
e-Diversity 1.41 1.48 0.5120 
e-Evenness 0.81 0.86 0.0262 
e-Richness 5.63 5.67 0.9269 
Table A6.4 Comparison of ecological measures in NCFB cohort and 
whether sample is culture-positive or negative. P value generated by Mann-
Whitney for e-Diversity and e-Evenness with values quoted as median. e-
Richness is reported as a mean and analysed by the t-test. 
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 P Value 
Gender 
- e-Diversity 
- e-Evenness 
- e-Richness 
 
0.2587 
0.162 
0.6136 
PA Colonisation 
- e-Diversity 
- e-Evenness 
- e-Richness 
 
0.4910 
0.6202 
0.7011 
Hi Colonisation 
- e-Diversity 
- e-Evenness 
- e-Richness 
 
0.8487 
0.1082 
0.4207 
Oral Prophylaxis 
- e-Diversity 
- e-Evenness 
- e-Richness 
 
0.3472 
0.7641 
0.2151 
Inhaled Prophylaxis 
- e-Diversity 
- e-Evenness 
- e-Richness 
 
0.3191 
0.5981 
0.1678 
IV antibiotic use in last 12 months 
- e-Diversity 
- e-Evenness 
- e-Richness 
 
0.2983 
0.7688 
0.3909 
Animal owner 
- e-Diversity 
- e-Evenness 
- e-Richness 
 
0.2448 
0.4993 
0.3109 
Urban livinga 
- e-Diversity 
- e-Evenness 
- e-Richness 
 
0.0294 
0.1046 
0.0098 
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Table A6.5 Comparison of ecological measures and potential influencing 
factors for NCFB cohort P values produced by the Mann-Whitney test when e-
Diversity or e-Evenness was compared, or the t-test for e-Richness. aThe 
scores for urban living were higher than rural living. 
 
  P Value R2 
Age 
- e-Diversity 
- e-Evenness 
- e-Richness 
 
0.7705 
0.6327 
0.9247 
 
0.001753 
0.004698 
0.00902 
FEV1 %predicted 
- e-Diversity 
- e-Evenness 
- e-Richness 
 
0.0216 
0.4268 
0.0111 
 
0.1052 
0.01321 
0.1269 
BMI 
- e-Diversity 
- e-Evenness 
- e-Richness 
 
0.5694 
0.7736 
0.5752 
 
0.006792 
0.001741 
0.006588 
Table A6.6 Comparison of ecological measures and continuous data by 
linear regression for CF patients Note one patient could not perform 
spirometry and BMI not performed on one 
 
 Culture-positive Culture-negative P Value 
e-Diversity 1.75 
(1.43-1.99) 
1.48 
(1.07-1.74) 
0.0182 
e-Evenness 0.9 
(0.83-0.92) 
0.89 
(0.73-0.9) 
0.1956 
e-Richness 7.23 
(2.4) 
5.55 
(1.44) 
0.0350 
Table A6.7 Comparison of ecological measures and culture status in the 
CF cohort Statistical analysis by Mann Whitney test with medians reported for 
e-Diversity and e-Evenness. For e-Richness, mean values are reported an the 
t-test used 
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 P Value 
Female Gender 
- e-Diversity 
- e-Evenness 
- e-Richness 
 
0.9888 
0.9888 
0.8544 
Oral prophylaxis 
- e-Diversity 
- e-Evenness 
- e-Richness 
 
0.9488 
0.4077 
0.6189 
Inhaled prophylaxis 
- e-Diversity 
- e-Evenness 
- e-Richness 
 
0.6312 
0.5221 
0.7406 
Urban Living 
- e-Diversity 
- e-Evenness 
- e-Richness 
 
0.3307 
0.1876 
0.6622 
Animal owner 
- e-Diversity 
- e-Evenness 
- e-Richness 
 
0.5941 
0.6197 
0.6379 
Table A6.8 Comparison of ecological measures and potential influencing 
factors for CF cohort P values produced by the Mann-Whitney test when e-
Diversity or e-Evenness was compared, or the t-test for e-Richness 
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Figure A7.1 linear regression of Diversity v Exacerbations Exacerbations 
are patient reported over the preceding 12 months (p= 0.0085; R2= 0.1003) 
0 5 1 0 1 5 2 0 2 5
0 .0
0 .2
0 .4
0 .6
0 .8
E x a c e rb a t io n s
E
v
e
n
n
e
s
s
 
Figure A7.2 linear regression of Evenness v Exacerbations Exacerbations 
are patient reported over the preceding 12 months (p= 0.0075; R2= 0.1035) 
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Figure A7.3 linear regression of relative abundance of Pseudomonas v 
BSI (p= 0.0274; R2= 0.07161) 
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